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CHAPTER! 
INTRODUCTION 
Vitamin A (all-trans-retinol) has been shown to be involved in many biological 
functions, including growth (Moore, 1957; Bieri et al., 1969), vision (Dowling and 
Wald,1960; Wald, 1968), reproduction (Thompson et al., 1964; Juneja et al., 1964), bone 
remodeling (Wolbach, 1947; Hayes, 1971), immunocompetence (Dennert, 1984) and 
normal cellular growth and differentiation (Hixson and Dening, 1978; Goodmann, 1984; 
McDowell et al., 1987). In large doses, retinoids (vitamin A and its analogs) also 
demonstrate potent chemopreventive and chemotherapeutic actions against various types of 
dermatologic disorders (Orfanos et al., 1981), tumors and cancers (Sporn, 1979; Mettlin et 
al., 1979; Zile and Cullum, 1983). Retinoids are a family of compounds including 
naturally occurring vitamin A, its natural derivatives (excluding carotenoids), and their 
synthetic analogs that exhibit some or all of the biological activities of naturally occurring 
vitamin A. The realization of the necessary function of vitamin A and its derivatives in 
normal differentiation and maintenance of many epithelial tissues in connection with their 
effectiveness in the treatment of some cutaneous disorders and cancerous diseases has 
generated great interest among many biochemists, cell biologists, nutritionists, 
pharmacologists, pathologists, and dermatologists. A great deal of collective effort has 
been expended in the exploration of the potential use of retinoids in clinical medicine. Little 
is known about the mode of retinoid actions, except for the process in vision. It has been 
proposed that retinoids trigger complex biological activities through cellular signaling 
systems (Mangelsdorf et al., 1990). The central theme of the proposal involves retinoid 
binding proteins (cellular retinol binding proteins, cRBPs, and cellular retinoic acid-binding 
proteins, cRABPs), nuclear retinoic acid receptors (RARs) and retinoid receptors (RXRs). 
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Briefly, retinoids are complexed with retinoid-binding proteins in the cell cytosol, and 
transported into the nucleus. In the nucleus, retinoids bind to the retinoid receptors. This 
binding activates the specific transcriptional properties of the receptors, which in tum 
interact with specific retinoid receptor response elements (RXREs) located in the region of 
the enhancers of target genes (Mangelsdorf et al., 1990; Blomhoff et al., 1990). The 
expression of a target gene is regulated by this chain reaction. All the reactions involved in 
the process are specific. The existence of distinct RAR and RXR subfamilies and of 
several receptor isomers in each retinoid receptor subfamily (to date, at least three isomers 
in each subfamily have been discovered) indicates that there are several distinct signaling 
pathways in response to different retinoids (Mangelsdorf et al., 1990). This notion is 
consistent with the fact that retinoids exert a broad range of biological effects. 
The mechanisms regarding the specific effectors that are regulated down stream in 
the retinoid-mediated signal transduction pathways are largely unknown. Thus far, protein 
kinase-C (PK-C) is the most well-studied effector whose critical role in the expression of 
many oncogenes has been: shown to be modulated by retinoids (Cope et al., 1986; Taffet et 
al., 1983; Cope and Boutwell, 1985). It is suggested that PK-C may be centrally involved 
in many of retinoids' anticancer actions, such as the effect of retinoids on omithine 
decarboxylase, intracellular polyamine levels, and epidermal growth factor receptors 
(Lippman et al., 1987). 
Although the symptoms of acute and chronic hypervitaminosis A (vitamin A 
toxicity) have been known for over 100 years, nearly a decade of clinical trials using 
retinoids as preventive and therapeutic anticancer agents has brought the problem of vitamin 
A toxicity under intense study. To date, the retinoids that have been used clinically, 
including naturally occurring and synthetic retinoids, are lipophilic in nature. They are 
poorly distributed in biological tissues and are very slowly eliminated from the body, 
causing serious prolonged toxicity (Yob and Pochi, 1987). The major toxic effects of 
clinical retinoid treatment include acute central nervous system damage, teratogenic effects, 
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mucocutaneous toxicities, major chronic reproductive, skeletal and liver toxicities, and lipid 
changes (Yob and Pochi, 1987). Therefore, the available retinoids at clinically tolerable 
doses have. only limited activity against human neoplastic processes. These limitations 
have prompted intense investigations in search of vitamin A derivatives with improved 
therapeutic values and reduced toxicities. 
In the past few decades, extensive chemical modification of the basic retinoid 
skeleton has led to the discovery of many new types of synthetic retinoids that possess 
potential therapeutic values in cancer treatment (Bollag, 1979; Bollag and Matter, 1981; 
Dawson and Okamula, 1990). In addition, synthetic analogs are found to posses marked 
species- or tissue-specificities (Aszalos, 1981 ). A group of aromatic retinoids, termed 
arotinoids, have attracted much attention because of their higher therapeutic potencies when 
compared to their naturally occurring retinoid counterparts. Unfortunately, they are also 
much more toxic. "Heteroarotinoids" are a group of compounds modified on the basis of 
arotinoids. Heteroarotinoids contain aromatic ring(s) and at least one heteroatom within the 
skeletal framework (Spruce et al., 1987). In several standard evaluation tests, 
heteroarotinoids have shown marked anticancer activities and much lowered toxicities when 
compared with some clinically utilized retinoids, such as all-trans -retinoic acid, 13-cis 
-retinoic acid, etc. (Dawson et al., 1984; Waugh, et al., 1985; Gale, 1988). 
The goal of the present study was to address the following aspects. The first 
objective was to evaluate the growth-promoting activity of selected heteroarotinoids. The 
weight-change of vitamin A-deficient rats was monitored for various lengths of time while 
the animals were fed a vitamin A-deficient diet periodically or continuously supplemented 
with these compounds. Second, the vitamin A-like activity of these heteroarotinoids was 
evaluated in terms of maintaining normal differentiation of epithelial cells. An in vivo 
vaginal-smear assay (VSA) was developed to quantitatively measure and compare the 
decornification activity of the selected heteroarotinoids with ovariectomized vitamin A-
deficient rats. A further investigation on the histopathological effect of the heteroarotinoids 
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was performed on various epithelial tissues from rats supplemented with these 
heteroarotinoids. Third, methodologies were developed to isolate and identify major biliary 
metabolites formed in vivo after a pharmacological dose of a selected heteroarotinoid was 
administered. 
The vital role of retinoids in growth and differentiation of many types of epithelial 
cells indicates their fundamental importance in chemoprevention and chemotherapeutic 
treatment of various cancerous diseases. The activity of an individual retinoid depends on 
its biological and phanhacokinetic properties, including metabolism. Investigation of the 
biological activities and metabolisms of these selected heteroarotinoids will provide 
important information for their pharmacological evaluation and potential clinical utilizations 
in the future. 
CHAPTER II 
LITERATURE REVIEW 
Historical Perspective 
The term "retinoids" was coined to refer to a family of structurally-similar 
compounds comprising naturally occurring retinoids, including all-trans-retinol (vitamin 
A), retinal, retinoic acid (Figure 1), and their synthetic analogs. This definition emphasizes 
the structural similarities regardless of their differences in biological activities. As revised 
from the original description of "fat-soluble A" and "vitamin A", which strictly referred to 
all-trans-retinol, the IUPAC-IUB Joint Commission on Biochemical Nomenclature in 1982 
recommended that, "The term vitamin A should be used as the generic descriptor for 
retinoids exhibiting qualitatively the biological activity of retinol. This term should be used 
in derived terms such as vitamin A activity, vitamin A deficiency, vitamin A antagonist." 
(1982). Chytil (1984) argued, however, that the term "vitamin A" should be strictly 
reserved for retinol because only this compound, when taken in sufficient quantities, 
satisfies all the vitamin A requirement for proper development and growth of an animal 
(Chytil, 1984). Some retinol metabolites, such as retinoic acid and retinal, are undoubtedly 
involved in many processes of vitamin A activity. Their functions, however, are not 
identical and frequently overlap. The author of this presentation tends to agree with Dr. 
Chytil's point of view and refers to all-trans-retinol only wherever "vitamin A" is used in 
this writing. Animals are not capable of de novo synthesis of vitamin A. The major 
sources of naturally-occurring retinoids are fish liver oils, visceral parts of fish, eggs, and 
animal kidneys, lungs, eyes, and intestinal mucosa (Underwood, 1984). Carotenoids are 
the precursors of vitamin A. They are synthesized exclusively by photosynthetic 
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R = CH20H Retinol 
= CHO Retinal 
= C02H Retinoic Acid 
Figure 1. The Naturally-occurring Retinoids. 
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microorganisms and plants (Underwood, 1984). Among carotenoids found in the most 
important mammalian food sources, (3-carotene has by far the most provitamin A activity 
(Bauernfeind, 1972). Vitamin A compounds are derived enzymatically from carotenoids in 
the intestinal mucosa and in the liver of animals (Goodman and Olson, 1969). 
Although the existence of an essential nutritional factor, later to be termed vitamin 
A, was recognized and its physiological effects were described more than 3500 years ago 
(Moore, 1957), systematic studies on the characterization of its chemical and physical 
properties did not begin until early this century (Hopkins, 1906; Stepp, 1909; McCullum 
and Davis, 1913; 1915; Osborne and Mendel, 1913). In 1920, Drummond named this 
essential factor "vitamin A" (Drummond, 1920). 
In the second quarter of this century, progress was made in the chemical isolation, 
characterization and synthesis of vitamin A, its natural derivatives, and their biologically 
active precursors (Aszalos, 1981; Frickel, 1984; Frolik, 1984; Sporn, et al., 1984; 
Pawson, et al., 1982). In the 1960s, the elucidation of the biochemical process of vision 
revealed, for the first time, the specific role of 11-cis -retinal in the visual cycle (Wald and 
Habbard, 1970). With the introduction and development of high-performance liquid 
chromatography (HPLC) in early 1970s, a great deal of information on the metabolism of 
natural retinoids was obtained (Frolik, 1984 ). At the same time, problems in human 
vitamin A deficiency (hypovitaminosis A) and vitamin A toxicity (hypervitaminosis A) had 
gained worldwide recognition as a series of activities in controlling these problems were 
initiated (WHO, 1976). 
Detailed descriptions regarding the classical discoveries in vitamin A research, 
including the original description of vitamin A substances and their carotenoid precursors; 
the development of quantitative chemical methods for the analysis and assay of vitamin A 
compounds; the elucidation of the chemical structure and the total synthesis of vitamin A; 
the pathology of hypovataminosis A and hypervitaminosis A in experimental animals and 
man; and the nutritional needs for vitamin A in humans and animals, can be found in 
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several references (Karrer and Jucker, 1950; Moore, 1957; Wald, 1968; Pommer, 1977; 
Wolf, 1980). 
In the late 1970s, the recognition of the variety of vitamin A activities in maintaining 
the normal physiology of the body, such as growth promotion, reproduction, bone 
remodeling, and the differentiation and integrity of epithelial tissues, led to rapid progress 
in the chemistry and biology of retinoids. The connection between vitamin A and cancer 
became increasingly clear as squamous metaplastic changes in epithelial tissues due to 
vitamin A deficiency were recognized as morphologically similar to the changes found in 
certain precancerous lesions caused by carcinogen exposures (Harris et al., 1972). Studies 
to reveal the molecular basis of the actions of retinoids have become the subject of much of 
the active research. As retinoids proved to be highly potent in controlling cell 
differentiation and proliferation, they have become valuable tools in studies dealing with the 
most fundamental problems in the field of biological research. By the same token, they 
have been enthusiastically trailed in clinical practices in the treatment of severe cystic acnes, 
psoriasis, and other dermatological disorders. Furthermore, potential uses of retinoids 
were explored in the prevention and treatment of various cancers, and the outcomes were 
promising (Dawson and Okamura, 1990). Investigation into the toxic effects of retinoids, 
although recognized long ago, has intensified since increased clinical utilizations of 
retinoids were inevitably accompanied by the problems of toxicity. 
In the last decade, great interest has been generated in the development of synthetic 
retinoids in a search for new drugs with greater tissue specificity, greater therapeutic 
efficacy, and lower toxicities. Major advances in synthetic organic chemistry have been 
made. As a result, over a thousand new retinoids have been synthesized (Dawson and 
Okamura, 1990). A series of in vitro and in vivo bioassay systems have been developed 
to screen the newly synthesized retinoids for their biological activities (Sporn, 1984). 
There has been a striking thrust in the development of the newly synthesized retinoids for 
prevention and/or treatment of diseases, particularly in the areas of oncogene and 
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dermatology. There are many similarities in the general effects that have been experienced 
with different systemic retinoids, although in varying degrees·(Dicken, 1984). Like those 
that have been observed for natural retinoids, the effects that are most notable with 
synthetic retinoids are in the areas of cellular differentiation, inflammation, 
immunomodulation, keratinization, cell membrane stability and organization, 
posttranslational glycosylation, and anticancer activity (Yob and Pochi, 1987). Structural 
modifications of the ring, the side chain, or the polar terminal group of the retinoid skeleton 
resulted in synthetic retinoids with improved therapeutic index over the two original 
retinoid drugs, all-trans- and 13-cis-retinoic acid (Pawson et al., 1982). The fact that 
some synthetic retinoids bear little structural resemblance to retinol or retinoic acid has led 
to a new definition of retinoids, namely, "a retinoid is a substance that can elicit biological 
responses by binding to and activating a specific receptor or set of receptors" (Sporn et al., 
1986). This new definition emphasizes the biological responses and the mode of action 
rather than the structure of a compound when it is considered to be a member of the retinoid 
family. 
This review will be focused on synthetic retinoids. The development of this 
contemporary domain of retinoid research will be discussed in conjunction with reviews of 
various aspects of the natural retinoids including the metabolism, biological activities, toxic 
effects, and mechanisms of actions. 
Synthetic Retinoids 
The basic structure of retinoids consists of three portions: a cyclic end group, a 
polyene side chain, and a polar end group (Figure 2). Synthetic retinoids have been 
prepared by making alterations in one or more parts of the basic retinoid skeleton (Lippman 
and Meyskens Jr., 1988). The first-generation synthetic retinoids were produced by 
alterations made at the polar end group and the polyene side chain. The most important 
first-generation retinoids are Tretinoin (all-trans-retinoic acid) and Isotretinoin (13-cis-
Cyclic End Group 
i~ Xj ~ ~ ~ ~;R 
~.... I 
I I 
Polyene Side Chain 
10 
Polar End Group 
------------ Basic Structure------------
~ COOH 
Tretinoin Isotretinoin 
~ 
COOH 
------------ First Generation------------
Etretinate 
-----------Second Generation1------------
R 
Arotinoids 
TINPB (R-COOH) 
------------Third Generation------------
X =0,S 
R = H, Et, etc. 
Monoaryl Heteroarotinoids 
X = 0, S, NH, NMe, etc. 
R = H, Me, Et, etc. 
Diaryl Heteroarotinoids 
------------Fourth Generation-----------
Figure 2. Classification of the Synthetic Retinoids. 
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retinoic acid). Some retinoamides and series of chlorinated and fluorinated vitamin A 
analogs were also synthesized. Some of them, such as fluorinated retinoids, have shown 
enhanced anti-turner activity (Lovely and Pawson, 1982). The second-generation retinoids 
were developed by aromatizing the cyclohexenyl ring. A representative second-generation 
molecule is Etretinate, which is widely used in clinics. Cyclization of the polyene side 
chain produced retinoids of the third generation, the retinoidal benzoic acid derivatives, also 
known as arotinoids. Arotinoids are structural systems that contain an aryl ring within the 
side chain or fused to the cyclohexyl ring of the basic retinoid skeleton. By condensing the 
polyene side chain onto one or more aromatic ring structures, the conformations of the 
molecules become more rigid and planer. The most extensively studied arotinoids in this 
category is (E )-4-[2-(5,6,7 ,8-tetrahydro-5,5,8,8.,tetramethyl-2-hephthalenyl)-1-propenyl] 
benzoic acid (Ro 13-7410), also known as TTNPB, and its ethyl ester (Ro 13-6298). 
These compounds were more potent than the first- or the second-generation retinoids in 
several standard screening tests and in the treatment of keratinizing and hyperproliferative 
disorders including psoriasis (Tsambaos and Orfanos, 1983). The newest class of 
synthetic retinoids are the heteroarotinoids developed on the the base of arotinoids by 
Berlin and co-workers (Waugh et al., 1985; Spruce et al., 1987; Spruce et al., 1991) and 
Dawson and co-workers (Dawson et al., 1984; Metra et al., 1986). Heteroarotinoids 
consist of at least one aryl ring and a heteroatom within the retinoid skeletal framework 
(Spruce et al., 1987). They are categorized as the fourth generation of synthetic retinoids 
in this writing. 
Metabolism of Retinoids 
Naturally Occurrin~ Retinoids 
Various aspects of the metabolism of the naturally-occurring retinoids have been 
reviewed (Olson, 1969; Roberts and Frolik, 1979; Frolik, 1984). The major nonoxidative 
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metabolism of vitamin A and its derivatives, namely esterification, isomerization and 
conjugation, mainly occur during the absorption and transportation processes. The 
utilization of vitamin A by the body starts with absorption in the intestine, which is 
followed by transportation to and storage in the liver. Dietary retinol is quickly esterified in 
the intestinal mucosa with long-chain fatty acids (Goodman et al., 1966). J3-Carotene, the 
main natural dietary precursor of vitamin A for man, is converted to retinol by two 
enzymatic steps. First, it is cleaved by J3-carotene 15, 15'-oxygenase found in the intestine 
and liver to two molecules of retinaldehyde (Goodmann and Huang, 1965), which is then 
reduced to retinol by retinaldehyde reductase in the intestinal mucosa (Huang and 
Goodmann, 1965). 
The esterified retinol is incorporated into chylomicra and transported via the lymph 
to the liver. The retinyl esters are then hydrolyzed and reesterified in the liver for storage 
(Lawrence et al., 1966; also see the Mode of Action for more detailed discussion on the 
transport and storage of retinoids). It was reported that retinyl palmitate is the major ester 
in both the lymph (Huang and Goodman, 1965) and liver (Mahadevan and Ganguly, 
1961). Another important ester of retinol formed in the liver is retinyl phosphate, which is 
further conjugated with mannose to form mannosyl retinyl phosphates (Masushige et al., 
1978). It has been postulated that retinoids control the glycoprotein synthesis through the 
formation of these glycosyl phosphoryl retinoid intermediates (De Luca et al., 1979; Wolf 
et al., 1979). Recently, Rimoldi et al. (1990) demonstrated that the incorporation of 
mannose into lipidic intermediates and glycoproteins was greatly reduced during the 
progression of vitamin A deficiency. Their study indicated that vitamin A deficiency 
caused major impairment in the GDP-mannose biosynthesis. 
Conjugation of retinol with glucoronic acid to form J3-glucuronide was first found 
in bile (Dunagin et al., 1965), but later was detected in the urine (Nath and Olson, 1967) 
and intestinal mucosa as well (Zile et al., 1982). Glucuronides of retinoids are water 
soluble agents and possess some biological activities of vitamin A. Stimulatory effects of 
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glucoronides of retinoids in the growth of vitamin A deficient rats (Chytil, 1985), and in 
the differentiation ofHI..60 cells and vaginal epithelial cells have been reported (Wong and 
Buel, 1971; Stahlmann et al., 1988). Marked inhibitory effect on hormone-induced 
differentiation of mammary glands in organ culture was also found (McDowell et al., 
1984). Recently, Mehta and co-workers (1992) demonstrated that the effects of retinoid 
glucuronides are independent of cRBP or cRABP in mammary gland organ culture. They 
speculated that retinoid glucuronides may either function through a mechanism different 
from that of retinoids, or they may be metabolized to active components of retinoids, which 
may in tum bind to retinoid binding proteins for the glucuronide action (Mehta et al., 
1992). 
Isomerization of retinoids occur in many physiological processes. For example, 
retinaldehyde functions in the visual cycle by isomerization of all-trans-retinaldehyde to 11-
cis-retinaldehyde (Wald, 1968). 13-cis-Retinoic acid was identified in tissue extract of rats 
given all-trans-retinoic acid (Zile et al., 1967; Lippel and Olson, 1968). In spite of the fact 
that isomerization of all-trans-retinoic acid to its 13-cis isomer occurred artificially during 
the extraction and chromatographic procedures, repeated detection of 13-cis isomers in the 
metabolism of all-trans-retinoic acid led many to speculate its occurrence as a normal 
physiological event and of possible physiological importance (see review in Frolik, 1984). 
Major oxidative pathways of natural retinoids have been extensively investigated in 
many in vitro and in vivo studies (see review by Gale, 1988). The major oxidation sites 
are: (1) at C(4) of the cyclohexenyl ring; (2) at C(S,6) double bond in the cyclohexenyl 
ring through epoxidation; (3) at the methyl groups on the ring and on the side chain; and (4) 
on the side polyene chain by oxidative shortening. The metabolism of retinoic acid in vivo 
is a complex process that gives rise to many metabolites, the relative quantities of which 
vary in different tissues (Chytil, 1984 ). This phenomenon may imply its diversified 
activities in different tissues. 
14 
To date, much of the research in the metabolism of the natural retinoids has focused 
upon a search for biological metabolites of retinol or retinoic acid that are more active than 
the parent compounds in biological functions. Although further investigation is still 
required, results from many in vitro and in vivo assay systems that are used to test various 
vitamin A activities indicated that retinoic acid is the most active form of vitamin A in 
maintaining normal cell differentiation (Lotan, 1980) and in reversing malignant tissue 
changes induced by exposure to carcinogens (see review by Lotan, 1986). It has also been 
shown that retinoic acid was just as active as retinol in supporting growth (Nelson et al., 
1964; DeMan et al., 1964; Zile and DeLuca, 1968). In addition, retinoic acid was detected 
as normal metabolite of retinol and retinaldehyde (see review by Frolik, 1984). For over 
three decades, it was widely accepted that retinoic acid was unable to satisfy the visual and 
reproductive requirements for retinal and retinol (Dowling and Wald, 1960; Thompson et 
al., 1964) because it could not be converted back to either retinaldehyde or retinol in the 
body (Dowling, 1961). More recently, however, Van Pelt and co-investigators reported 
that retinoic acid, like retinol, could support spermatogenesis when a large dose was 
administered repeatedly (Van Pelt and De Rooij, 1991). They concluded that all-trans-
retinoic acid (RA) was able to induce synchronous proliferation and differentiation of A-
spermatogonia, and support the full development of spermatogenic cells into elongated 
spermatids. 
Synthetic Retinoids 
As mentioned earlier, the use of natural retinoids in dermatology and in the 
prevention of epithelial cancer has generated great interest in the fields of clinical medicine 
and basic research. Because of the unacceptable toxic effect of the natural retinoids at 
pharmacological levels, seeking less toxic analogs has become the focus of much research 
in this area. Compared to the number of retinoid analogs that have been synthesized and 
screened for biological activity, studies on the metabolism of synthetic retinoids has lagged 
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behind. Only a few synthetic retinoids have been studied extensively (Frolik:, 1984). The 
major route of the metabolism of 13-cis-retinoic acid (considered a synthetic retinoid 
although evidence has indicated that it is a natural retinoid and a physiological metabolite of 
all-trans-retinoic acid) in hamsters, rats, and humans was found to be the oxidation at C(4) 
of the cyclohexenyl ring (Frolik:, 1984). Like all-trans-retinoic acid, 13-cis-retinoic acid 
and its metabolites were rapidly excreted from the body via bile. 
The metabolism of Etretinate (Ro 10-9359), the TMMP analog of ethyl retinoate 
and a drug widely used in the clinics, was also reported. Hanni and co-workers (1977, 
1979) were able to identify a number of metabolites in human plasma, urine and feces after 
an oral dose of Etretinate. The types of metabolic pathways can be generalized as follows: 
(1) conjugation with glucuronic acid, sulfuric acid, or glycine; (2) initial hydrolysis of the 
ethyl ester to free acid; (3) hydrolysis of the methoxy group, or the 3-methyl group in the 
aromatic ring (see the structure of Etretinate in Figure 2); and (4) oxidative cleavage of the 
tetraene side chain. The major metabolic product of Etretinate was found to be its 
corresponding acid Ro 10-1670 in the bile of rats (Hanni et al., 1977) and in human 
epidermal keratinocytes in an in vitro study (Kitano et al., 1982). This hydrolysis was 
believed to be the activation step in the therapeutic activity of Etretinate (Hanni et al., 
1977), and the responsible esterase was found to be widely distributed in many tissues 
(Wang and Hill, 1977). 
Studies on the metabolism of various analogs of retinamide have also been reported 
(Kalin et al., 1982; Wang et al., 1980; Swanson et al., 1980, 1981). A few glucoronide 
conjugates and fatty acid esters were identified. Biliary polar metabolites were generally 
observed, but none of the structures were identified. 
The metabolism of difluoro analogs was found to be very similar to that of vitamin 
A (Barua and Olson, 1984). Esters, 4-oxidative products, and polar conjugated derivatives 
were the major metabolites identified in the intestine, liver, kidney and plasma. 
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The pharmacokinetic tissue distribution and placental permeability of a 
representative arotinoid, TTNPB (Ro·13-7410), was studied after a single oral bolus was 
administered to pregnant hamsters (Howard et al., 1989). The absorption of the retinoid as 
determined in the blood plasma level was fast (t 1/2 = 1.2 h), with a peak plasma level at 
2.4 h. The tissue distribution following an 100 µg/kg [3H]-TTNPB administration was in 
the order of liver > fetus > adrenal > lung = kidney > plasma. An unidentified polar 
metabolite was detected at 0.5 h in the blood plasma, and constituted > 90% of the total 
circulating radioactivity by 12 h. TTNPB was cleared more slowly, and concentrated in the 
conceptus to a higher degree. These findings were consistent with the markedly high 
teratogenic activity of TTNPB as compared to the natural retinoids. 
The Role of Retinoids in the Control and Maintenance 
of Epithelial Tissue Differentiation 
The main theme regarding the biological activity of vitamin A is its activity in 
maintaining normal differentiation and growth of epithelial cells and cell-surface structures 
(Pawson et al., 1982). The processes of cell differentiation and growth are regulated by 
vitamin A compounds ( Floyd and Jetten, 1988). In the reproductive system, vitamin A is 
required for maintaining a normal epithelium in processes such as spermatogenesis, 
gestation, organogenesis, and embryonic development (Thompson et al., 1964; Juneja et 
al., 1964; Takahashi et al., 1975). Vitamin A is important in the bone structuring because 
it regulates the normal differentiation of mesenchymal "undifferentiated" cells (Hayes, 
1971 ), and the balance between the number and the activity of osteoblasts and osteoclast 
cells (Gallina et al., 1970). 
The hypothesis that retinoids control epithelial differentiation was initiated in the 
early 1920s. In 1922, Mori (1922) conducted the first detailed study of epithelial tissue 
changes in rat eyes resulting from vitamin A deficiency. He reported the loss of secretions 
by the lacrimal gland and marked keratinization of the rat cornea and conjunctiva due to 
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vitamin A deficiency. As an ultimate result, the cornea lost its normally ordered 
architecture, and developed an ulcer. This symptom was later termed as keratomalacia 
(Wolf, 1980). The first sign of the pathological process was xerophthalmia, or dry eye, as 
a result of abnormal tear production due to vitamin A deficiency (Moore, 1957b). Wolbach 
and Howe (1925) showed that epithelial tissues in general were affected by vitamin A 
deficiency. They demonstrated that the columnar and transitional epithelium of the 
respiratory tract, alimentary tract, genitourinary tract, eyes, and glands were all replaced by 
stratified squamous keratinized cells in vitamin A-deficient animals. The generalization was 
further supported by the correlation between low vitamin A status and high incidence of 
tumors as observed by many other investigators (Fujimaki, 1926; 1929; Burk and Winzler, 
1944). Tumor development was the result of abnormal differentiation of epithelial tissues. 
An important nature of the vitamin A-deficiency-induced epithelial changes is that the 
conditions are reversible as repletion of vitamin A results in the reappearance of ciliated and 
mucus-secreting columnar cells replacing the squamous cells of the deficient state (Wolbach 
and Howe, 1933). The role ofretinoids in the modulation of epithelial differentiation was 
firmly established in some more recent studies (Olson et al., 1983; Ong and Chytil, 1983; 
De Luca and Shapiro, 1981). 
Epithelial cells in different tissues interact differently with retinoids (Olson, 1972). 
The morphological appearances of different epithelial cells as the result of vitamin A 
deficiency are therefore different. Epidermis, a stratified squamous epithelium, is on one 
extreme of the spectrum. The proliferating basal cells of the epidermis are the lowest layer 
of cells. Studies showed that cells superi<:>r to the basal cells became more stratified and 
further differentiated as they moved up and ultimately differentiated into keratinized cells 
(Matoltsy, 1976). Retinoids inhibited keratinization and induced mucus metaplasia (Yaar et 
al., 1981; Fuchs and Green, 1980; 1981). Intestinal cells are at the other extreme of the 
spectrum. The major goblet cells of the intestine normally synthesize and secret mucus 
materials. It was found that the number of the mucus-secreting goblet cells was greatly 
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reduced in vitamin A deficiency (Manville, 1937; De Luca and Wolf, 1969). Later, it was 
determined that the rate of differentiation of a particular subclass of goblet cells from 
precursor cells was decreased in vitamin A deficiency (De Luca et al., 1971; Olson et al., 
1981). Other epithelial tissues, such as the cornea, the respiratory tract, and the genital 
tract, contain both goblet and keratinized cells in normal situations. Nevertheless, they 
respond to vitamin A in the same manner, i.e., in the absence of vitamin A, tissues are 
transferred into more keratinized status (see review by Shapiro, 1986). In addition to the 
loss of goblet cells, the normally columnar-like goblet cells appeared flattened (Wong and 
Bulk, 1971), and the overall surface integrity of the epithelium was affected because of the 
loss of protective mucoid secretions (De Luca and Wolf, 1969). 
Toxicity and Pharmacology 
The development and clinical utilization of retinoids represent the most significant 
achievement in the dermatological therapy since the introduction of corticosteroids. The 
problem of toxic effects of these compounds is the major setback for the wide application 
of retinoid treatments. Although endogenous retinoids are essential for a broad spectrum of 
normal physiological processes, the same compounds are highly toxic in excessive 
amounts. The toxic effect of excessive retinoids in human have been known for more than 
100 years (Kamm et al., 1984). The primary targets of retinoid toxicity are the 
mucocutaneous, skeletal, and central nervous systems (Yob and Pochi, 1987). The effect 
can be acute, subchronic, and chronic, depending on the dosage and duration of the 
administration, as well as the pharmacokinetic property of the drug (Chytil, 1984). The 
major symptoms of vitamin A toxicity, termed as "Hypervitaminosis A Syndrome", are 
reviewed in a recent article by Lippmann and co-investigators (Lippman et al., 1987). The 
major symptoms manifested in humans include cheilitis, severe headaches, conjunctivitis 
inflammation, nausea, vomiting, dryness and scaling of skin, tenderness of bone, and 
bulging fontanelles in infants (Lippman et al., 1987). Clinically important synthetic 
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retinoids include all-trans-retinoic acid (Tretinoin, Retin-A), 13-cis-retinoic acid 
(Isotretinoin, Accutane), Etretinate (Tigason, Tegison) and Acritretin (Neotigeson, 
Soriatane ). These compounds have proven highly effective in the treatment of severe 
forms of psoriasis, particularly generalized pustular psoriasis. These synthetic retinoids, 
however, have similar adverse effects. Reported side effect in the oral use of Tretinoin and 
Isotretinoin include headache, dizziness, cheilitis, xerosis, anoresia, abdominal pain, 
conjunctivitis, and excessive thirst. Topical application of Tretinoin can result in skin 
irritation and reversible hypopigmentation. The most serious toxic effect of retinoids is 
their teratogenic properties, which have been observed in laboratory animals and more 
recently in humans. Retinoids at high concentrations are cytotoxic because they damage 
lysosomal membranes via a detergent-like action (Lotan, 1980). The teratogenic effect of 
retinoids is often characterized by the malformation of the face, thymus, and great vessels, 
reflecting the failure of tissues to reach their normal size and shape (Geelen, 1979). The 
embryopathy of isotretinion was studied recently by Webster and co-workers in animal 
models (1986). Their study indicated that the drug directly interfered with the development 
of cranial neural crest cells. One of the metabolites, 4-oxo-isotretinion was found to be 
more toxic than the parent compound, 13-cis-retinoic acid. Retinoids developed recently, 
such as heteroarotinoids, possess comparable therapeutic effects but less toxicity (Dawson 
et al., 1984; Metha et al., 1986; Gale, 1988). Increased hydrophilicity and altered 
metabolic oxidative pathways due to the structural characteristics of the heteroarotinoids 
may partially contribute to the therapeutic improvement (Spruce et al., 1991). 
Several assay systems have been developed to evaluate the biological activities of 
retinoids, especially of newly synthesized retinoids (Sporn, 1984). Two popular assays, 
the ornithine decarboxylase (ODC) assay and the hamster tracheal organ culture (TOC) 
assay, have been widely used to examine the activities of synthetic retinoids. In ODC, the 
ability of a test substance to inhibit the biosynthesis of the enzyme ornithine decarboxylase 
is measured. This inhibitory effect reflects the extent to which the substance inhibits skin 
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tumor promotion (Verma et al., 1978, 1979). The standard hamster tracheal organ culture 
assay permits measurement of biological activity of test retinoids to reverse keratinization of 
basal cells in the tracheobronchial epithelium of vitamin A-deficient hamsters. The TOC 
bioassay has been extremely valuable for providing information on retinoid structure-
activity relationships. Heteroarotinoids have shown remarkable activities, in comparison 
with that of retinoic acid, in a number of these tests, including TOC, ODC, and in the 
induction ·of human promyelocytic cell (HL-60) differentiation assay (Waugh et al., 1985; 
Spruce et al., 1987; Spruce et al., 1991). 
In conclusion, retinoids, especially synthetic retinoids, represent a group of 
compounds that have profound therapeutic values for a variety of diseases, most 
importantly for cancerous diseases. The goal of clinical studies of the relationship between 
retinoids and cancer prophylaxis is to search for retinoids that have minimal toxicity at 
effective dose levels. 
Structure and Biological Activity 
Numerous comparative studies on analyzing structure-function relationships of the 
retinoids have demonstrated that vitamin A activity is eliminated or reduced by 
modifications such as the saturation of a side chain double bond, removal of the methyl 
group at C(13), shortening at the side chain, and the oxidation of either the C(4) position or 
the C(5, 6)-double bond (Newton et al., 1980; Zile et al., 1980; Sietsema and DeLuca, 
1982a). These metabolic pathways are generally considered to be degradation and/or 
inactivation processes. Presumably, arotinoids and heteroarotinoids are more active 
because the aromatic ring in conjunction with the cyclohexyl ring may block the oxidative 
degradation at C(4) position and at the C(5,6)-double bond (Loeliger et al., 1980, Spruce et 
al., 1987). In addition, heteroarotinoids with oxygen substituting the carbon atom at C(4) 
eliminates the oxidation at this position (Spruce et al., 1987). Therefore, increases in the 
metabolic half-lifes of arotinoids and heteroarotinoids, due to the blockage of the oxidative 
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degradation processes, may contribute to their higher therapeutic potencies observed in the 
screening tests. In addition, incorporation of an aryl ring on the side chain maintains C(13) 
in a fixed cis arrangement has been predicted to be a favorable configuration for improved 
biological activities (Loeliger et al., 1980; Dawson, et al., 1989). 
The electron density at C(4) has been suggested as an important factor for the 
biological functions ofretinoids because differences in electron density at C(4) may alter 
the cellular transport of a retinoid or may interfere with its interaction at critical sites (Miller 
et al., 1985). Oxidation at C(4) reduces the electron density at this position, resulting in the 
loss of activity. It has been predicted that compounds having comparable electronegative 
functional groups or atoms at this position may have similar activities (Miller, et al., 1985). 
The oxygen or sulfur atoms in heteroarotinoids alter the electron densities at this position , 
which may account for the increased activities of these compounds. 
Mode of Action 
The molecular basis for the broad range of biological activities of retinoids is largely 
unknown, except for that in the visual cycle. The concept of vitamin A activity is 
constantly changing. The profound functions of retinoids upon many different types of 
cells are widely demonstrated, but are often confusing and inconsistent (Pawson, 1982; 
Sporn, 1984). This phenomenon reflects the complexity ofretinoid activities. There have 
been a number of mechanisms proposed for the action of retinoids, such as the 
enhancement of the immune response by retinoids, controlling membrane permeability, and 
the regulation of gene expression ( Aszalos, 1981). To date a substantial amount of 
research data have firmly indicated that interaction between retinoids and genetic machinery 
of the cells is the most fundamental mechanism through which retinoids manifest their 
many cellular effects such as those on immunology and membrane changes. The major 
routes that retinoids modulate behavior of cells are (1) influencing growth rates, (2) altering 
differentiation state of cells, and (3) changing cell surface properties (Pawson et al., 1982). 
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Retinoids are thought to exert their effects by interacting with a complex system of 
cytoplasmic binding proteins and nuclear receptors, resulting in the ultimate regulation of 
the target gene expression (Raysdale and Brockes, 1991 ). 
Retinoids are transported from the intestine through the blood stream to target cell 
nuclei. The transportation pathways are specific, yet fully understood (Blomhoff et al., 
1990). Chylomicron reminants, formed in the general circulation, contain almost all the 
intestinally absorbed retinol and are taken up mainly by hepatocytes during the early stages 
of hepatic uptake of retinyl esters (Blomhoff et al., 1990). The retinyl esters are then 
hydrolyzed at the plasma membrane, and the retinol compounds are taken into the 
endosomes by a receptor-mediated endocytosis and consequently transferred to the 
endoplasmic reticulum (ER) (Blomhoff et al., 1985). 
The involvement and importance of cellular retinoid-binding proteins for retinoid 
functions has been indicated in many studies (see review by Blomhoff et al., 1990 and 
Sani, 1991). The ER in the liver is rich in retinol-binding proteins (RBPs). Retinol binds 
to RBP. The retinol-RBP complex is then transported into the hepatic satellate cells, which 
may secrete retinol-RBP directly into blood plasma (Blomhoff et al., 1990). The plasma 
transport of all-trans-retinoic acid (RA) is believed to occur through the binding of RA to 
serum albumin (ALB) (Goodman and Blaner, 1984). The exact mechanisms of cellular 
retinoid uptake are unclear. Specific RBP receptor-mediated retinol uptake and 
spontaneous transfer of RA from RA-ALB to a membrane-bound cellular retinoic acid 
binding protein have been suggested among various possible mechanisms (Blomhoff et al., 
1990; Sani, 1991). In the cell cytosol, retinol and RA bind to the cellular retinol-binding 
protein (cRBP) and the cellular retinoic acid-binding protein (cRABP), respectively (Sani, 
1991). 
The cellular retinoid-binding proteins, cRBP and cRABP, were first identified by 
Chytil and Ong (1978). They proposed that these binding proteins function like steroid 
receptors in that they transport retinoids into the nucleus, where retinoids interact with 
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transcriptional factors to modulate gene expression. Indeed, retinol-cRBP and retinoic 
acid-cRABP complexes have been found to bind specificly to cell nuclei (Takase et al., 
1979; Mehta et al., 1982, McCormick et al., 1984), which was followed by specific 
binding of retinol or retinoic acid to chromatin (Lian et al., 1981; McCormick et al., 1984). 
Since then, many tissue-specific intracellular retinol- and retinoic acid-binding proteins 
have been identified (Chytil and Ong, 1984; Nashiwaki et al., 1990; Blomhoff et al., 
1990). Recently, the expression of retinoid binding proteins were found to be tissue and/or 
cell-cycle-dependent (Tsutsumi et al., 1992). Blaner's group in Columbia University 
reported that adipose tissues are dynamically involved in retinoid storage and retinoid-
binding protein synthesis (Tsutsumi et al., 1992). Furthermore, their study suggested that 
the expression of RBPs is cell-differentiation-dependent (Zovich et al., 1992). 
Some studies seemed to indicate that the presence of cRBP or cRABP may not be 
sufficient and/or necessary for cells to exhibit retinoid responses. In a retinoic acid 
resistant S91 melanoma cell line, similar or even higher concentrations of cRABP were 
found when compared to the control S91 cells (Lotan, 1985). Other studies have shown 
that cells devoid of cRBP or cRABP still respond to retinoids (Chytil and Ong, 1984; 
Breitman et al., 1980). Recently, a number of nuclear retinoid receptors have been 
identified. Based on their primary structures, difference in affinity to retinoid ligands, and 
ability to regulate expression of different target genes, they are classified into two 
subfamilies, retinoic acid receptors (RARs) and retinoid X receptors (RXRs), (Giguere et 
al., 1987; Petkovich et al., 1987, Mangelsdorf et al., 1990, 1991; Raysdale and Brockes, 
1991). At least three isomers in each subfamilies have been discovered, designated as 
RARa., Bandy, and RXRa., B, and y, respectively (Giguere et al., 1987; Petkovich et al., 
1987; Brand et al., 1988; Zelent, et al.,1989, Krust et al., 1989). These receptors contain 
both DNA-binding and ligand-binding domains. The DNA binding domains of RARs 
display a high degree of homology with the DNA-binding domains of other members of the 
nuclear receptor family (Petkovich, 1992). The amino acid sequence of the DNA-binding 
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domain is also highly conserved among diversified species (Petkovich, 1992). The ligand-
binding domains of RARs are almost completely identical, and bind to retinoic acid 
specificly and with high affinity. Each member of a receptor subfamily may have its own 
specific function as interspecies conservation of a member within the RAR subfamily was 
found to be much higher than the conservation of all three receptors within a given species. 
In addition, the expression of RARs was found in almost all cell types in the body, and 
was highly tissue-specific (Krust et al., 1989; Zelent et al., 1989). Furthermore, it seems 
that the tissue-specificity of RAR expression is further specified by the cell's positions on 
the same tissue. Schofield and co-workers demonstrated in their study with chick limb bud 
that the expression of retinoic acid receptor-~ (RARp) was position-dependent in that its 
expression was repressed at the distal tip of the bud, but was highly expressed in the 
proximal tissue of the bud (Schofield et al., 1992). In contrast to RARs, the expression of 
RXRa was most abundant in visceral tissues such as the liver and the kidneys 
(Mangelsdorf et al., 1990). 
The retinoid receptors are ligand-dependent transcription factors (Petkovich, 1992). 
They are activated upon binding by specific retinoid ligands, resulting in the regulation of 
the expression of different genes. Two retinoic acid isomers, all-trans -retinoic acid and 9-
cis-retinoic acid, were found to be the specific physiological ligands of RARa. and RXRa., 
respectively (Heyman et al., 1992). This finding implies that, as in the visual system, 
isomerization of retinoids may be the key step in controlling different signal transduction 
pathways. 
In the nucleus, the RAR-RA complex binds to a short, specific sequence, termed as 
retinoic acid response element (RARE) in the enhancer of target DNA. The expression of 
the target gene is regulated through the interaction between the RA-RAR complex and the 
RARE (Evans, 1988). The nature of the interaction between the receptor and the RARE has 
not been thoroughly studied. Various RAREs have been identified that are responsive 
specificly to different RARs (Vasios et al., 1989; de The et al., 1990). Based on the 
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findings supportive of this model, it appears quite convincing that the diversity of the 
biological effects of retinoids are the result of regulation of gene expression through 
complex cellular signal transduction processes (Heyman et al., 1992). 
It is clear from the above discussion that the broad range of biological responses 
triggered by retinoids are not mediated by a common process involving all-trans-retinoic 
acid. The existence of various retinoid-binding proteins, distinct RAR and RXR 
subfamilies, their various isomers, their specific response to different retinoids, and 
specific interactions with various types of RAREs, indicate clearly that cellular responses to . 
retinoids are carried out by many very complex, but specificly organized signalling 
pathways. This inference is consistent with the enormous diversity of biological responses 
that retinoids elicit. 
Retinoid-modulated Cellular Enzymes and Effectors 
The number of cellular enzymes and effectors whose expression and/or activation 
are modulated by retinoids is numerous. Among them are ornithine decarboxylase and 
transglutaminase, cyclic AMP and cyclic AMP-dependent protein kinases, prostaglandins, 
plasminogen activator, collagenase, surface antigens, keratins, and glycoconjugates 
including glycoproteins, glycolipids and proteoglucans (see reviews by Sporn, 1984 and 
Chytil, 1984). The exact mechanisms by which retinoids exert their effects on the 
expression of these enzymes and effectors are largely unknown. The most well studied 
system thus far is the protein kinase C (PK-C) cascade, which is believed to play an 
important role in the carcinogenic process. The mechanism of retinoids in modulating PK-
C system may explain the preventive effect of retinoids in promoter-induced carcinomas 
(Lippman and Meyskens Jr., 1988). Phorbol esters, such as 12-0-tetradecanoylphorbol-
13-acetate (TPA), are the major tumor promoting agents. Thus, PK-C, the phorbol ester 
receptor, plays a critical role in the carcinogenic processes. Recent studies (Einat et al., 
1985; Nishizuka, 1986; Jetten and Shirley, 1986) have suggested that PK-C may mediate 
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many phorbol ester-promoted actions such as the induction of oncogenes, c-myc, c-fos, ~-
actin, omithine decarboxylase (ODC), which affects intracellular polyamine levels and 
epidermal growth factor (EGF) receptor down regulation. Exposure of quiescent 
fibroblasts to phorbol esters moves the cells out of the Go phase of the cell cycle, into the 
G1 phase (Pledger et al., 1978). Further stimulation by EGF drives the completion of the 
G1 phase, keeping fibroblasts in the division cycle rather than in a quiescent state. It has 
been hypothesized that retinoids may exhibit their anticancer activity by modulating PK-C 
activity (Jetten and Shirley, 1986, Lippman et al., 1987). Support of this hypothesis has 
come from a number of studies (Cope et al., 1986; Gensler et al., 1986; 1987). RA-
cRABP_complex has been shown to inhibit PK-C activity (Cope et al., 1986). The ability 
of some retinoids to prevent phorbol ester-induced ODC activity was found in correlation 
with their ability to inhibit tumor promotion (Verma et al., 1979). More convincingly, it 
was demonstrated that retinoic acid can block TPA-induced activation of PK-C (Taffet et 
al., 1983; Cope and Boutwell, 1985) 
CHAPTER III 
GROWTH-PROMOTING ACTIVITY 
Introduction 
Promoting normal growth in a biological system is one of the major functions of 
vitamin A (Coward, 1938; Wolbach, 1947). The phenomenon of growth is the result of 
cell growth and cell division. The importance of vitamin A in the early stage of embryonic 
development of birds and mammals has been known for decades (Juneja et al., 1964; 
Thompson et al., 1969). Depressed growth is one of the earliest and most reliable external 
signs of vitamin A deficiency. Vitamin A deficiency can be induced easily in early life, but 
is difficult to induce in mature individuals solely by dietary restriction of vitamin A 
(Johnson and Baumann, 1948). The use of a growth assay for the evaluation of vitamin A 
activity began in the early 1920s, and became a standard approach for evaluating the 
adequacy of vitamin A in diets (see review by Underwood, 1984). It is still popular even 
today (Anzano et al., 1974; Goodman et al., 1974; Stephens-Jarnagin et al., 1985; 
Goswami and Basumatari, 1988). Goswami and Basumatari (1988) reported that the initial 
vitamin A-deficiency led to the cessation of growth or weight loss in freshwater fish. 
Supplementation of vitamin A to the fish compensated the loss of body weight. Laboratory 
animals fed a vitamin A-deficient diet cease to grow when their initial liver reserves of 
vitamin A in the body are exhausted (Underwood, 1984; Goswami and Basumatari, 1988). 
After reaching a weight plateau, the animals rapidly lost weight and, if continued on 
vitamin A deficient diet, they eventually died. The initial decline in weight-gain may be the 
consequence of inefficient utilization of nutrients required for cell proliferation due to 
vitamin deficiency (Zile et al., 1981). Various kinds of physical, physiological and clinical 
27 
28 
stresses further increase the body requirement of vitamin A. For full utilization of vitamin 
A, other dietary components, such as vitamin E, proteins, fat, and zinc, must also be 
adequately provided (see review by Underwood, 1984). A recent study by Mobarhan and 
co-investigators (1992) demonstrated that hepatic cRBP was greatly reduced in zinc 
deficient rats. They suggested that zinc may be an essential element for the intra-cellular 
transport of vitamin A, in addition to its well-established role in the intercellular transport of 
vitamin A (Solomons and Russell, 1980; Smith et al., 1973). 
Comparative studies conducted using conventionally reared rats and germ-free rats 
fed with the same vitamin A-deficient diet strongly demonstrated that cessation of growth is 
the direct consequence of vitamin A deficiency (Beaver, 1961; Rogers et al., 1969). 
However, it is often difficult to separate the secondary physical signs of general health 
deterioration from those of vitamin A deficiency per se (Beaver, 1961). Commonly, 
animals do not die of vitamin A deficiency, but rather due to secondary infections (Rogers 
et al., 1971; DeLuca, 1979). This view was supported by the findings that animals 
suffering vitamin A deficiency were more susceptible to bacterial (Scrimshaw et al., 1968), 
viral (Nauss et al., 1985; Underdahl and Young, 1956), and parasitic (Sturchler et al., 
1985; Stoltzfus et al., 1989) infections. Furthermore, antibiotic supplements significantly 
reduced the rate of mortality (Anzano et al., 1979). 
In the present study, the ability of three synthetic heteroarotinoids, ethyl (E)-4-[2-
(3,4-dihydro-4,4-dimethyl-2H-1-benzopyran-6-yl)-l-propenyl]benzoate (abbreviated as 
DHA that stands for diary! heteroarotinoid), ethyl (2E,4E,6E)-3,7-dimethyl-7-(1,2,3,4,-
tetrahydro-4,4-dimethyl-6-chromanyl)-2,4,6-heptatrienoate (abbreviated as MHA-1 that 
stands for monoaryl heteroarotinoid-1), and (2E,4E,6E)-3,7-dimethyl-7-(l,2,3,4,-
tetrahydro-4,4-dimethyl-6-chromanyl)-2,4,6-heptatrienoic acid (abbreviated as MHA-11 
that stands for monoaryl heteroarotinoid-11), in supporting the growth of vitamin A-
deficient rats was tested. Two known growth-supporting vitamin A compounds, all-trans 
retinoic acid (RA) and all-trans retinyl palmitate (RP) were included in the study as positive 
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controls. The structures of these three heteroarotinoids, along with the two control 
retinoids RA and RP, are shown in Figure 3. Synchronous vitamin A deficiency was 
introduced in all rats before testing. Two approaches, namely periodic feeding and 
continuous feeding, were employed 
Materials and Methods 
Animals and Animal Care 
For the periodic feeding experiment, 24 male rats (Fisher-344, Charles River 
Breeding Laboratories, Inc., Wilmington, Massachusetts) were obtained one week after 
weaning. They were then 4 weeks of age, and were at their early growth plateau (weighed 
about 60 g). They were housed in groups of 2 in plastic cages, and were weighed every 1-
3 days. The weighing was done at approximately the same time of the day to avoid diurnal 
variations. The rats were reared on a vitamin A-deficient diet (Teklad Test Diets Inc., 
Madison, Wisconsin) available ad libitum. This vitamin A-deficient diet was specially 
formulated and the components are listed in Table I. A second growth plateau was reached 
when the rats were near maturity and weighed about 300 g. The rats were then separated 
individually into clear polycarbonate cages, and continued on the vitamin A-deficient diet 
for an additional 3 days. 
For the continuous feeding experiment, 40 male rats (Fisher-344, Sasco Inc., 
Omaha, Nebraska) were obtained at the age of 17 days with their dams (10 pups per dam). 
The dams were fed with the same vitamin A-deficient diet immediately after arrival. The 
pups were weaned at the age of 19 days, and maintained on the same vitamin A-deficient 
diet. The weanling rats were housed in groups of ten in plastic cages for another 2 1/2 
weeks before they were separated into individual cages They were weighed every 1-3 days 
· to monitor their vitamin A-deficiency status. This early vitamin A-deprivation period 
continued until they reached a growth plateau. They were then 6 weeks of age, and 
average about 160 g. 
Ethyl (E )-4-[2-(3,4-Dihydro-4,4-dimethyl-2H-
-1-benzopyran-6-yl)-1-propenyl]benzoate 
OH 
(2E,4E,6E)-3, 7-Dimethyl-7 "'.(l,2,3,4-tetrahydro-
-4,4-dimethyl-6-chromany 1);;2,4,6-heptatrienoic Acid 
Ethyl (2E,4E,6E)-3,7-Dimethyl-7-(1,2,3,4-tetrahydro-
-4,4-dimethy l-6-chromanyl)-2,4,6-heptatrienoate 
All-trans-retinoic Acid 
0 
II 
0-C-(CH:J 14-C~ 
All-trans-retinyl Palmitate · 
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MHA-11 
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Figure 3. The Structures ofHeteroarotinoids (DHA, MHA-Iand 
MHA-II), All-trans-retinoic acid (RA), and All-
-trans-retinyl Palmitate (RP). 
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TABLE I 
THE ·vrrAMIN A-DEFICIENT DIET 
(CUSTOM FORMULA# 1D 83081) 
COMPONENTS 
Casein, "Vitamin-Free" Test 
DL-Methionine 
Com Starch 
Cottonseed Oil 
Fiber (cellulose) 
Mineral Mix, AIN-76 (CAT. #170915) 
Biotin 
Vitamin B12 (0.1 % trituration in mannitol) 
Calcium Pantothenate 
Choline Dihydrogen Citrate 
FolicAcid 
Menadione Sodium Bisulfite Complex 
Niacin 
Pyridoxine HCl 
Riboflavin 
ThiaminHCl 
DL-Alpha Tocopheryl Acetate (1000 U/g) 
Vitamin D2 in Com Oil (400,000 U/g) 
g/KgFeed 
193.0 
3.0 
665.1343 
50.0 
50.0 
35.0 
0.0004 
0.0297 
0.0661 
3.4969 
0.002 
0.05 
0.0991 
0.022 
0.022 
0.022 
0.05 
0.0055 
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All the animals were kept in a special animal room, and were cared for according to the 
Guide for the Care and Use of Laboratory Animals (Prepared by The Institute of 
Laboratory Animal Resources, NIH Publication No. 86-23, Revised 1985). The room 
was controlled at a constant room temperature (about 72-75° F), and in a 12 hr light-12 hr 
dark daily cycle. Humidity was maintained between 30-70%. Air was well circulated with 
10-15 complete air changes per hour. Fresh food and water were given daily and were 
accessible ad libitum . Cages were bedded with hardwood Sani-Chips (P.J. Murphy 
Forest Products Co., Rochelle Park, New Jersey). This type of bedding chips are free of 
all splinters, shavings, slivers, excessive dust and all foreign matter. No detrimental effect 
of this bedding material on liver functioning has been found in tests. A wire base was also 
placed in each cage so that feces could drop through. The cages were placed side-by-side 
for visual and odor socialization, and were switched frequently in a random fashion to 
avoid any geographic variations. The room was cleaned daily and the cages were changed 
twice a week. 
Chemicals 
The heteroarotinoids DHA, MHA-I and MHA-II were synthesized and crystallized 
by the research group headed by Dr. Berlin (Waugh et al., 1985; Spruce et al., 1987). 
They were tightly capped under a N2 atmosphere, wrapped in aluminum foil, and kept in 
the dark at -20° C. All-trans-retinoic acid (RA) was a gift from Dr. W. E. Scott, Hoffmann 
La Roche, Inc. (Nutley, New Jersey), and was kept in the dark in a desiccator at room 
temperature. Another form of RA was stabilized gelatin beadlets containing RA at a level 
of 10.3% (Hoffmann-La Roche Inc., Nutley, New Jersey). RP was fed in stabilized 
gelatin-sugar-starch beadlets that contained not less than 4.45 mg RP per kilogram 
(Rovimix A-325, Hoffmann-La Roche Inc., Nutley, New Jersey). 
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Introduction of Synchronous Vitamin A-deficiency 
To induce a reliable synchronous vitamin A-deficiency, rats were fed first with diets 
supplemented with RA (45 µg RNrat/day, in the form of RA beadlets) and then with diets 
void of RA for two consecutive weight-gain and weight-loss cycles (Lamb et al., 1974). 
RA beadlets were premixed with the vitamin A-deficient diet at a level of 15 mg RA 
beadlets/Kg feed. Before the feeding experiments, a final period of RA beadlets 
supplementation was implemented to negate signs of the deficiency from the preceding 
deprivation phase. The gross appearances and body weight of the rats were closely 
monitored during this final period to ensure that none of the rats were inadvertently 
deficient and all of them had resumed norinal growth. For continuous feeding, the final 
RA supplementation period was 8 days. Most of the rats employed in the periodic feeding 
experiment were ill at the end of the long vitamin A-depletion period. Therefore, twelve to 
fourteen days of RA supplementation was required for the rats to recover. Rats were then 
grouped randomly into five groups (4 to 5 rats in each group) for the feeding assay. 
Stock Solutions and Peedin& Procedures 
Stock solutions of the test compounds were prepared in aldehyde-free ethanol at a 
concentration of 500 µg/ml. A 4-5 day supply was made each time. Stock solutions were 
tightly capped and stored at -200 C except at the times of diet preparation. To determine the 
average food consumption, 30 g of diet was given to each rat on the first day of the 
measurement, and residual food was weighed before the next feeding at approximately the 
same time in the next day. The average food consumption was the mean difference 
obtained by subtracting the weight of the residual diet from 30 g. It was estimated that each 
rat, on the average, consumed 25 g of diet per day in periodic feeding and 20 g per day in 
continuous feeding. A rat's appetite was directly related to its general health, which was 
directly affected in this experiment by the physiological vitamin A status (Anzano et al., 
1979), and was manipulated by the feeding patterns designed in the experiments. 
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Therefore, adjustments in the amount of diet given to the rats were made accordingly, 
depending on the appetites of the animals in a certain group. 
Fresh diets with various amount of drug supplementations were prepared daily by 
mixing measured volumes of stock solutions into the vitamin A-deficient diet while stirring. 
The ratio of vitamin A-deficient diet (g):volume of stock solution (µl) was determined by 
the level of dosing and the estimated consumption of diet per day per rat in a certain group. 
The diet was thoroughly mixed by stirring for about 2-3 min to ensure that all ethanol was 
evaporated. 
The experimental procedure of periodic feeding is shown in Figure 4. The group 
designations are explained as follows. Group RA was designated to the animals that were 
fed on diets with periodic supplementation or withdrawal of retinoic acid (100 µg/day). 
The time length of each supplementation or withdrawal period was determined by the status 
of the animals' weight-change. In like manner, rats of group RP, group DHA, and group 
MHA-1 were fed on diets with supplementation or withdrawal of retinyl palmitate (28 
µg/rat/day), DHA (100 µg/rat/day), and MHA-1 (100 µg/rat/day), respectively. Rats of 
Group CF (Cross-fed Group) were fed on diet supplemented daily with 100 µg of RA, 
DHA, and MHA-1 alternatively after each weight-loss phase. 
The experimental procedure of continuous feeding is shown in Figure 5. 
Compounds RA, DHA and MHA-11* were given to the animals in the amounts of 10, 100, 
or 200 µg/rat/day for an extended time period of 21-24 days. For example, rats of Group 
DHA-10 were given a diet supplemented with 10 µg ofDHA per day. 
The rats were weighed daily immediately prior to feeding. . Occasionally in the 
periodic feeding experiment, weighing was done once every few days when rats were in 
steady weight-gaining periods. The weighing and feeding were done each time at 
* The use of MHA-II, in stead of MHA-1, in the continous feeding experiment was simply because 
of the shortage of the MHA-1 supply. Owing to the existance of many hydrolytic enzymes in the digestive 
system, MHA-1 and MHA-11 should have the same effect since MHA-11 is simply the acid form of MHA-1. 
Figure 4. Diagrammatic Presentation of the Periodic F®<iing Experiment. 
RA: All-trans-retinoic Acid 
RP: All-trans-retinyl Palmitate. 
DHA: Diaryl Heteroarotinoid Ethyl (E)-4-[2-(3,4-Dihydro-4,4-dimethyl-2H-
1-benzopyran-6-yl)-1-propenyl]benzoate 
MHA-I: Monoaryl Heteroarotinoid Ethyl (2E,4E,6EJ-3,7-Dimethyl-7-
(l,2,3,4,-tetrahydro-4,4-dimethyl-6,chromanyl)-2,4,6-heptatrienoate 
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approximately the same time of the day to avoid possible diurnal variations. Any noticeable 
physical signs of vitamin A deficiency were recorded. 
Results and Discussions 
Synchronization Curves of Vitamin A Deficiency Induction 
In this study, we used the synchronous vitamin A deficiency induction method 
described by Lamb, et al. (1974). This method provided a practical approach in terms of 
the speed and the synchronism for inducing the deficiency status in the entire laboratory 
animal population. It also offered reliable cause-effect sequences in terms of the flexibility 
in controlling the onset of vitamin A-deficiency and the quick responsiveness of the animals 
to the changes of the dietary supplements. These two aspects are the two most important 
elements in establishing reliable methodologies in this type of study. 
Figure 6(a) and (b) show the synchronous vitamin A-deficiency curves of the rats 
used in the periodic feeding and continuous feeding experiment, respectively. Although the 
rats were in different stages of their life spans (rats in the periodic feeding experiment were 
twice as old compared to the rats in the continuous feeding experiment), the durations of 
each weight-gain and weight-loss phases and the patterns of the synchronization curves 
were very similar. It is clear that at a dietary RA supplementation of 45 µg/day/rat, the 
vitamin A-deficient rats quickly resumed normal growth. The rats in continuous feeding, 
for example, resumed an average growth rate of 3.1 g/day during RA supplementation, 
which was very close to the normal 3.8 g/day measured before the first growth plateau was 
observed. Withdrawal of RA resulted in the onset of the vitamin A-deficiency, which was 
indicated in the growth curves by a short plateau or a slightly declining phase. Normal 
growth resumed quickly (in about 1-2 days) after RA was added back to the diet. Such 
supplementation-deprivation cycles subsequent to the primary growth plateau were needed 
to promote a systemic, rather than a peripheral, vitamin A deficiency (Lamb et al, 1974). 
Residual amounts of growth-supporting retinoids in extrahepatic tissues were sufficiently 
Figure 6. Synchronization Curves of Vitamin A-deficiency Introduction. (a) Periodic 
Feeding Experiment. (b) Continuous Feeding Experiment. 
n: Number of Rats. 
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eliminated after two cycles with 45 µg of daily retinoic acid supplementation in each cycle. 
At the end of the last cycle, rats were synchronously vitamin A-deficient as their average 
body weight-gain had dropped to 0.9 g/day, and many of them had lost weight. 
Early nutritional treatment of animals is an important factor in the induction of 
vitamin A deficiency. Rats that were used in the continuous feeding experiment were 
subject to a diet deficient in vitamin A from 19 days of age. This restriction in vitamin A 
intake during early nourishment resulted in a much earlier onset of vitamin A deficiency 
when compared to the animals employed in the periodic feedings. The rats used in the 
periodic feeding experiment had not been on a vitamin A-deficient diet until they reached 
the first growth plateau. Due to the relatively high vitamin A storage in their bodies, these 
rats did not show a distinctive vitamin A deficiency until near maturity. This result was 
consistent with the earlier observations by Mason and Wolf (1935). They reported that 
when rats with a moderate storage of vitamin A and average weight of 40 g were put on 
vitamin A-deficient diet, the onset of the vitamin A-deficiency of these rats was much 
earlier than that of rats that had not been fed a vitamin A-deficient diet until they weighed 
around 50-75 g. Others also reported that induction of vitamin A deficiency by stringent 
dietary restriction of vitamin A was difficult in fullgrown individuals (Johnson and 
Baumann, 1948). 
Growth Patterns of Rats with Periodic Feedin~s 
Figure 7 to 11 show the growth curves of the vitamin A-deficient rats in response to 
periodic dietary supplementation and withdrawal of test compounds. Each experiment was 
carried out on a group of 5 animals and each data point given on the curves represents the 
mean of the weight-changes measured from five rats. Results in Figure 9 clearly indicated 
that DHA supplementation of 100 µg per rat per day was sufficient to promote a normal 
growth. The average growth rate of rats under DHA supplementation (3.8 g/day, 
extrapolated from the two DHA supplementation periods in Figure 9) was even higher that 
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Figure 9. Growth Curve of the Vitamin A-deficient Rats Fed with Periodic 
Supplementation (100 µg/day/rat) and Withdrawal of a Heteroarotinoid, Ethyl 
(E)-4-[2-(3,4-Dihydro-4,4-dimethyl-2H-1-benzopyran-6-yl)-1-
propenyl]benzoate (DHA). 
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the growth rate obtained from RA supplementation (2.4 g/day, extrapolated from the two 
RA supplementation periods in Figure 7 in the same manner). An irregular growth pattern, 
however, was observed in rats supplemented periodically with MHA-I (Figure 10). The 
rats either gained or lost weight irregularly or lost weight steadily in MHA-I 
supplementation periods. This distinctive difference between rats in response to DHA 
feeding and to MHA-I feeding was again observed in cross-fed rats (Figure 11). During 
the two MR.A-I supplementation periods, the rats lost weight dramatically, while during the 
DHA feeding, the rats gained weight. The positive growth rate of DHA feeding in cross-
fed rats was 1.7 g/day, again higher than that of RA feeding (1.3 g/day), although the 
difference is insignificant in this case. A different growth pattern emerged from rats 
supplemented with retinyl palmitate (RP). It seemed that rats could live normally and 
indefinitely after only a 5-day supply of RP at 28 µg per day, if other nutrients were held 
sufficient (Figure 8). This result demonstrated that retinyl palmitate was a very good 
source of vitamin A, and could be stored as a long-term vitamin A source. By the same 
token, however, RP was not a good control agent in this type of study. Its long-term and 
nearly irreversible effect makes it undesirable since flexibility in controlling growth pattern 
by manipulating dietary supplements is required in this type of experiments. RP, therefore, 
was not used in the later experiments. 
Growth Patterns of Rats with Continuous Feedin~s 
Figure 12, 13 and 14 show the growth curves of the vitamin A-deficient rats 
supplemented daily with either 10, 100 or 200 µg of test compounds. Over a continuous 
25-day dietary supplementation period, neither DHA nor MHA-Il at the level of 10 
µg/day/rat was sufficient to support growth (Figure 12). While DHA apparently sustained 
positive growth for about 2 weeks, rats fed with 10 µg Pill per day began to lose weight 
5-6 days after the feeding started. Despite the difference in timing, the rates of weight-loss 
between the two groups were very similar, with -2.4 g/day for DHA-fed rats and -2.0 
Figure 12. Growth Curves of Vitamin A-deficient Rats Each Fed with Continuous Daily 
Supplementation of 10 µg of RA, DHA, or MHA-11, Respectively. 
RA: All-trans-retinoic Acid. 
DHA: Ethyl (E)-4-[2-(3,4-Dihydro-4,4-dimethyl-2H-1-benzopyran-6-yl)-1-
propenyl]benzoate. 
MHA-11: (2E,4E,6EJ-3,7-Dimethyl-7-(l,2,3,4,-tetrahydro-4,4-dimethyl-6-
chromanyl)-2,4,6-heptatrienoic Acid. 
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Figure 13. Growth Curves of Vitamin A-deficient Rats Each Fed with Continuous Daily 
Supplementation of 100 µg of RA, DHA, or MHA-II, Respectively. 
RA: All-trans-retinoic Acid. 
DHA: Ethyl (E)-4-[2-(3,4-Dihydro-4,4-Dimethyl-2H-1-benzopyran-6-yl)-l-
propenyl]benzoate. 
MHA-II: (2E,4E,6E)-3,7-Dimethyl-7-(l,2,3,4,-tetrahydro-4,4-dimethyl-6-
chromanyl)-2,4,6-heptatrienoic Acid. 
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Figure 14. Growth Curves of Vitamin A-deficient Rats Each Fed with Continuous Daily 
Supplementation of 200 µg of RA, DHA, or MHA-II, Respectively. 
RA: All-trans-retinoic Acid 
DHA: Ethyl (E)-4-[2-(3,4-Dihydro-4,4-dimethyl-2H-l-benzopyran-6-yl)-l-
propenyl]benzoate. 
MHA-11: (2E,4E,6EJ-3,7-Dimethyl-7-(l,2,3,4,-tetrahydro-4,4-dimethyl-6-
-chromanyl)-2,4,6-heptatrienoic Acid. 
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g/day for MHA-11-fed rats, respectively (growth rates were extrapolated from the growth 
curves). It is very likely that a 10 µg daily supply of MHA-11 did not support growth at all 
since the rats were pretreated with 45 µg RA per day for 8 days before switching them on 
the test compounds (see previous description in Materials and Methods). The apparent 
growth for the 10 µg MHA-11-fed rats in the first 5-6 days may only reflect the residual 
effect of RA that remained in the body. The results also suggested that supplementation of 
RA at 10 µg/day level was not sufficient to maintain the normal growth although it was 
reported that the weight-maintenance dose for RA was 2 µg/rat/day by injection (Stephens-
Jamagin et al., 1985). The results obtained in this study probably did not conflict with the 
previous report, however, as the actual intake of RA for rats that were allowed to eat ad 
libitum was probably a great deal less than 10 µg owing to their generally poor health and 
accompanying poor appetite. In addition, some RA activity might be lost or reduced due to 
the oxidation of the compounds exposed to air and light. 
In contrast, a different picture emerged when rats were given 100 µg drug/day 
(Figure 13). The growth-promoting activity of DHA was very similar to that of RA at this 
level. The initial rate of weight-gain was 2.3 g/day for RA-fed rats and 2.1 g/day for 
DHA-fed rats. The growth pattern of the rats given 100 µg of MHA-11 daily was basically 
not different from that of the rats fed 10 µg MHA-11 per day except for a delay in the 
beginning of weight-loss (about 13 days after the feeding started), and a lowered rate of 
weight-loss (-1.3 g/day compared to -2.0 g/day for 10 µg MHA-11-fed rats). 
Figure 14 shows the growth curves of the rats with daily supplementation of 200 
µg of drugs. Both RA and DHA supported growth at this level. The average growth rate 
of the rats fed 200 µg of DHA per day (2.3 g/day) was actually higher than that of the rats 
fed 200 µg of RA per day (1.8 g/day). Two hundred micrograms of daily supplement of 
DHA stimulated growth in rats substantially, especially in the early stage with an initial rate 
of 3.6 g/day. In contrast, the growth curve obtained from the feeding of MHA-11 at the 
level of 200 µg/day was almost identical to that of MHA-11 feeding at 100 µg/day (see 
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Figure 13). The results again demonstrated that MHA-11 was not an effective growth 
promoter, although supplementation of MHA-11 at high dosages (>100 µg/day) maintained 
growth in rats for a short period of 1-2 weeks (at least partially the result of RA 
supplementation before MHA-:II feeding), no substantially long-term effect in terms of 
growth-supporting activity was demonstrated. 
It was noted that rats fed with 200 µg RNday did not gain more weight when 
compared to the rats fed with 100 µg RA/day (see Figure 13 and 14). Supplementation at 
the level of 200 µg RNday resulted growth retardation when compared to the growth curve 
of 100 µg RNday. This phenomenon of lower weight-gain at higher supplementation level 
may reflect the toxicity of RA. Likewise, fourteen days after the feeding began, there was 
a 7-day weight loss period in rats supplemented with 200 µg DHA/day (Figure 14). 
Although the rats in this group appeared to gain weight again after day 21, the overall slow-
down in weight gain after two weeks of DHA supplementation may also indicate a toxic 
effect at the level of 200 µg/day. Should the feeding period be extended, the rats in Group 
RA-200 and DHA-200 might display steady weight loss if this speculation of toxicity were 
true. Further experiments are needed to evaluate this possibility. 
Conclusions 
Results from both the periodic feeding and the continuous feeding experiment 
clearly demonstrated the potent growth-promoting activity of compound DHA. The activity 
of DHA was very similar to, in some cases even higher than that of RA. Firstly, both 
compounds at levels of greater than 10 µg/day/rat sustained steady weight-gain in vitamin 
A-deficient rats when their diet was supplemented either periodically or continuously with 
these two compounds. Secondly, similar growth rates were obtained with 100 µg of 
continuous daily supplementation of either RA or DHA, while greater growth rates were 
demonstrated in rats given 100 µg of DHA periodically or 200 µg of DHA continuously 
per day when compared to RA supplementations at the same levels. Thirdly, growth in rats 
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was depressed within 1 to 2 days after the withdrawal of either 100 µg of RA or DHA. 
This temporary growth depression could be rapidly reversed after dietary RA or DHA 
supplementation was resumed, and the normal growth rate was restored. These 
comparative effects of RA and DHA held true in cross-fed rats. In contrast, two monoaryl 
heteroarotinoids (MHA-1 and II) apparently did not support normal growth effectively, 
even at a supplementation level as high as 200 µg/day . Neither DHA nor RA could 
effectively support growth for more than two to three weeks when supplemented through 
diet at low dosage (10 µg/day/rat), although RA appeared to be able to sustain growth 
slightly longer. Results also indicated possible toxic effect when RA and DHA were 
supplemented at the level of 200 µg/day. 
CHAPTERN 
VAGINAL-SMEAR ASSAY 
Introduction 
The vaginal and uterine epithelia of mammals exfoliates continuously in response to 
the hormonal surges of the estrous cycle. Three basic types of cells are routinely found in 
vaginal washes: nucleated epithelia cells, cornified epithelial cells, and neutrophils 
(polymorphyl leucocytes) .. The estrous cycle consists of four successive stages, namely 
proestrus, estrus, metestrus, and diestrus, and normally requires four to five days in rats 
for completion. Each stage of the estrous cycle is identified by the predominant 
representative type(s) of cells present as well as those absent from vaginal washes. During 
the stage of proestrus, the vaginal smear is dominated by nucleated epithelial cells. The 
stage of estrus is the period of heat that lasts from 9 to 15 hours. During estrus, ovulation 
occurs and the epithelial lining of the vaginal mucosa is hyperplastic. As new cells 
accumulate in the epithelium, the superficial layers become squamous and cornified. The 
cornified cells are eventually lost into the lumen of the vagina. The vaginal smear at this 
stage therefore, consists of mainly cornified epithelial cells. Shortly after ovulation, 
metestrus occurs, lasting from 10 to 14 hours. A large number of neutrophils along with a 
few cornified cells are present in the vaginal lumen during metestrus. In the following 
diestrus stage, the vaginal mucosa is thin, and neutrophils migrate through the cell layers 
easily, producing a vaginal smear consisting almost entirely of neutrophils. Diestrus lasts 
from 60 to 70 hours. As diestrus progre&ses, neutrophils become fewer in number and 
show degenerative changes. 
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The timing of the estrous cycle can be influenced by external factors such as 
temperature, stress, presence of males, and nutritional status. Mason et al. ( 1935) reported 
that, as the result of vitamin A deficiency, the estrous cycle in rats became irregular, 
lengthened, and was associated with growth retardation . It has been known since the 
1920s that vaginal epithelial cornification is a very sensitive indication of early vitamin A 
deficiency, and that the retinoids, which have keratinization suppressing activity, reverse 
the cornification effect resulting from vitamin A deficiency (Evans and Bishop, 1922; 
Evans, 1928; Macy et al., 1927). A vaginal-smear method was developed by a number of 
researchers (Coward, 1929; Schmidt and Schmidt, 1930; Bauman and Steenbock, 1932; 
Coward et al., 1938) for the bioassay of vitamin A substances. The method, however, 
was considered insensitive and unreliable because of the endogenous ovarian hormone 
interference and oral administration of the retinoids. In the early applications of this 
method, the vaginal comification could be either the result of the stage of estrus ( estrogen 
influence) or vitamin A deficiency. Oral administration was associated with reduced 
bioavailability because much of the substance being tested might be poorly absorbed or 
destroyed in the gastrointestinal tract. In addition, direct effects of the test compounds on 
the vaginal epithelium could not be determined since a large percentage of the drugs 
absorbed would be distributed to all the tissues. 
The methodology and the sensitivity of this in vivo assay was greatly improved by 
using ovariectomized vitamin A-deficient animals (Pugsley et al., 1944; Clarke and Todd, 
1957), and by direct topical application of the test compounds (Kahn, 1954). In 
ovariectomized rats the comification status of the vaginal epithelium is solely determined by 
their physiological vitamin A status. In the early practice of this method, Mason and Wolfe 
reported that ovariectomy did not significantly change the time of the onset of the vitamin 
A-deficiency in ovariectomized rats when compared to their intact litter-mates given the 
same treatment (Mason and Wolfe, 1935). Therefore, the continual vaginal comification 
reported by those authors was not the result of the hormonal impairment, but a direct 
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consequence of vitamin A deficiency. Topical application of compounds exhibiting vitamin 
A-like activity upon the epithelium of the vagina reversed this effect, and the results 
correlated directly with the efficacy of the test substances (Mason and Wolfe, 1935). These 
findings promoted wide applications of this method in the quantitative determination of 
vitamin A and related compounds. With the development of more sensitive and accurate 
spectrophotometric methods for the quantitative determination of vitamin A compounds, the 
vaginal smear assay became nearly obsolete. Since the early 1980s, however, DeLuca and 
coworkers have used this method repeatedly in their studies (Sietsema and DeLuca, 1982; 
Skare et al., 1982; Miller et al., 1985). They reported success in the application of this 
method for testing the relative activities of small amounts of substances with vitamin A 
activity. Although a variety of in vitro assays have been developed which are 30- to 100-
fold more sensitive than the vaginal smear assay (Sporn, 1984), this in vivo method still 
has great merit as a screening method in retinoid research. 
The vaginal smear assay was used in the present study to test the ability of 
heteroarotinoids to reverse vaginal cornification and to compare the activity of 
heteroarotinoids with that of all-trans-retinoic acid (RA). The method was modified in an 
attempt to increase sensitivity and accuracy. 
Materials and Methods 
Chemicals 
The heteroarotinoids DHA and MHA-II (see their structures in Figure 2) were 
synthesized and crystallized by the research group headed by Dr. Berlin (Waugh et al., 
1985; Spruce et al., 1987). They were tightly capped under a N2 atmosphere, wrapped in 
aluminum foil, and kept in the dark at -20° C. All-trans-retinoic acid (RA) was a gift from 
Dr. W. E. Scott, Hoffmann La-Roche, Inc. (Nutley, New Jersey), and was kept in the 
dark at room temperature. 
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Animals and Diets. 
A diagrammatic representation of the· feeding and the experimental procedure is 
shown in Figure 15. Forty female rat pups (Fisher-344, Sasco Inc., Omaha, Nebraska) 17 
days of age, were obtained in three separate batches along with their dams. The dams were 
fed a vitamin A-deficient diet (TABLE I) immediately after arrival. The young rats were 
weaned at the age of 19 days and fed the same vitamin A-deficient diet. The animal housing 
facilities and care procedures were the same as previously described (See Materials and 
Methods in Chapter Ill). Their growth and vitamin A-deficiency status were monitored 
every 1-2 days by examining the vaginal smears (see below for detailed procedures) and 
by checking their weight changes. The rats were maintained on the vitamin A-deficient 
diet until their weight-change and their vaginal smears indicated that they had become 
vitamin A-deficient (about three to four weeks). The primary signs of vitamin A-deficiency 
included continuously comified vaginal epithelium, xerophthalmia (tearless, swollen and 
bloody eyelids), and cessation of growth, etc. Ovariectomy was performed near the end of 
this vitamin A-deprivation period. 
Ovariectomized vitamin A-deficient rats were used in the vaginal smear assays. At 
the completion of each assay, the rats were brought back to their normal rate of weight-gain 
by dietary supplementation with 45 µg RA/day/rat for 7-8 days. Withdrawal of this RA 
supplementation resulted in vitamin A-deficiency again in about 10-14 days, at which time 
the rats could be used in another round of VSA. None of the rats, however, were used 
more than three times. 
Sur~cal Procedures of Ovariectomy 
Estrogen-dependent vaginal opening in rats occurs at about 6 weeks of age, 
marking the onset of regular estrous cycling under the control of ovarian hormones 
(Baumann and Steenbock, 1932; Clarks and Todd, 1957). Estrous cycling was monitored 
by the vaginal smear assay (see below for detailed procedures). Ovariectomy was 
0 
Dams on vit.amin A-deficient diet 
10 20 30 40 
Ovaxiectomy 
Assay 
RA supplementation 
50 60 70 80 90 
Age of the Rats (Days) 
Vit.amin A-deficient diet 
100 
~ RA supplementation ( 45 _µ glday) 
Figure 15. Diagrammatic Presentation of the Experimental Procedure of the Rat 
Vaginal-smear Assay (VSA). 
RA: All-trans-retinoic Acid. 
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performed when rats were 7 .5-8 weeks of age, by which time almost all rats had started 
estrous cycling. Their average body weight was 100 ± 1.2g. Ovariectomy was performed 
as follows. Rats were lightly anesthetized with diethyl ether (EM Sciences, Gibbstown, 
New Jersey) in a closed container. They were then removed from the jar and placed on 
their back with anesthesia continued via an ether nose cone. The abdominal area was 
wetted with a 1:15 dilution of chlorohexidine diacetate (Nolvasan solution, Fort Dodge 
Laboratories, Inc., Fort Dodge, Iowa). A 3 x 3 cm square of abdominal hair coat, 
beginning just posterior to the umbilicus and centered on the mid line, was shaved. All 
surgical instruments were cold sterilized in chlorohexidine diacetate solution. The skin and 
linia alba, beginning approximately 0.5 cm distal to the umbilicus and extending 2.0 cm, 
were separately incised. The animal was rotated to lie on its right flank, the abdominal 
muscle elevated and the periovarian fat pad grasped. The ovarian pedicle with ovarian 
artery and the distal tip of the fallopian tip were clamped as one and tired with 4-0 silk 
(black braided type B, Ethicon, Inc., Somerville, New Jersey). The ovarian tissue and the 
adherent fat were severed distal to the ligature. The procedure was repeated on the right 
site by turning the animal on its left flank. Excised tissue was evaluated for completeness 
of removal of ovarian tissues. 
The abdominal muscles were closed with continuous interlocking sutures of 4-0 
nylon (1.5 Metric Black Monofilament Nylon, Cyanamid Canada Inc., Montreal, QUE., 
Canada). The skin was closed with simple interrupted 4-0 nylon sutures spaced at 4 mm 
intervals. The incision area was gently cleaned with diluted chlorohexidine diacetate, patted 
dry and sprayed with furazolidone (Topazone Aerosal Powder, Norden Laboratories, Inc., 
Lincoln, Nebraska). Skin sutures were removed in 7 days. 
Va1P,nal-smear Assay 
Smear Preparation. The procedure used in this study was a modification of the 
method described by Sietsema et al. (1982). Rats were slightly anesthetized with ether. 
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Vaginal smears were taken using a glass disposable pipet (Pasteur Pipet, 5 3/4 inches, 
VWR Scientific, Toronto, Ontario, Canada). The pipets were briefly fired at the tip prior to 
use to narrow the openings and smooth the edges. The vagina was gently flushed 2 to 3 
times with approximately 0.5 ml of distilled water. A small amount of the resulting cell 
suspension was placed on a microscope slide . Isotonic saline was not used in sampling 
because salt crystals remaining on the slides interfered with the examination of the cells. 
Smears were allowed to air dry undisturbed for about 3-4 hours, stained with 0.9% 
(mg/ml) methanol solution of Wright Stain (Sigma Chemical Co., St. Louis, Missouri) for 
2 min, and neutralized in pH 6.4, 0. lM phosphate buffer for 1 min. Slides were then 
rinsed gently with a slow steady flow of tap water, air dried completely, and covered with 
cover slips. Xylene (Fisher Scientific, Grade R, Fair Lawn, New Jersey) and Cytoseal 
280 (Staphens Scientific, Denville, New Jersey) were used as mounting solution and 
mounting medium, respectively. A phase contract microscope (Nikon 72739, Tokyo, 
Japan) was used for low (lOx) and medium (43x) power examination. Another phase 
contract microscope system (Nikon Biological Microscope Optiphot with 
Photomicrographic Attachment Microflex Model UFX-11, Tokyo, Japan) was used for 
further examination and photomicroscopy. 
Scorin~ Procedure. A numerical scoring system (Table II) was developed in an 
attempt to quantitatively measure the cellular changes in the rat epithelium. Scores (0-6) 
represent certain typical combinations of cells in the vaginal smears. This scoring system 
was a modification from the scoring systems used by Robson (Robson, 1938) and 
Sietsema et al. (1982). The modification consisted in the addition of scores given to 
situations where the content of nucleated epithelial cells was more than 25%. No scores 
were given to such situations in the study reported by Sietsema and co-workers (1982). 
From the author's experience, any given vaginal smear could be scored by one of the 13 
typical cell combinations shown in Table II. The greater the concentration of the comified 
epithelial cells in a vaginal smear, the higher the score that was given to the smear sample. 
TABLE II 
VAGINAL SMEAR SCORING SYSTEM 
Neutrophils 
(%) 
75 < X < 100 
25 < X < 75 
X:: 100 
X < 1 
75 < X < 100 
50<x<75 
50 <x <75 
0<x<25 
x<l 
x<l 
25 < X < 50 
x<l 
10<x<25 
x<l 
O<x<lO 
Epithelial Cells 
Nucleated 
(%) 
0<x<25 
0<x<25 
x<l 
20 < X < 80 
x<l 
0<x<25 
x<l 
0<x<25 
50 < X < 80 
25 < X < 50 
x<l 
5<x<25 
x<l 
0<x<5 
x<l 
Cornified 
(%) 
x<l 
0<x<25 
x<l 
0<x<20 
0<x<25 
0<x<50 
25 < X < 50 
25 < X < 75 
20<x<50 
50 < X < 75 
50<x<75 
75 < X < 95 
75 < X < 90 
95 < X < 100 
90 < X < 100 
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Score 
0 
1 
1 
1 
2 
2 
3 
3 
3 
4 
4 
5 
5 
6 
6 
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Highly comified vaginal epithelium in ovariectomized rats indicated a severe vitamin A 
deficiency status. Vitamin A-like compounds that achieved physiological concentrations in 
the vaginal epithelium would reverse the comification in a dose and potency dependent 
manner. In this situation, increased numbers of nucleated epithelial cells and neutrophils 
would be observed in the vaginal lumen. The relative activity of such a compound, at 
certain times after a specific dose was applied, was quantitated by a score that reflects the 
relative percentages of these cells in the entire vaginal lumen content. Therefore, the 
numerical scores represent progressive cellular changes in relation of one vaginal smear to 
another. 
A group of 4 to 5 rats was used for each test compound at each dosing level. As no 
significant correlation was found between the initial body weight of the animals and their 
response to a test substance in a preliminary study (Clarke and Todd, 1957), the animals 
were allocated to different treatment groups randomly regardless of their individual weight. 
The numbers of neutrophils, nucleated epithelial cells, and comified epithelial cells were 
carefully counted in three different viewing fields for each slide. The fields were chosen 
by initially determining the first viewing field at low power setting (lOOx), which was 
usually at the center of the smear with cells most evenly and densely distributed, and then 
moving horizontally and vertically the same distance from the first viewing point to locate 
the second and the third field. Cells were counted at medium power ( 430x) in all three 
fields. Thus, each slide had three scores based on the cell counts in three viewing fields. 
The three scores were then averaged to give the mean. All slides were counted in the same 
manner unless small alterations were made for counting poorly distributed and/or stained 
smears. For smears with low cell count and/or faintly stained, fields with the best visibility 
of the cells were chosen while conforming to the established method as much as possible 
for consistency. The final score for a compound tested at a specific dosing level was 
calculated by averaging the mean scores obtained from all the rats in the group dosed with 
C, 
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the compound at that level. Standard deviations and standard errors of the means were 
determined. Statistical comparisons were made according to Student's t -test. 
Dru~ Ap_plication Pm£edures 
Stock Solution frta,aration. For compounds RA and MHA-11 (MW= 300), 150 
µg (500 nmol) of each was weighed out using an automatic electrobalance (Cahn 29 
Automatic Electrobalance, Cahn Instrument Company, Paramount, California) and 
dissolved in 100 µl of aldehyde-free ethanol to make an initial stock solution oo-8 
moV2µ1). For compound DHA (MW = 350), 175 µg (500 nmol) was weighed out to 
prepare the initial stock solution. Serial dilutions of the compounds were made from these 
initial stock solutions oo-8 moV2µ1) by diluting to-fold at each time with aldehyde-free 
ethanol. All dilutions, with concentrations ranging from 1 o-9 to 1 o-14 moles per 2 µl, 
were prepared immediately before dosing and were kept at-200 C before the next dilutions 
were made. 
Dosin~ Solution Pre.paration and Administration, The dosing solutions were 
prepared by mixing 16 µl stock solution with 200 µl isotonic saline solution immediately 
before dosing. A total volume of 27 µl of this dosing solution (containing the test 
compound in the amount of 10-9 moles, 10-10 moles, and so on, at each dosing level) was 
administered to each test rat with the exception of the 10-8 mol application. Owing to the 
limited solubilities of the compounds in saline, an additional 24 µl of aldehyde-free ethanol 
was added when preparing the dosing solution for the 10-8 mol application, and a total 
volume of 30 µI of dosing solution (containing 10-8 moles of test compound) was applied 
to the vaginal epithelium of each rat . 
The drugs were applied intravaginally using an automatic pipet immediately after the 
first vaginal smear was taken (at time 0). Rats were under light ether anesthesia during 
dosing and in all the subsequent smear-taking procedures. The second vaginal smears 
were taken from the rats 18 hours after the drug application, and then every 24 hours 
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thereafter. A stretch of 6-7 days of continuous sampling was usually needed for each 
round of assay. 
Controls. Assay controls were run concurrently with the drug-testing assays. A 
blank dosing solution, a mixture of 25 µl saline and 2 µl aldehyde-free ethanol, was 
applied to each of the control rats with all the experimental procedures and treatments done 
in exactly the same manner. This negative control assay was done twice, with the first one 
at the beginning and the second one at the end of the entire VSA study (2.5 months apart). 
Results from the assays with RA, tested at the same and each dosing level as to the 
heteroarotinoids, served as reference points for comparisons between the three test 
compounds. Furthermore, each rat was its own control with respect to the comification 
status since they had exhibit vaginal smear scores of 5 or 6 (indicating complete or near 
complete comification status) for at least two consecutive days before they were employed 
in the assays. 
Results and Discussions 
Growth Rates 
The average weight-gain of the young rats during the last two weeks of the vitamin 
A deprivation period (before ovariectomy was performed) is plotted in Figure 16. The 
average rate of growth (2.1 ± 0.2 g/day) reflected a retarded growth since normal growth 
rate for young rats of 5-6 weeks of age is usually around 5 g/day. However, the growth 
rate indicated that the rats were still gaining weight quite steadily during this period. 
Random sampling of the vaginal smears indicated continuous estrous cycling. About a 
week later, the growth had almost ceased. The vaginal smears taken at this time showed 
continual cornification and the rats were ready for the assay. The average weight-gain was 
0.2 ± 0.3 g/day at the beginning of an assay. 
The length of time that each round of vaginal-smear assay required was usually 
between 6 to 7 days, during which time the vaginal smears were taken daily and the rats 
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were kept in a vitamin A-deficient status Towards the end of this time, the severity of the 
deficiency had worsened so that many rats appeared very sick. Most of them lost weight 
and showed swollen, bloody eyelids (the symptoms of xeropthalmia). Some rats 
developed respiratory difficulties, and diarrhea. Retinoic acid, equivalent to 45 µg per day 
in stabilized gelatin beadleds, was given to each rat immediately at the completion of an 
assay. On the average, about one week of retinoic acid supplementation reversed the 
vitamin A-deficient conditions and restored growth rate to normal. Two rats died of 
vitamin A deficiency-initiated complications. The average growth rate was 1.3 ± 0.1 g/day 
two days after the completion of an experiment. Though lower than the normal growth, 
this rate indicated the beginning of recovery from vitamin A deficiency. The rate of growth 
increased to 3.0 ± 0.1 g/day by one week after the rats were on the RA supplemented diet. 
The signs of xeropthalmia disappeared for most rats at this time. The above observations 
were consistent with the early observations reported by others (Baumann and Steenbock, 
1932; Aberle, 1933). 
Re.petitive Use of Rats 
After the rats recovered from vitamin A-deficiency, RA was removed from the diet 
to prepare the rats for another assay. On the average, the rats became vitamin A-deficient 
again in 10-14 days. In earlier studies of the vaginal smear assay, rats were used 
repeatedly for up to eight times (Pugsley et al., 1944). Although it was reported that the 
differences in the previous treatments, as well as the number of the previous treatments, 
had no significant effect on the successive assays, the time required to re-deplete the rats 
following the removal of a "maintenance diet that devoid of vitamin A" was decreased with 
successive assays (Clarke and Todd, 1957). The reason may simply be the fact that body 
retinol storage was further decreased, or even exhausted, in the successive assays. This 
phenomenon was not obvious in this study, perhaps due to the fact that no rats were used 
more than three times. 
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Vai:i,nal Smears 
As described earlier, the vaginal smear score is a relative measurement of the 
vaginal epithelial cornification status (see the section of Scoring Procedure for detailed 
description). Figure 17 through Figure 20 present the photomicrographs of four 
representative rat vaginal smears obtained from this study. The identities of these smears 
along with their scores are given in the legends. 
At the beginning of this study, the scoring system presented by Siesma and co-
workers (1982) was used. It was found later that their scoring system was insufficient in 
the present study because it does not include situations in which the percentage of nucleated 
epithelial cells exceeds 25% of the entire cellular content in the lumen of rat vagina. In a 
more recent work done by the same research group (Miller, 1985), a modified scoring 
system was used, in which the number of nucleated epithelial cells were not quantitatively 
differentiated from that of the neutrophils. The total content of these two types of cells in a 
vaginal smear was measured as non-cornified cells. This newest scoring system, although 
it is much simpler and less time consuming, was not adapted for the present study. A new 
scoring system was developed in order to measure those situations in which nucleated 
epithelial cells exceeded 25% of total cells present in the smears. In fact, these situations 
were often encountered (see Figure 18) and might be of additional physiological 
significance. 
It was reported that the absolute number of nucleated epithelial cells was reduced in 
ovariectomized rats as compared to that of intact rats (Mason and Wolfe, 1935). Nucleated 
epithelial cells were found predominant in the vaginal smears after the administration of 
vitamin A-active substances (De Venarizi and Montenegro, 1945). There are four 
possibilities that may result in large numbers of nucleated epithelial cells. a) Vitamin A-
like activity of test compounds stimulated both the epithelial differentiation and proliferation 
in such a way that large numbers of nucleated epithelial cells appeared in the epithelial 
tissues as the ultimate result of the activity. Recent studies have demonstrated that cell 
Figure 17. A Representative Vaginal Smear That Contains Entirely the Cornified Epithelial 
Cells. 
Magnification: 400x 
Identity: Control-II at Hour 42. 
Score: 6.0 
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Figure 18. A Representative Vaginal Smear That Contains a Large Number of the 
Nucleated Epithelial Cells. 
Magnification: 400x 
Identity: RA-13 mol/rat at Hour 42. 
(RA: All-trans-retinoic Acid) 
Score: 4.3 
• .. 
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Figure 19. A Representative Vaginal Smear That Contains a Majority of Neutrophils. 
Magnification: 400x 
Identity: DHA-8 moVrat at Hour 66. 
(DHA: Ethyl (E)-4-[2-(3,4-Dihydro-4,4-dimethyl-2H-1-benzopyran-6-yl)-
1-propenyl]benzoate) 
Score: 1.0 
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Figure 20. A Representative Vaginal Smear with the Co-existence of Three Cell Types: 
Neutrophils, the Nucleated Epithelial Cells and the Comified Epithelial Cells. 
Magnification: 400x 
Identity: DHA-14 mol/rat at Hour 138. 
(DHA: Ethyl (E)-4-[2-(3,4-Dihydro-4,4-dimethyl-2H-1-benzopyran-6-yl)-
1-propenyl]benzoate) 
Score: 2.7. 
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proliferation and differentiation can be mediated concordantly by retinoids, rather than only 
reciprocally as commonly believed (Marcelo and Madison, 1984). b) The test compounds 
might exhibit estrogen-like or progesterone-like hormonal effect. A situation similar to 
metestrus might be observed if the test compounds could partially mimic the action of 
estrogen on the estrus cycle. Robson (1937) reported that the vaginal comifying action 
produced by estrogens could be inhibited by the simultaneous administration of 
progesterone. Since the ligand-binding domain of recently discovered retinoic acid 
receptors (RARs) is similar to that of the steroid hormone receptors, speculations that the 
actions of retinoids may share some characteristics of steroid hormones may have some 
validity. DHA and MHA-Il might bind to steroid receptors to mimic some of the actions of 
steroid hormones, resulting in large number of nucleated epithelial cells. c) Estrous cycling 
might continue to some extent due to estrogen ( or other luteal hormones, such as 
progesterone) released from extra-ovarian sites, such as adrenal glands. Normally, small 
amounts of estrogen and progesterone are released from the adrenal (Turner, 1963). The 
removal of ovaries posts a negative feedback that stimulates the luteal hormone production 
in adrenal glands. d) Estrous cycling might continue due to incomplete removal of ovarian 
tissue. However; the possibility of a residual hormone-controlled estrous cycling is not 
likely in the present case as the typically persistent, rather than periodic, comification of 
vaginal epithelial tissue was observed for all the animals used in the assays. In addition, 
the time periods required for de-comification by dietary RA supplementation after the 
completion of an assay and for re-comification following the removal of RA supplement 
were almost the same for all treated rats. Such synchronous responses would not be 
possible if residual ovarian and/or adrenal tissue of each individual rat was supplying any 
estrogenic stimulus. 
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Time:eourse Curves of Va~nal Epithelial Re§Ponse 
In order to directly compare the relative activities of RA, DHA, and MHA-11, the 
time-course curves of vaginal response to the test compounds at each dose level are plotted 
in Figure 21 through Figure 27. The control curves are shown in Figure 28. The statistical 
analysis of the vaginal smear scores was summarized in Table III. Statistical significances 
in relative activities were compared with respect to that of time O for each compound at each 
dose level (p<0.1, 0.05, and 0.005). 
No response was observed in the control rats (Figure 28), which indicated that 
dosing solution had no effect on comifieci. vaginal epithelial. All three compounds, RA, 
DHA and MHA-11, were active, and their activities were comparable (Figure 21 to Figure 
27). The comparable activities of these three compounds were obvious, especially at high 
dosages. Overall, MHA-11 was slightly less active than RA and DHA. At dose ranging 
from 10-8 moVrat to 10-10 moVrat, the peak activity of MHA-11 was consistently lower 
than that of RA and DHA. Furthermore, the duration of the response did not always 
correlate with the dosages as other investigators have reported for some other retinoids 
(Sietsema, et al., 1982). 
Late Rea:lll)Carance of Neutrophils 
The activity curves obtained at lower doses (< 10-ll moVrat) revealed two 
phenomena that were not observed at high dosing levels (Figure 25 to Figure 27). First, at 
low dosing levels, the peaks of the activity shifted towards later time points, especially for 
the two heteroarotinoids. Secondly, there were repeatedly no clearly defined peaks of 
activities in the curves of low doses as compared to those obtained at the higher doses. The 
activity levels did not drop noticeably after the highest activity points were reached. The 
activity levels remained at about the same level, or in some cases increased, with the time 
basically because of the reappearance of large numbers of neutrophils in the smears. In 
some cases, excessive neutrophils appeared in only one smear. In others, the reappearance 
Figure 21. Time-course Curves of the Vaginal-smear Assay at the Dose of 10-8 mol/rat. 
RA: All-trans-retinoic Acid. 
DHA: Ethyl (E)-4-[2-(3,4-Dihydro-4,4-dimethyl-2H-1-benzopyran-6-yl)-1-
propenyl]benzoate. 
MHA-11: (2E,4E,6EJ-3,7-Dimethyl-7-(l,2,3,4,-tetrahydro-4,4-dimethyl-6-
chromanyl)-2,4,6-heptatrienoic Acid. 
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Figure 22. Time-course Curves of the Vaginal-smear Assay at the Dose of 10-9 mol/rat. 
RA: All-trans-retinoic Acid 
DHA: Ethyl (E)-4-[2-(3,4-Dihydro-4,4-dimethyl-2H-1-benzopyran-6-yl)-1-
propenyl]benzoate. 
MHA-11: (2E,4E,6EJ-3,7-Dimethyl-7-(1,2,3,4,-tetrahydro-4,4-dimethyl-6-
chromanyl)-2,4,6-heptatrienoic Acid. 
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Figure 23. Time-course Curves of the Vaginal-smear Assay at the Dose of 10-10 mol/rat. 
RA: All-trans-retinoic Acid 
DHA: Ethyl (E)-4-[2-(3,4-Dihydro-4,4-dimethyl-2H-l-benzopyran-6-yl)-1-
propenyl]benzoate. 
MHA-II: (2E,4E,6E)-3,7-Dimethyl-7-(l,2,3,4,-tetrahydro-4,4-dimethyl-6-
chromanyl)-2,4,6-heptatrienoic Acid. 
0 
-
1 0 
1 
~ 2 0 (.) 
r/'l 
~ 3 s 
r/'l 
4 ! 
5 c:1:::$ > 
6 t.~ 
0 
- 1 o Mol/Rat 
-
1 8 42 66 
-~ 
-0-RA 
- _. - DHA 
- - - - -El- - - MHA-II 
" 
" 
" ~1-----------~ 
90 11 4 138 
HOURS AFTER DOSING 
'° 0 
Figure 24. Time-course Curves of the Vaginal-smear Assay at the Dose of 1 Q-11 moVrat. 
RA: All-trans~retinoic Acid 
DHA: Ethyl (E)-4-[2-(3,4~Dihydro-4,4-dimethyl-2H-1-benzopyran-6-yl)- l-
propenyl]benzoate. 
MHA-11: (2E,4E,6EJ-3,7-Dimethyl-7-(l,2,3,4,-tetrahydro-4,4-dimethyl-6-
chromanyl)-2,4,6-heptatrienoic Acid. 
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Figure 25. Time-course Curves of the Vaginal-smear Assay at the Dose of 10-12 moVrat. 
RA: All-trans-retinoic Acid. 
DHA: Ethyl (E)-4-[2-(3,4-Dihydro-4,4-dimethyl-2H-1-benzopyran-6-yl)-1-
propenyl]benzoate. 
MHA-II: (2E,4E,6E )-3, ?-Dimethyl-7-(1,2,3,4,-tetrahydro-4,4-dimethyl-6-
chromanyl)-2,4,6-heptatrienoic Acid. 
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Figure 26. Time-course Curves of the Vaginal-smear Assay at the Dose of IQ-13 moVrat. 
RA: All-trans-retinoic Acid. 
DHA: Ethyl (E)-4-[2-(3,4-Dihydro-4,4-dimethyl-2H-1-benzopyran-6-yl)-1-
propenyl]benzoate. 
MHA-II: (2E,4E,6E )-3, 7-Dimethyl-7-(1,2,3,4,-tetrahydro-4,4-dimethyl-6-
chromanyl)-2,4,6-heptatrienoic Acid. 
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Figure 27. Time-course Curves of the Vaginal-smear Assay at the Dose of 10-14 moVrat. 
RA: All-trans-retinoic Acid. 
DHA: Ethyl (E)-4-[2-(3,4-Dihydro-4,4-dimethyl-2H-1-benzopyran-6-yl)-1-
propenyl]benzoate. 
MHA-11: (2E,4E,6EJ-3,7-Dimethyl-7-(l,2,3,4,-tetrahydro-4,4-dimethyl-6-
chromanyl)-2,4,6-heptatrienoic Acid. 
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Figure 28. Time-course Curves of the Vaginal-smear Assay Controls. 
The Controls Were Done Concurrently with the Drug-testing Assays with All 
the Experimental Procedures and Treatments Done in Exactly the Same 
Manner. Vaginal Smears Were Taken After the Administration of a Blank 
Dosing-solution: a Mixture of 25µ1 of Normal Saline and 2µ1 of 
Aldehyde-free Ethanol. 
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TABLE III 
SUMMARY OF VAGINAL-SMEAR ASSAY 
Test Dose No. of Rats Mean VSA Scores at Time (hour) 
Compound (Mol/Rat) 0 18 42 66 90 114 138 
Control-1 NIA 5 6.0±0.0 6.0±0.0 6.0± 0.0 5.9 ±0.1 6.0± 0.0 5.9 ± 0.1 
Control-2 NIA 5 5.1 ± 0.6 4.9 ± 0.6 5.3 ± 0.3 5.9 ± 0.1 5.5 ± 0.4 6.0± 0.0 
RA 10-8 5 5.3 ± 0.4 3.5 ± o.5h 2.6 ± 0.5a 1.6 ± 0.5a 2.7 ±o.9a 5.4 ± 0.4 
lQ-9 4 5.8 ±0.2 5.9 ± 0.1 4.7 ± 0.7c 2.2 ± 0.7a 4.5 ± 0.4h 4.5 ± 0.2h 
10-10 4 5.4 ± 0.3 5.4 ± 0.5 4.0 ± 0.9a 2.9 ± 0.8a 5.3±0.5 5.5±0.2 
10-11 4 5.7 ± 0.2 4.2 ± 0.7C 4.6±0.5 3.1 ± 0.8a 3.2 ± 0.7a 5.3 ± 0.4 
10-12 4 6.0±0.0 5.4 ± 0.3 3.3 ± 0.2a 4.2 ± 0.6a 4.3 ± 0.4a 4.7±0.6h 
10-13 4 6.0±0.0 5.5 ± 0.3 4.8 ± 0.4h 3.2 ± 0.5a 2.5 ± 0.4a 4.4 ± 0.4a 5.0±0.6C 
lQ-14 4 5.6±0.2 5.4 ± 0.4 4.5 ±0.6 4.5 ± 0.8 4.6±0.9 4.4 ± 0.5 
DHA 10-8 5 6.0±0.0 3.5 ± 1.oa 2.9 ± 1.oa 1.3 ± 0.2a 2.5 ± 1.1a 3.8±1.lC 
10-9 4 5.5 ± 0.5 4.6±0.9 4.4 ± 0.3 2.3 ± 0.9a 4.5 ± 1.0 5.6 ± 0.3 
10-10 5 5.9 ± 0.1 4.0 ± 0.9h 4.3 ± 0.3h 2.7 ± 0.8a 3.1 ± 0.5a 5.0± 0.2 
10-11 5 5.7 ± 0.1 4.7 ± 0.4 3.9 ± 0.7h 4.4 ± 0.7c 2.8 ± 0.5a 3.5 ± 0.4a 
10-12 4 6.0±0.0 4.7 ± 0.8 3.8 ±0.2h 2.9 ± 0.9a 3.9 ± 1.0h 3.9 ± 0.5h 
10-13 4 5.2 ± 0.4 4.4 ± 0.7 3.9 ± 1.0 4.1 ± 0.7 3.1 ± 0.5h 3.8 ± 0.5 3.8 ± 0.6 
10-14 6.0±0.0 5.2 ± 0.5 4.5 ± 0.3h 3.4 ± 0.3a 4.3 ± 0.5h 4.8 ± 0.7C 3.9 ± 0.6a -4 0 
-
Test Dose No. of Rats 
Compound (Mol/Rat) 
MHA-11 10-8 
10-9 
10-10 
10-11 
10-12 
10-13 
10-14 
VSA - Vaginal-Smear Assay 
RA: All-trans-retinoic Acid 
5 
5 
5 
4 
4 
4 
5 
0 
5.7 ± 0.2 
5.1 ± 0.4 
5.9± 0.1 
5.4 ± 0.3 
6.0±0.0 
5.6±0.2 
5.8 ±0.1 
TABLE m (Continued) 
Mean VSA Scores at Time (hour) 
18 42 66 90 114 138 
3.6± 0.8b 2.5 ± 0.5a 2.1±0.la 2.6 ± 1.2a 5.1 ± 0.6 
4.2±0.2C 4.7 ±0.4 2.5 ± 0.9a 4.7 ± 0.6 5.5 ± 0.3 
4.1 ± 0.5b 3.7 ± 0.6a 3.3 ± O.la 5.1 ± 0.1 5.1 ±0.2 
5.4 ± 0.5 5.2±0.6 3.9 ±0.7C 2.9±0.9a 5.1 ± 0.1 
5.2±0.8 4.4 ± 0.6C 4.9 ± 0.4 3.6± 0.7a 2.9±o.5a 
5.0±0.4 3.8 ± 0.4b 4.2 ± 0.5C 3.3 ± 0.6a 3.4 ± 0.5a 4.0±0.8h 
5.0±0.3 5.0±0.8 5.0±0.7 5.1 ± 1.0 5.6±0.2 
DHA: Diaryl Heteroarotinoid Ethyl (E)-4-[2-(3,4-Dihydro-4,4-dimethyl-2H-1-benzopyran-6-yl)-1-propenyl]benzoate 
MHA-11: Monoaryl Heteroarotinoid (2E,4E,6E)-3,7-Dimethyl-7-(l,2,3,4,-tetrahydro-4,4-dimethyl-6-chromanyl)-2,4,6-
-heptatrienoic Acid 
NI A - Not Applicable 
a Significantly Different Compared with the Score at Time O at 99% Confidence Level 
b Significantly Different Compared with the Score at Time O at 95% Confidence Level 
c Significantly Different Compared with the Score at tTme O at 90% Confidence Level -s 
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of neutrophils was persistent for a few days. A typical smear of such a case is shown in 
Figure 29. This phenomenon was apparently more obvious for the two heteroarotinoids, 
DHA and MHA-II. 
A review of the available literature involving the vaginal smear assay made it clear 
that the phenomenon regarding the reappearance of neutrophils was more common than 
expected. Similar observations were reported by a number of investigators since the early 
1930s (Baumann and Steenbock, 1932; Aberal, 1933; Pugsley et al., 1944; DeLuca, 
1985). Speculative rationale, however, was lacking in those reports. The neutrophils 
observed at this time were distinguishable from those in the high neutrophils-containing 
smears that represented high decornification activities ( compare the neutrophils shown in 
Figure 19 and Figure 29). The reappearing neutrophils were morphologically more 
degenerative, and were often accompanied by large amounts of debris and colloidal 
materials. In another words, they may very likely reflect some pathologic changes as the 
result of vitamin A-deficiency. 
Aberle (1933) reported that when vaginas of vitamin A-deficient rats were 
sectioned, 15% of the rats had developed necrosis in the mucosa. Leukocytes could be 
seen migrating between the comified cells in 60% specimens of the intact mucosae. It is 
possible that a new and different mechanism might have been involved. Another 
possibility is that an excessive number of neutrophils might be the result of vaginal 
infection (Pugsley et al., 1944). When the epithelium becomes cornified, the vagina 
becomes very dry. Although every precaution was exercised when taking the lavage in 
order to prevent trauma to the mucosa of the vagina, the tissue might still become irritated 
and infected. Regional infection could be the cause of the presence of a large number of 
neutrophils migrating into the lumen of the vagina. Whatever the cause might be, since the 
scoring system does not distinguish neutrophils at different stages of development, this 
phenomenon was sometimes quite misleading in the measurement of vitamin A-like 
activities by the scoring system used in this study. 
Figure 29. A Representative Vaginal Smear with Reappearance of Neutrophils. 
Magnification: 400x 
Identity: DHA-14 moVrat at Hour 138. 
(DHA: Ethyl (E)-4-[2-(3,4-Dihydro-4,4-dimethyl-2H-1-benzopyran-6-yl)-
1-propenyl]benzoate) 
Score: 4.0 
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Dose-response Curves 
The responses of the rat vaginal epithelia to the compounds at 18 hours after the 
drug administration were generally not significant statistically except for those at the high 
dosing level (see Table III). Tissue irritations, resulting from drug applications, might 
contribute to the apparent responses at this early stage. In most cases, the responses first 
became significant at 42 hours, and peaked at about 66 hours (see Table III). The dose-
response curves of the test compounds at 66 hours after dosing are plotted in Figure 30. It 
is demonstrated from these computer-generated best-fitted curves that, overall, compound 
DHA was more active than RA, while compound MBA-II was less active than RA. The 
difference in activity was more significant at lower dosing levels. The relative activities of 
the test compounds were compared by means of their ED50 values, the effective dose at 
50% maximum activity level. ED50 is often used in drug evaluations. An ED50 value in 
this study is the molarity of a retinoid required to reverse the vaginal epithelial cornification 
by 50% from its maximum cornification status. The ED50 values were determined on the 
dose-response curves from the point at which the curve crosses the vaginal smear score of 
3, and were listed in Table IV. The relative potencies determined from the ED50 indicated 
that the biological activity of compound DHA, in terms of stimulating epithelial 
differentiation in rat vaginal tissue, was comparable to that of RA, while that of MBA-II 
was about 10-fold less active when compared to RA. 
Mechanism of Action 
That vitamin A plays an important role in protein synthesis and protein metabolism 
was suggested nearly 57 years ago to explain the action of vitamin A-active compounds 
observed in the vaginal smear assay (Mason and Ellison, 1935). However, to date no 
systematic research data addressing this problem are available. Extensive investigations, 
however, have revealed substantial evidence regarding the regulatory effect ofretinoids on 
epithelial differentiation of other tissues~ most representitive of which is trachea (Shapiro, 
Figure 30. Dose-response Curves of the Vaginal-smear Assay at 66 Hours After the Drug 
Administration. 
RA: All-trans-retinoic Acid 
DHA: Ethyl (E)-4-[2-(3,4,-Dihydro-4,4-dimethyl-2H-1-benzopyran-6-yl)-1-
propenyl]benzoate. 
MHA-11: (2E,4E,6E )-3, ?-Dimethyl-7-(1,2,3,4,-tetrahydro-4,4-dimethyl-6-
chromanyl)-2,4,6-heptatrienoic Acid. 
1 
.. 
~ . -0-RA ~ • -DHA 0 2 
..d %, /D \.Q - -EJ - MHA-11 ~ / \.Q 
~ 
• e 3 -----. . ~ ~ / 
0 0 
u • 
--
(/.) 
/ ~ 4 .121 s 0.,...... /"' 
Cl'.) 0 
--
---ro 
--
-
D 
.s 5 -bl) D 
ro 
> 
6 
-1 4 - 1 3 - 1 2 - 1 1 -1 0 -9 -8 
Log (Moles) Administered Intravaginally 
-0 00 
TABLEN 
RELATIVE POTENCIES OF THE TEST COMPOUNDS OBTAINED 
FROM THE VAGINAL-SMEAR ASSAY 
Test Compound 
RA 
DHA 
MHA-11 
RA: all-trans-retinoic acid 
EDso (moVrat) 
4.0 X lQ-11 
1.0 X 10 -11 
4.0 X lQ-10 
Relative Potency 
1 
4 
0.1 
DHA: ethyl (E)-4-[2-(3,4-dihydro-4,4-dimethyl-2H-1-benzopyran-6-yl)-1-
-propenyl]benzoate 
MHA-II: (2E,4E,6E)-3,7-dimethyl-7-(l,2,3,4,-tetrahydro-4,4-dimethyl-6-
-chromanyl)-2,4,6-heptatrienoic acid 
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1986; Jetten, 1987). The process of comification and the process of keratinization in the 
terminal differentiation of epithelia are complex series of events. The role of retinoids in 
these processes is not fully resolved. Nevertheless, the production of glycoproteins, mucin 
in particular, and keratin species appears to be directly affected by vitamin A status 
(Shapiro, 1986). 
Keratins are proteins that form the 8-10 nm intermediate intracellular filaments of 
epithelial cells. There are approximately 20 keratins, a subset of which is expressed in any 
given epithelial cell type depending on its state of growth and differentiation (Edmondson, 
et al., 1990). Therefore, the expression of certain keratins serves as a biological marker 
reflecting the type and the differentiation state of epithelial cells. The normal 
tracheobronchial epithelium consists of three major cell types: ciliated cells, basal cells and 
a variety of secretory cells. During Vitamin A deficiency, the epithelium undergoes 
hyperplasia followed by squamous metaplasia at the levels of the basal cells. The outmost 
layer of these squamous cells constitutes a fully comified surface with numerous keratin 
filaments (Wong and Buck, 1971; Evans et al., 1986). A recent in vitro study with 
hamster tracheal epithelial (HTE) cells indicated that the complex keratin synthesis pattern 
with the expression of specific keratins characteristic of lesions of squamous metaplasia 
was observed under vitamin A-deficient conditions. In contrast, fewer and simpler species 
of keratins were formed in HTE cells cultured in vitamin A-supplemented medium 
(Edmondson et al., 1990). Synthetic retinoids have also been shown to affect epithelial 
keratinization processes. Madison et al.(1981) reported that the aromatic retinoid Ro 10-
9395 inhibit both epidermal keratinocyte proliferation and specific differentiation in vitro .. 
Arotinoid Ro-1698 was shown to significantly reduce the synthesis of non-covalently and 
disulfide cross-linked keratins, while enhancing the synthesis of keratohyalin granule-
associated proteins that were thought to be relevant in the effectiveness of retinoid treatment 
of psoriasis (Stadler et al., 1984). 
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An antagonist effect of retinoids on estrogen-induced keratinization is also possible. 
Kahn pointed out that the inhibition of vaginal response to estrogen by vitamin A may 
suggest certain intimate relationship between the hormone and the vitamin (Kahn, 1954). 
The recent discovery of the structural similarities between nuclear retinoic acid receptors 
(RARs) and steroid hormone receptors may suggest that retinoids and steroids might share 
certain receptors, although there are no apparent chemical similarities between retinoids and 
steroid hormones. This possible antagonism between retinoids and estrogen was also 
suggested in a very recent study. Fontana et al ( 1992) demonstrated that retinoic acid 
inhibited estradiol-induced expression of the transforming growth factor a (TGF-a) and 
pS2 gene in a breast carcinoma cell line. On the other hand, the expression of retinoic acid 
receptor transcripts was reduced by estradiol. The presence of retinoic acid, however, 
prevented this reduction. 
Retinoids modulate the synthesis and secretion of many cell surf ace 
glycoconjugates (Shapiro, 1986). The effect of vitamin A on cell surface mucous 
glycoproteins (mucins) was studied by Clark and Marchok with rat tracheal epithelial 
tissues (1979a and 1979b). They found that, overall, vitamin A stimulated mucin 
production, but the quantity and identity of mucin species were dependent upon the vitamin 
A concentrations in the media. In the absence of vitamin A, the epithelium became 
keratinized and squamous with little mucus secretion. Similar effects were also observed 
by Jetten and co-workers (Jetten et al., 1986). A culture system using rabbit tracheal 
epithelial cells were developed to investigate the stimulatory effect of secretory phenotypes 
by vitamin A and its synthetic analogs. Release of mucous glycoproteins was 
demonstrated upon retinoid stimulation and was concentration dependent. Most strikingly, 
the arotinoid Ro 13-7 410 was shown to be effective at concentrations as low as 10-12 M. 
From the above discussion, it appears quite clear that epithelial tissues, primarily 
tracheal epithelium, produce secretory cells in the presence of vitamin A-active retinoids, 
and become squamous and comified when depleted of vitamin A-active retinoids. The 
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effects of retinoids on the synthesis of keratins and mucins are important aspects 
responsible for this phenomenon. 
Only MHA-11 was tested in this assay because of the shortage in MHA-I supply. It 
is believed, however, that the effect of MHA-I and MHA-11 should be very similar in this 
assay because MHA-Il is the acid form of MHA-1. Miller and co-workers (1985) reported 
that methyl retinoate was equipotent compared with all-trans-retinoic acid in vaginal smear 
assay. They suggested that either the methyl ester is as active as retinoic acid without 
change or sufficient esterases are present in the vaginal lumen to convert methyl retinoate 
into the free acid. 
Conclusions 
The vaginal smear assay measures the changes occurring in the sensitive vaginal 
epithelial tissues in response to the regional supply of vitamin A-like compounds. The 
vaginal epithelium of a vitamin A-deficient ovariectomized rat is marked by persistently 
comified epithelial cells that can be clearly observed in the vaginal smears. The increased 
thickness of the vaginal epithelium as the result of vitamin A deficiency is in accord with 
the increase in mitotic activity in the vaginal epithelium (Aberle, 1933), and with 
metaplastic alterations observed in other epithelial tissues (Wolbach and Howe, 1925). 
The anti-keratinization activity of heteroarotinoids was clearly demonstrated in this 
study. The reversal of keratinization, which led to the thinning of the vaginal epithelium 
and the occurrence of diapedesis, was measured by the disappearance of cornified epithelial 
cells and the appearance of large numbers of neutrophils and nucleated epithelial cells after 
a single application of a heteroarotinoid. Both monoaryl and diaryl heteroarotinoids are 
active. Comified vaginal epithelium as the result of vitamin A deficiency was reversed by 
dose levels as low as lQ-14 mol/vagina. The relative activity ofDHA is comparable or even 
slightly higher than all-trans-RA, while MHA is 10-fold less active that all-trans-RA. 
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Neutrophils were occasionally observed in the lumen of rat vagina 6-7 days after 
the drugs were applied. This phenomenon was more profound when animals were treated 
with the heteroarotinoids and at low dosing levels. The cause of this effect is unclear. 
The major desirable features of the vaginal smear assay can be summarized as 
follows: 
(1) Vaginal epithelial cornification of ovariectomized rats occurs before the 
appearance of other symptoms of vitamin A-deficiency, such as weight loss and 
xeropthalmia Therefore, severe vitamin A-deficiency can be avoided. 
(2) The onset of vitamin A deficiency judged by the continual vaginal cornification 
is more uniformly manifested among all test animals, i.e., less variation in the timing of 
the symptom appearance when compared to that of oth~ signs of vitamin A deficiency, for 
instance, the eye changes. 
(3) The use of ovariectomized vitamin A-deficient rats and direct topical 
administration of the test compounds makes the method more sensitive, more specific and 
reliable in terms of cause-effect relations involved in this assay. Vaginal smear 
cornification is not significantly influenced by other factors such as inherent growth 
capacities of the animals, general debility, and extraneous causes of irritations and 
infections. 
( 4) The response is rapid and easy to recognize. 
(5) The method is economical as rats are reusable, and the relatively simple 
procedure requires very little access to complicated and expensive equipment. 
(6) The method is simple to perform. 
The major setbacks of the method are: 
(1) Time consuming. The entire assay requites a considerable amount of tedious 
work. 
(2) Relative inaccuracy indicated by the relatively large standard deviations when 
compared with other in vivo bioassays such as growth assay. This problem was observed 
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in this study as well as in some early reports (Coward et al., 1935). A few differences may 
be accountable for this relative inaccuracy. First of all is the difference among rats. 
Because the rats were not all at exactly the same stages of vitamin A deficiency, they might 
have responded to the same treatment differently. The response was also affected by the 
general health of the rats. Secondly, variations occurred in the counting process. The 
actual counting of the cells is more error-bound than theoretically described in the method. 
The cellular content in the lumen of the rat vagina is complicated. There are more than three 
types of cells in the lumen of the vagina. Often it is quite difficult to distinguish one cell 
type from another, and the identities are not always easy to ascertain. The cells are also not 
evenly distributed. Therefore, the proportions of the cells can be quite different from one 
field to another. Furthermore, the cells vary in their degenerative stages, which is not 
distinguished in the scoring system. The inclusion of internal standards, such as retinoic 
acid used in this study, can alleviate the variations to a certain extend. More importantly, 
reducing the number of individuals who are involved in the actual "bench-work" of the 
experiment would be more effective in eliminating possible human bias. To be consistent, 
only one person should be assigned to the counting. In conclusion, the vaginal smear 
assay should not be used as a primary method in quantification. It is more desirable to be 
used in the measurement of relative activities. 
CHAPTERV 
HISTOPATIIOLOGICAL EXAMINATION OF TIIE EFFECTS OF 
RETINOIC ACID AND 1WO HE1EROAROTIN0IDS 
ON VARIOUS EPITIIELIAL TISSUES 
Introduction 
Pathologic alterations of various epithelial tissues as the result of vitamin A 
deficiency has been extensively investigated in the classic study of Wolbach and Howe 
(1925). They concluded that the effect of vitamin A deprivation is "the substitution of 
stratified keratinizing epithelium for normal epithelium in various parts of the respiratory 
tract, alimentary tract, eyes, paraocular glands and the genitourinary tracts". In general the 
sequence in which different organs exhibit tissue follows the order: the respiratory tract, 
the salivary glands, eye, the genitourinary tract, the paraocular glands and the pancreas. 
No changes were observed in the liver, parenchyma of the kidney, stomach, and intestine 
(Wolbach and Howe, 1925). According to Wolbach and Howe (1925) and Anzano et 
al.(1980), as the vitamin A deficiency progresses, widespread keratinization with or 
without squamous metaplasia of the ducts and antrophy of gland tissues proceed, followed 
by edema, degeneration of secretory acinar cells of the submaxillary gland, and reduction 
of mucin formation in acinar cells of the sublingual gland. The epithelial cells become 
separated from their acini, the nuclei of the cells degenerate, the cells become rounded, 
vacuolated, and eventually comified. Manifestations of atrophy include an increase in 
interlobular spaces, fibrosis, dilatation of ducts, and eventually cyst formation and 
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suppuration. Infiltration of lymphocytes, plasma cells and polymorphnuclear leucocytes 
usually indicates a late stage of vitamin A deficiency, when infections often occur. 
Wolbach and Howe also concluded that the stratified keratinizing epithelia 
( epidermoid metaplasia) primarily resulting from vitamin A deficiency are identical in 
appearance in all locations, and the keratinized cells arise from focal proliferation of basal 
cells. In addition, increases of chromatin and in the size of nuclei are among the early 
morphological changes (1925, 1928). This premise was challenged later when marked 
decrease in the replication of columnar secretory (mucous) cells of the tracheal epithelium 
were observed, while the replication of the basal cells continued (McDowell et al., 1984a). 
Therefore, the "hyperplastic" appearance of basal cells was simply the result of a 
disproportional growth between the columnar secretory cells and basal cells. The same 
research group also reported that the flattening (from columnar to cuboidal cell type) and 
reduced DNA synthesis of the secretory cells, accompanied by multinucleation and 
dispersion of nuclear heterochromatin, are all primary effects of vitamin A deficiency 
(McDowell et al., 1987). They demonstrated that the basal cells clustered in groups, but 
did not differentiate into any cell types. It was the altered secretory cells that expressed the 
epidermoid (squamous) phenotype. They argued that epidennoid metaplasia is a secondary 
event that occurs late during vitamin A deficiency as an attempt for epithelial regeneration 
because morphologically it shares many characteristics of rapidly induced metaplastic 
lesions following injuries. In prolonged vitamin A deficiency, however, the restoration of 
a mucociliary state from metaplastic state is blocked, and the metaplastic phenotype persists 
(McDowell et al., 1987). 
Studies have shown that retinoids are important in maintaining normal growth, 
shape and differentiation of epithelial tissues, as well as in the recovery of epithlial tissues 
from pathologic injuries following vitamin A deprivation (Wolbach and Howe, 1932, 
Anzano et al, 1980; McDowell et al., 1984b). The present study reports the effect of two · 
heteroarotinoids in comparison with that of all-trans-retinoic acid in this regard. Vitamin A-
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deficient rats were fed through dietary supplementation with three compounds at various 
dosing levels for an extended period of time. Animals were then sacrificed. Tissues 
containing representative epithelial linings.were stained sectioned. Morphological and/or 
pathological effects on various epithelial tissues resulting from the primary vitamin A 
deficiency, the ability or the inability of the test compounds to replace the complete 
physiological effects of vitamin A, and the direct toxicity of the compounds were evaluated. 
The effects of the different test compounds (inter-compound comparisons), and of the same 
compound but with different dose levels (intra-compound comparisons) were compared 
both quantitatively and qualitatively. 
Materials and Methods 
Animal Preparation 
The rats that were used in the continuous feeding experiment (Chapter III) were 
employed in this study. Detailed description of the rats, animal care measures, and feeding 
procedures of the vitamin A-deficient rats are referred to Materials and Methods in Chapter 
m. Briefly, weanling rats (Fisher-344, Sasco Inc., Omaha, Nebraska) were weaned 19 
days post-natal and were maintained on a vitamin A-deficient diet (TABLE I) until they 
were 6 weeks of age. Rats ceased growth at the end of this vitamin A-deprivation period. 
They were then maintained on the same diet but first supplemented with and then lacking 
retinoic acid (RA 45 µg/rat/day) for two consecutive weight-gain and weight-loss cycles. 
After a final 8-days of RA supplementation, the animals were randomly grouped into nine 
groups with 4-5 rats in each group. Retinoic acid and two heteroarotinoids, DHA and 
MHA-11 (see Figure 3 for the structures), were given to the rats daily as dietary 
supplementations at dose levels of 10, 100 or 200 µg per rat per day. Each group of rats 
received only one type of supplement, for instance 10 µg DHA/day/rat (Group DHA-10), 
for a period of 25-40 days. At the end of this period, the animals, at 4 to 4 1/2 months of 
age, were killed by diethyl ether overdose (rats in Group MHA-II-10 were terminated on 
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Day 21 because they were moribund). Control animals were age-paired rats of the same 
strain (Fisher-344, Retired breeders, Sasco Inc., Omaha, Nebraska). They had been fed 
with normal laboratory rodent chow (Ralston Purina, St. Louis, Missouri). 
Necropsy Procedures 
An animal was washed on the external surface to thoroughly wet the haircoat. A 
midline incision through the skin and subcutaneous tissue was made from the apex of the 
mandible to the pubis. The skin was separated from the underlying facia of the external 
muscles and bluntly dissected laterally. The muscle layers were then incised from the apex 
of the mandible to the pubis, exposing the abdominal viscera and the thoracic cage. Heavy 
scissors were used to puncture the diaphragm and cut the rib cage, exposing the thoracic 
viscera. Throughout this chapter, fixative will always refer to phosphate buffered (pH 7.4) 
10% formalin. 
The trachea was grasped just anterior to the larynx, and the trachea and esophagus 
were freed from adherent tissue with dissection posteriorly into the thoracic cavity. Here 
mediastinal attachment was dissected free, and the pluck was freed with the severance of 
the posterior vena cava and distal esophagus. The pluck was placed in a cold saline wash 
and then placed in toto into fixative. Hemostatic forceps were placed across the esophagus 
just distal to the diaphragm and across the distal-most portion of the colon to contain 
intestinal content. Tissue was severed on the distal side of each clamp. With elevation of 
the anterior forceps, the intestinal tract was freed from the omental attachments and 
dissected free from the abdominal cavity, and then placed in a cold saline wash and then 
placed in toto in fixative. Submandibular salivary glands were excised from both the right 
and left sides of jaw, hemisected in several places and placed in toto into fixative. The left 
and right adrenal glands were dissected free of mesenteric attachments and each gland was 
hemisected for penetration of fixative and placed in formalin. The left and right kidneys 
were freed of mesenteric tissue, the capsule was elevated off the surface of both organs. 
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The kidneys were halved from pole to pole and then three horizontal incisions were made in 
each to provide better penetration of fixative. The ventral prostatic tissue was dissected 
from its attachment to the urinary tract, hemisected and then placed in toto into the fixative. 
The urinary bladder was excised at the neck, incised for 3/4 of its length and placed in toto 
into the fixative. Each of the testis was removed from the scotral sac with a portion of the 
vas deferens. One half to 1 ml of formalin was injected into each of the testis before being 
placed in toto into the fixative. The left caudal lobe of the liver was excised and several 
generous longitudinal incision were made deep into the parenchyma to allow for optimal 
fixative penetration. After two weeks in fixative, the organs of interest were removed, 
washed with tap water and small sections of tissue were taken for paraffin impregnation. 
When possible, 3 to 5 mm thick sections were made, with the knife-facing surface, the · 
surface that was exposed to fixative originally. Sectioning was done to obtain 6 micron 
thick specimens and routinely stained with hematoxylin and eosin. 
While many organs were fixed, including the brain, spleen, pancreas and salivary 
glands, only those tissues with significant epithlial components and/or known to be 
affected by vitamin A deficiency were evaluated in this study. The tissues and the 
sectioning of the tissues are listed in Table V. 
Results and Discussions 
Gross Patholo&Y 
The external appearances of the rats varied in response to the different treatments. 
Rough, dull haircoat was generally observed in heteroarotinoids supplemented rats, but not 
in the RA supplemented rats. Crusted eyes with no secretions, pale lips, pinnea, and feet 
were mainly observed in Group DHA-10, occasionally in other groups. Elevated intra 
orbital area was repeatedly observed in Groups DHA-10 and MHA-II-10. Thickened soft 
tissues in these ares were not obvious in post mortem examination. Although skeletal 
changes in the scull were not measured, this phenomenon was believed to be the result of 
TABLEV 
TISSUES AND THE SECTIONING OF THE TISSUES 
IN THE HISTOPA TIIOLOGICAL STUDY 
TISSUE 
Kidney (rt) 
Testis 
Cuput Epididymus 
Prostate (ventral) 
Urinary Bladder 
Trachea 
Lung (rt middle lobe) 
SECTIONING 
Mid-portion, through pelvis, perpendicular to 
the long axis 
Five mm from caudal pole, perpendicular to 
long axis 
Three mm from cranial pole, perpendicular to 
long axis 
Five mm from cranial margin, transversely 
Two mm distal to the rounded apex, transversely 
Five mm distal to the larynx, transversely 
Five mm caudal to branch of right middle lobar 
bronchus 
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TISSUE 
Liver 
Gastrointestinal Tract 
a. Stomach 
b. Duodenum 
c. Jejunum 
d. Ileum 
e. Cecum 
f. Colon 
g. Esophagus 
TABLE V (Continued) 
SECTIONING 
Five mm distal to attachment of right madial lobe 
to right lateral and right caudate lobes 
Across junction of glandular and non-glandular 
portion 
One cm distal to pyloric sphincter 
Midway between pylorus and ileocecal valve 
One cm proximal to the ileoceral valve 
An 1 cm x 1 cm section on antimesenteric border 
One cm distal to the cecocolic valve 
Included in the cross section of trachea 
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an increased cerebrospinal fluid (CSF) pressure due to vitamin A deficiency (Nelson et al., 
1964). In studying young vitamin A-deficient rabbits that suffered hydrocephalus, Millen 
and Wollam (1956) reported that distorted bone growth in the skull resulted in the abnormal 
expansion of the animal's frontal area due to increased CSF pressure. The gaits were 
generally quite normal. Humped posture was seen in a number of rats. Teeth appeared 
normal in all the rats, but gums of three DHA-10 rats were gray in color. Post mortom 
examinations revealed atrophic adrenal glands in almost all heteroarotinoid treated rats, and 
sometimes in RA treated rats as well, regardless of dosages. The adrenal glands were 
mushy, much smaller than normal, and bead-shaped instead of normal triangle-shaped. 
The situation was worse in rats treated with MHA-II. Very little or none abdominal fat was 
observed in DHA treated rats. 
Histopathology 
The specific tissue pathology is described as follows. 
Respiratoty Tract 
Trachea. The effects of the drug treatment viewed in the tracheal sections were 
unremarkable. In one DHA-treated animal, some degenerate neutrophils were seen in the 
lumen but did not appear to have come from the local area. The lung section of this animal 
did not provide an etiology. In all groups there were representative animals which 
displayed some mild lymphocytic infiltration in the tracheal mucosa and occasionally the 
submucosa. There appeared to be good integrity of all cellular elements, with no evidence 
of squamous metaplasia. 
Lungs. In the lung sections viewed, no evidence of squamous metaplasia was 
found. Most treated and control rats displayed some degree of peribronchiolar lymphoid 
accumulation. In most cases, these were lymphoid in character but occasionally 
neutrophils and/or eosinophils were present in increased numbers. In none of these 
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sections could an etiology be located in the lumen of the bronchiole. A lack of capsule 
suggested that these were not the recognized peribronchiolar associated lymphnodes 
because the latter are extra-parenchymous and few in number. 
Male Genital Tract 
Prostate, In the cross section of the prostate gland (ventral prostate and 
occasionally including some of the lateral prostate), cells of the epithelial lining were mostly 
squamous to cuboidal. They were evaluated for lesions of the epithelial linings as well as 
the presence of secretory material in the cell lumen. While not enumerated, the number of 
mitotic figures were subjectively assessed for the different groups. 
All sections of the tissues from RA-treated rats had a homogeneous, acellular, 
eosinophilic material in the duct lumen (Figure 31). It was probably the normal fluid 
product of the epithelium. There was no inflammatory response in the RA rats and the low 
dosage (10 µg/day/rat) DHA rats. However, 50% of the DHA-100 and 100% of the DHA-
200 rats exhibited necrotic granulomatous lesions (small areas of granulated tissues 
associated with infections) within the tubular lumen. Inflammatory cells were essentially 
neutrophils or neutrophils and plasmacytes (Figure 32). In 50% of the DHA-200 rats, the 
tubular lumen was obliterated by hyperplastic growth of epithelial cells of a metaplastic 
nature. One out of four rats of the MHA-11-100 showed a granulocytic response mixed 
with metaplasia, and 75% of the MHA-11-200 rats showed a mixed granulocyte/lymphocyte 
inflammatory response with one of them (1/4) exhibiting metaplasia (Figure 33). 
In all drug-treated rats, the number of mitotic figures in the secretory epithelium of 
the prostate was greatly reduced or essentially absent, the number of cells with secretory 
substance was reduced to zero in most cases, and the epithelium tended to be much more 
squamous to cuboidal in nature rather than cuboidal to columnar when compared to the 
control group. In addition, the cell linings along the duct were thickened in 
heteroarotinoid-treated rats. 
Figure 31. The Epithelial Tissue of the Rat Prostate Gland. 
Identity: RA-200 
Magnification: lOOx 
RA: All-trans-retinoic Acid 
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Figure 32. The Epithelial Tissue of the Rat Prostate Gland 
Identity: DHA-100 
Magnification: 1 OOx 
DHA: Ethyl (E)-4-[2-(3,4-Dihydro-4,4-dimethyl-
-2H-1-benzopyran-6-yl)- l-propenyl]benzoate 
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Figure 33. The Epithelial Tissue of the Rat Prostate Gland. 
Identity: MHA-Il-200 
Magnification: 1 OOx 
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In evaluating these findings, one must consider that lesions may be due to: (i) a 
lack of vitamin A activity of a particular drug; (ii) the absence of adequate testosterone 
(based on paucity of Leydig cells in the testes); (iii) direct toxic effects of the agents. 
Obviously, combinations of these factors could exist with variations dependent upon dose 
levels. Chopra and Wilkoff reported that carcinogen-induced hyperplasia in the mouse 
prostate organ cultures was inhibited and/or reversed by a variety of retinoids ( 1977 a and 
b ). A more recent study showed that excessive vitamin A increased the risk of prostate 
cancer in elderly men (Kolonel et al., 1987). These varied accounts suggested that the 
effects of retinoids at different dose levels might be dramatically different. 
Epididymus. In this tissue, the epithelial lining was the focus of attention with 
secondary interest in the vascular endothelium. Inflammatory reactions of any nature were 
uniformly absent from all of the drug groups. Degenerate epithelial lining cells from the 
seminiferous tubules along with degenerate spermatazoa were uniformly present in either 
the epididymal tubular lumen and/or the vas tubular lumen. A peculiar interlumenal cystic 
structure (Figure 34) was found in representative rats of all the drug-treated groups at all 
dose levels. Epithelial pillars growing into the lumen closed upon themselves to form 
multiple cystic and ciliated-cell lined structures within the original lumen. All RA-treated 
animals, regardless of dose levels, showed a 100% incidence. A 7 5% incidence was seen 
in DHA-10, DHA-200 and MHA-11-100 rats. A 50% incidence was seen in DHA-100 and 
MHA-11-200 rats. 
The interlumenal cystic structure seen in this study resembled the morphological 
changes in the epididymis that Wolbach and Howe observed in their 1925 study, although 
they did not show the picture. The epithelial cells of the epididymis in vitamin A deficient 
rats increase in number, they described, " .. .inasmuch as they form a deep epithelium layer, 
often with large vacuoles between cells and occasionally with secondary gland-like 
formation of cells with cuticular borders bounding a lumen." If this is indeed the case, this 
(a) 
(b) 
Figure 34. The Epithelial Tissue of the Rat Epididymus. 
Identity: RA-200 
Magnification: (a) 40x 
(b) 200x 
RA: All-trans-retinoic Acid 
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observation seems to indicate that all three compounds at the doses tested are unable to 
function as vitamin A for maintaining a healthy epididymal epithelium in the rats. 
Tum. Overall, the size and volume of the testes of all groups appeared to be quite 
comparable. The drug treated groups, however, exhibited testes that were tan-brown when 
viewed from the external surface while those of the control group were white. In all drug 
treated groups, seminiferous tubules were essentially void of viable cellular elements and 
the basement membranes were collapsed into the center of the lumen. If cells were present, 
they were usually primary spermatogonia rather than Sertoli cells, based on morphology. 
These desquamated, degenerate cells were found in the lumen of the epididymis along with 
degenerated sperm. The intersitital spaces were acellular to a great extent though the 
capillary density appeared to be the same as in controls. Leydig cells were difficult to 
identify in many preparations and appeared to be devitalized based on staining properties. 
To summarize, the changes seen in the testes indicated atrophic alterations in the 
tissue. The phenomenon described above seems similar to the lesions resulting from 
vitamin A deficiency, which was described as such: when edema and atrophy of the testes 
reached extremes, the seminiferous tubules "seemed floating in a liquid medium" (Wolbach 
and Howe, 1925). 
Gastrointestinal Tract 
Esopha&us. Measuring keratin layers of the esophagus epithelium did not 
demonstrate any significant difference in any treatment group. There was no evidence of 
squamous metaplasia. 
Stomach. The level (average thickness) of keratinization of the non-glandular 
portion of the stomach (extension from the esophagus) was evaluated at its junction with 
the glandular portion. One test animal, which was clinically ill and moribund at the time of 
necropsy, had severe hemorrhagic gastritis, though this lesion was not considered an 
adverse effect of the drug as it appeared in a low dose animal but not at higher doses. 
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Duodenum. Evaluation of the villi length, mitotic numbers/villus and ratio of 
mucosa to submucosa in thickness, were unaffected by treatment when compared to 
controls. 
Jejunum. Evaluation of villus length, ratio of mucosa to submucosa and the 
occurrence of mitotic figures/villus were unaffected by treatment when compared to control 
animals. 
~- Evaluation of length of villi, the number of mitotic figures per villus and the 
ratio of the depth of mucosa to the depth of submucosa were unchanged parameters when 
compared to the control animals. Peyer's patches did appear to be greatly enlarge in all 
treatment groups compared to the control animals. The numbers of mucoid secreting cells 
in the drug-treated animals did not appear different from control animals. 
Cecum and Colon. There were no differences in the histology of these structures in 
the treated animals when compared to the control animals. 
It was noted that, for the majority of the animals in the treatment groups, there were 
no bacteria adherent to the mucosa or present in the lumen of the intestine, irrespective of 
the identity of the drug. In contrast, large colonies of various bacteria were found present 
in the lumen of the control animals (given regular rat chow as opposed to the synthetic 
diet), and were adherent to the mucosal surface. 
Others 
Liver. Cross sections of the liver were evaluated with respect to the epithelial cells 
of the bile ducts, the endothelial cells of the vessels (arterioles and veins), epithelial cells of 
the liver capsule and cell vitality in the periportal area (those most sensitive to xenobiotic 
and oxygen deprivation toxicity). 
There were no identifiable lesions with respect to the structures of interest in any of 
the three drug groups, irrespective of the levels of the agent in the feed. One animal in the 
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DHA-100 group had some focal fatty changes but this is consistent with animals of this 
age. Some were also seen in the control animals. 
Kidney. In all heteroarotinoid-treated rats, renal tissues with tan-brown, 
amorphous concretions that were intracellular in the proximal tubular cells as well as in the 
lumen of this segment of the tubule and collecting ducts were seen at all dose levels. While 
there was occasional eosinophilic, amorphous, non-cellular casts in a few of the control 
animals, the presence of these casts was greatly intensified in DHA, MHA-II and, to a 
lesser extent, RA treated rats. In all dose levels of the heteroarotinoids, there were 
scattered, focal areas of cellular basophilia and pyknosis indicative of dying or aged cells. 
These foci were not associated with inflammatory reactions and primarily were located in 
the cortical regions of the proximal tubular networks. In rats of DHA-treated groups, there 
was ample evidence of interstitial edema accumulation identified as clear, eosinophilic 
staining. 
Urinary Bladder. In this tissue, the transitional epithelium of the bladder was the 
primary focus. All RA animals showed focal, mild to moderate desquamation 
(inappropriate shedding or loss) of epithelial cells (Figure 35). In 75% RA-100 and 25% 
RA-200 rats, there was microscopic hemorrhage into the lumen of the bladder. All DHA-
10 rats had normal epithelial cells while there was mild focal desquamation in 50% DHA-
100 and 50% DHA-200 rats. Of the MHA-II-100 rats, 75% showed normal epithelia, 
while 25% had focal, very mild desquamation and clusters of cells with very pyknotic 
nuclei. Seventy five percent of the MHA-II-200 rats also appeared normal, while 25% 
showed metaplastic activity and some amorphous, granular eosinophilic material in the 
lumen. 
Rapid growth suggestive of neoplastic potentiality and desquamation was observed 
by Wolbach and Howe (1925) in vitamin A-deficient rats. However, extensive 
keratinization and dermoid cyst-like formation identified by these authors as pathological 
changes of vitamin A-deficiency were not displayed in this study. 
Figure 35. The Epithelial Tissue of the Rat Urinary Bladder. 
Identity: RA-200 
Magnification: 200x 
RA: All-trans-retinoic Acid 
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Conclusions 
It was the purpose of this study to examine the effect of dietary supplementation of 
three drugs, all-trans- retinoic acid (RA) and two heteroarotinoids (DHA and MHA-II), on 
the epithlial tissues that are most susceptible to vitamin A deficiency. Since all rats used in 
this study were vitamin A deficient prior to the drug treatment, normal epithelia observed in 
this study in the organ tissues that were reportedly injured by vitamin A deficiency would 
indicate recovery from the lesions. The findings are summarized as follows: 
1) Epithelia of all organs in gastrointestinal tract, respiratory tract and liver 
appeared normal. 
2) Slight atrophy in the kidney manifested as edema, amorphous concretions and 
cellular pyknosis in the proximal tubular networks was seen primarily in heteroarotinoid-
treated rats, and only occasionally in RA-treated rats. Edema was only seen in DHA-
treated rats. 
3) Moderate desquamation of epithelial cells was the main pathology observed in 
the urinary bladder. The situation was most severe in RA-treated animals, and less severe 
in DHA-treated animals than MHA..:treated rats. In addition, the effect was more profound 
in rats treated· at high doses. Twenty five percent of the rats dosed with MHA-11 
manifested slight atrophy. 
4) Severe pathologies of metaplastic, atrophic and inflammatory reaction were 
overwhelming in all three male genital organs examined. While no inter-compound 
differences could be demonstrated in the testes, the damage in the prostate gland was more 
severe in heteroarotinoid-treated rats than RA-treated animals, and the damage in the 
epididymis was greater in RA-treated rats than heteroarotinoid-treated rats. 
5) Intra-compound differences were generally not obvious. 
The characteristics of the changes observed in this study, such as edema, 
inflammation, atrophy and metaplastic growth, were all indications of vitamin A-deficiency; 
however, the location and the severity of the lesions are different from those simply 
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resulting from vitamin A deficiency. The changes seen in this study may reflect the effects 
of the drugs, or may be due to the lesions remaining from the previous vitamin A-
deficiency with the drugs causing no effects on them. It appears quite likely that 
heteroarotinoids have activities similar to that of RA in terms of their functions on epithelial 
tissues. The main organs where neither RA nor the heteroarotinoids tested herein could 
maintain the integrity of their epithelial tissues were the eye and those located in the 
genitourinary tract. 
CHAPTER VI 
MASS SPECTROMETRY ANALYSIS OF THE SYNTHETIC STANDARDS 
Introduction 
The metabolism of xenobiotic substances is essential to pharmacological and 
toxicological research. The metabolic pathways are usually complex, and the quantity of 
the metabolites is very small, often in a trace amount (Pudewicz and Straub, 1986). The 
identification of the metabolites is further complicated by the existence of complex 
biological matrixes (Pudewicz and Straub, 1986). A number of analytical methodologies 
have been developed to study drug metabolism (Frigerio and Ghisalberti, 1977; Coutts and 
Jones, 1980). Conventional methods usually involve many steps of metabolite separation, 
isolation and purification. HPLC is a good technique in purification.and separation, but it 
requires detectors of sufficient specificity to provide structural information (Hines, 1984). 
Application of any single type of spectroscopic analysis, such as NMR, usually requires 
substantial quantity of purified metabolites. The size, solubility restrictions, nonvolatile 
and unstable nature of most drugs and their metabolites, limit the utilization of the powerful 
technique of capillary gas chromatography/mass spectrometry (CGC/MS) in structure 
determination (Newton, 1990; Bellar and Budde, 1988). 
The complementary combination of HPLC separation and MS detection (LC/MS) 
with ultimate structural identification provides the method of choice for the analysis of 
complex drug metabolites (see review by Tomer and Parker, 1989). Various types of 
interfaces coupling HPLC and MS, such as thermospray and direct liquid introduction, 
have been designed and applied in the metabolism study of many types of drugs (Vestal, 
1984; Tomer and Parker, 1989). The rapidity and power of the LC/MS technique in 
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providing detailed structural information of drug metabolites was clearly demonstrated in 
the structure elucidation of various types of drug metabolites including N-oxides, sulfates, 
glucuronides, sulfoxides, decarboxylated products, taurine conjugates and dealkylation 
products (see review by Tomer and Parker, 1989). One of the greatest advantages of 
LC/MS is the direct analysis of the metabolites within a complex biological matrix without 
excessive clean-up and compound isolation (Blake and Beattie, 1989). 
The first application of mass spectrometry in the study of the metabolism of vitamin 
A (all-trans-retinol) and its related compounds was reported by Vecchi and co-workers 
(1967). The mass spectra of vitamin A and a number of its analogs were also obtained 
using the direct inlet technique (Lin et al., 1970; Reid et al., 1973). Although mass 
spectrometry served as a major technique in the identification of many metabolites of 
vitamin A and its analogs, isolation and derivatization of the unknown compounds were 
usually required prior to the application of mass spectral analysis (Skare et al., 1982a). 
An on-line HPLC-plasmaspray liquid chromatography/mass spectrometry system 
(LC/MS) was developed for its application in the analysis of synthetic heteroarotinoid 
standards, individually and in a mixture. A liquid secondary ion mass spectrometry 
technique (LSIMS) was used in the analysis of individual standards. 
Materials and Methods 
Chemicals 
Based on the general pathways of drug metabolism, and the pathways of retinoid 
metabolism in particular, more than a dozen potential metabolites of DHA (see Figure 3 for 
the structure) have been designed and synthesized by Dr. Berlin's group in the Department 
of Chemistry, Oklahoma State University (Waugh et al., 1985; Sunthankar et al., 1991). 
Some of those synthetic standards (Table VI) were used in this study. The designations 
(Sl, S2, and so on with S stands for "standard") used in this writing are for the purpose of 
simplicity and clarity only. They are not the formal designations used in any publications, 
TABLE VI 
STRUCTURES OF THE SYNTHETIC HETEROAROTINOIDS 
Designations Structures MW Designations Structures MW 
DHA 
. ~CO,C,H, 
350.4 S-1 ~ 322.4 0% % S-2 366.4 S-3 364.4 
COiC2H5 eoic;a, 
coi (d>o S-4 380.4 S-5 244.3 I 
C02C2Hs 
~o S-6 w 204.3 S-7 206.3 
S-8 WCOzC2H, 274.4 S-9 QY"~· 246.3 
OC03H 
S-10 OC03H 150.1 S-11 166.1 COaH 
CHO 
0COiC2Hs OCOiC3Hs S-12 178.1 S-13 194.2 
COiH CHO 
-MW: Molecular Weight. w 
-..J 
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nor do they indicate any significance of any kind. These compounds, with a wide range of 
polarities, served as standards in establishing proper separation and detection protocols that 
were used in the analysis of real metabolites. 
The other reagents used in sample preparation and analysis were methanol (Optima 
grade, Fisher Scientific, Fair Lawn, New Jersey), water of either Optima grade (Fisher 
Scientific, Fair Lawn, New Jersey) or laboratory doubly distilled, and acetic acid 
(Tracemetal grade, Fisher Scientific, Fair Lawn, New Jersey). Compressed N2 gas 
(HPLC grade, Sooner Supplies, Inc., Shawnee, Oklahoma) was used for sample 
condensing, and He gas (HPLC grade, Sooner Supplies, Inc., Shawnee, Oklahoma) was 
used for solvent degasing. 
Principle and Apparatus. 
Plasmaspray LC/MS An on-line HPLC-Plasmaspray Liquid Chromatography / 
Mass Spectrometry technique (LC/MS) was developed and employed in the study. The 
basic principle of plasmaspray ionization can be briefly described as such: the eluant from 
the HPLC system enters the plasmaspray interface through a 1/16 union mounted on the 
base of the HPLC and passes through a length of fused silica capillary which has the 
ground voltage. The eluant then passes through a further union into a stainless steel 
capillary termed "the vaporizer". The vaporizer is electronically heated (3210 v) and the 
eluant enters the ion source block (2700 v) as a fine spray of droplets. A different voltage 
is applied between the vaporizer and the ion source block to create a DC plasma of sample 
and solvent ions. In this study, a 510 v plasma voltage was applied on the cathode (the 
steel capillary) with respect to the anode (the ion source), causing a low discharge 
ionization (Figure 36). 
The analysis of a mixture of twelve standards was performed on a LC/MS system, 
which included a VG Tritech TS-250 mass spectrometer equipped with a VG Tritech 
Plasmaspray interface (VG Tritech, Manchester, United Kingdom), a Waters-600MS 
PLASMASPRAY 
FROM H.P.L.C.-. -
.. t 
ION SOURCE BLOCK 
2700V 
STEEL CAPILLARY I I 
3210V • 
------:=) • ~ e • • TO M.S. 
, .. 
•••• 
• COPPER HEATING BLOCK 
PUMP-OUT LINE 
Figure 36. Diagrammatic Ulustration of the Plasmaspray Interface in the On-line HPLC-
Plasmaspray Liquid Chromatography/Mass Spectrometry System. 
-vl \0 
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multisolvent delivery system, a Waters 6000-MS system controller.and a Waters U6K 
injector (Waters Associates, Milford, Massachusetts). A C1g reversed phase column (P/10 
ODS 3, 0.47 x 23.5 cm, Particle size 5 µm, Whatman Inc., Clifton, New Jersey) and a 
six-port sampling value (N60, Valeo Instruments Co., Inc., Houston, Texas) were used in 
this system. Each standard was also analyzed individually through by-passing the HPLC 
portion of the system, and was directly introduced into the plasmaspray interface. 
Liquid Secondary Ion Mass Spectrometry (LSIMS) LSIMS was performed on a 
VG-ZAB-2SE mass spectrometer (VG Tritech, Manchester, United Kingdom) using 
cesium ions at 35 Kv for the ionization. LSIMS mass spectra of the standards were 
obtained on LSIMS+ or LSIMS- (both modes were used for some standards) depending on 
the relative positive ionization and negative ionization potentials of the standards. 
Standards were first dissolved in methanol (5-10 µg standard/ µl CH30H), and then 
loaded on the LSIMS probe by dripping 3 µl solution on the tip of the probe using 
thioglycerol as the matrix. Linked scan mass spectral analysis (MS/MS) in a magnetic 
section/electric section geometry (B/E) was also performed by selecting the known 
molecular ion of the standards. Fragment ions (daughter ions) specific to each selected 
molecular ion were detected through collisionally activated dissociation (CAD) using He as 
the activating gas. 
Results and Discussions 
Analysis of the Standards by LC/MS 
A reconstructed total ion chromatogram (TIC) of a mixture of twelve standards is 
shown in Figure 37 using an 120 min linear solvent delivery program (detailed analytical 
information including the gradient program is shown in the legend of Figure 37). The 
peaks representing the corresponding standards are indicated on the TIC. The mass spectra 
of the standards obtained from this LC/MS system are presented in Figures 38 through 
Figure 49. Interpretation of the spectra is limited, and is shown on each spectrum. 
Figure 37. Reconstructed Total Ion Chromatogram (TIC) of a Mixture of Twelve Synthetic 
Standards. 
Instrument: Waters-6000 HPLC system 
Plasmaspray LC/MS, VG-TS 250 
Column: Whatman C1s ODS-3, 5 µm Particle, 0.47 x 23.5 cm 
Flow Rate: 1.0 mVmin 
Solvent Program: 80% HAC (0.01M) 
20% CH30H Hold 10 min j Linear, 120 min 
100% CH30H Hold 20 min 
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Figure 38. The Plasmaspray LC/MS Spectrum of the Standard S-10. 
Instrument: Waters-6000 HPLC System 
Plasmaspray LC/MS, VG-TS 250 
Mode: Positive Ionization 
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Figure 39. The Plasmaspray LC/MS Spectrum of the Standard S-11. 
Instrument: Waters-rooo HPLC System 
Plasmaspray LC/MS, VG-TS 250 
Mode: Positive Ionization 
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Figure 40. The Plasmaspray LC/MS Spectrum of the Standard S-12. 
Instrument: Waters-6000 HPLC System 
Plasmaspray LC/MS, VG-TS 250 
Mode: Positive Ionization 
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Figure 41. The Plasmaspray LC/MS Spectrum of the Standard S-13. 
Instrument: Waters-6000 HPLC System 
Plasmaspray LC/MS, VG-TS 250 
Mode: Positive Ionization 
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Figure 42. The Plasmaspray LC/MS Spectrum of the Standard S-7. 
Instrument: Waters-(i()()(} HPLC System 
Plasmaspray LC/MS, VG-TS 250 
Mode: Positive Ionization 
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Figure 43 The Plasmaspray LC/MS Spectrum of the Standard S-5. 
Instrument: Waters-(i()()(} HPLC System 
Plasmaspray LC/MS, VG-TS 250 
Mode: Positive Ionization 
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Figure 44. The Plasmaspray LC/MS Spectrum of the Standard S-6. 
Instrument: Waters-6000 HPLC System 
Plasmaspray LC/MS, VG-TS 250 
Mode: Positive Ionization 
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Figure 45. The Plasmaspray LC/MS Spectrum of the Standard S-2. 
Instrument: Waters-(>()()() HPLC System 
Plasmaspray LC/MS, VG-TS 250 
Mode: Positive Ionization 
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Figure 46. The Plasmaspray LC/MS Spectrum of the Standard S-4. 
Instrument: Waters-(,()()() HPLC System 
Plasmaspray LC/MS, VG-TS 250 
Mode: Positive Ionization 
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Figure 47. The Plasmaspray LC/MS Spectrum of the Standard S-3. 
Instrument: Waters-6000 HPLC System 
Plasmaspray LC/MS, VG-TS 250 
Mode: Positive Ionization 
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Figure 48. The Plasmaspray LC/MS Spectrum of the Standard S-1. 
Instrument: Waters-(i()()() HPLC System 
Plasmaspray LC/MS, VG-TS 250 
Mode: Positive Ionization 
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Figure 49. The Plasmaspray LC/MS Spectrum of the Standard DHA. 
Instrument: Waters-6000 HPLC System 
Plasmaspray LC/MS, VG-TS 250 
Mode: Positive Ionization 
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Each standard was also analyzed individually with this system through HPLC by-
passing. The mass spectra of the standards obtained in this manner are almost identical to 
those presented above, except that, in some cases, the relative intensities of the mass peaks 
are not the same (spectra not shown). 
Analysis of the Standards by LSIMS Technique 
Figure 50 through Figure 64 show the ten positive ion LSIMS spectra and five 
negative ion LSIMS spectra of the standards, as well as their corresponding daughter ion 
CAD mass spectra. As in the data presentation of LC/MS analysis, interpretation of the 
spectra is limited, and is shown on each spectrum. 
Conclusions 
The techniques of the on-line HPLC plasmaspray LC/MS, the LSIMS and the B/E 
linked scan mass spectrometry were successfully applied for the analysis of the synthetic 
heteroarotinoid standards. In most cases, LC/MS spectra provided molecular weight 
information, and a few major fragment ions resulting from loss of water and/or other small 
gaseous molecules. Methylated molecular ions were generally obtained when a free 
carboxylic group was present in the structure. Therefore, when methanol was used as a 
component of an acidic solvent mixture, methylation on free carboxylic group occurred 
readily in this LC/MS system. 
Information on the molecular weight was well provided by the LSIMS spectra. 
Though LC/MS and LSIMS were both soft ionization techniques, LSIMS provided more 
fragment peaks when compared to the LC/MS spectra of the same compounds. The results 
indicated that LC/MS and LSIMS can serve as complementary methods in the structural 
determination of unknown metabolites. The MS/MS spectra showed fragment ions 
apparently resulted from some rearranged ions. 
Figure 50. LSIMS Spectra of the Standard DHA. 
Instrument: VG-zAB-2SE 
Mode: (a) Straight, Positive Ionization 
(b) MS/MS, B/E CAD, Positive Ionization 
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Figure 51. LSIMS Spectra of the Standard S-1: 
Instrument: VG-ZAB-2SE 
Mode: (a) Straight, Positive Ionization 
(b) MS/MS, B/E CAD, Positive Ionization 
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Figure 52. LSIMS Spectra of the Standard S-2. 
Instrument: VG-ZAB-2SE 
Mode: (a) Straight, Positive Ionization 
(b) MS/MS, B/E CAD, Positive Ionization 
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Figure 53. LSIMS Spectra of the Standard S-3. 
Instrument: VG-ZAB-2SE 
Mode: (a) Straight, Positive Ionization 
(b) MS/MS, B/E CAD, Positive Ionization 
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Figure 54. LS IMS Spectra of the Standard S-4 .. 
Instrument: VG-ZAB-2SE 
Mode: (a) Straight, Positive Ionization 
(b) MS/MS, B/E CAD, Positive Ionization 
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Figure 55. LSIMS Spectra of the Standard S-5. 
Instrument: VG-ZAB-2SE 
Mode: (a) Straight, Positive Ionization 
(b) MS/MS, B/E CAD, Positive Ionization 
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Figure 56. LSIMS Spectra of the Standard S-7. 
Instrument: VG-ZAB-2SE 
Mode: (a) Straight, Positive Ionization 
(b) MS/MS, B/E CAD, Positive Ionization 
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Figure 57. LS IMS Spectra of the Standard S-9. 
Instrument: VG-ZAB-2SE 
Mode: (a) Straight, Positive Ionization 
(b) MS/MS, B/E CAD, Positive Ionization 
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Figure 58. LSIMS Spectra of the Standard S-10. 
Instrument: VG-ZAB-2SE 
Mode: (a) Straight, Positive Ionization 
(b) MS/MS, B/E CAD, Positive Ionization 
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Figure 59. LS IMS Spectra of the Standard S-13. 
Instrument: VG-ZAB-2SE 
Mode: (a) Straight, Positive Ionization 
(b) MS/MS, B/E CAD, Positive Ionization 
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Figure 60. LSIMS Spectra of the Standard S-2. 
Instrument: VG-ZAB-2SE 
Mode: (a) Straight, Negative Ionization 
(b) MS/MS, B/E CAD, Negative Ionization 
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Figure 61. LSIMS Spectra of the Standard S-3. 
Instrument: VG-ZAB-2SE 
Mode: (a) Straight, Negative Ionization 
(b) MS/MS, B/E CAD, Negative Ionization 
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Figure 62. LSIMS Spectra of the Standard S-4. 
Instrument: VG-ZAB-2SE 
Mode: (a) Straight, Negative Ionization 
(b) MS/MS, B/E CAD, Negative Ionization 
!I 
• 
• 
II 
A 
.. 
~ 
• 
11 
15 
II 
!I 
• 
15 
• 
75 
II 
'5 
II 
51 
II 
45 
.. 
l'i 
JI 
11 
11 
II 
II 
(0) 117.4 
121.7 
,1 .1 
(b) ~H 
14 ., 
S-4 
I .! 
I .5 
214.1 
% MW= 380.4 
COiCiHs 
lllG.2 
m/z 
181 
lll .4 
125 .1 
334.I 
(M-H)· 
3/3.6 
lit.I 
198.1 
361.1 
,~ J 
(M-H-C02)· (M-H)· 
(M-H-CO)· 
• 
Figure 63. LSIMS Spectra ()f the Standard S-9. 
Instrument: VG-ZAB-2SE 
Mode: (a) Straight, Negative Ionization 
(b) MS/MS, B/E CAD, Negative Ionization 
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Figure 64. LSIMS Spectra of the Standard S-10. 
Instrument: VG-ZAB-2SE 
Mode: (a) Straight, Negative Ionization 
(b) MS/MS, B/E CAD, Negative Ionization 
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CHAPTER VIl 
METABOLISM STUDY OF ETIIYL (E)-4-[2-(3,4-DlllYDR0-4,4-DIMETHYL-
-2H-1-BENZOPYRAN-6-YL)-1-PROPENYL]BENZOATE 
Introduction 
Since the 1960s, major pathways of vitamin A metabolism have been discovered}' 
I; 
and recently reviewed by Frolik (1984). Although studies in this area continue, metabolites 
identified from many in vitro and in vivo investigations have demonstrated that 
esterification, conjugation, isomerization, and oxidation are the major pathways that occur 
during various stages of vitamin A metabolism and functioning processes (see Metabolism 
of Retinoids in Chapter II). As studies of synthetic retinoids have rapidly developed with 
the exciting prospect that they may be of clinical use in the treatment of many diseases 
including cancer, knowledge concerning their pharmacokinetic properties and metabolism 
becomes especially important. In a number of screening tests, the biological activities of 
the newest synthetic retinoids, the heteroarotinoids, have been shown to be comparable to 
or even higher than some of the retinoids that are currently being used in clinical studies 
(see Toxicity and Pharmacology in Chapter II). One of the most promising aspects of the 
heteroarotinoids is their much lowered toxicities. In the present study, methodologies in an 
in vivo study of a selected heteroarotinoid, ethyl (E)-4-[2-(3,4-dihydro-4,4,dimethyl-2H-
1-benzopyran-6-yl)-1-propenyl]benzoate (abbreviated as DHA in this writing, see Figure 3 
for the structure), are described including the tentative identification of three major biliary 
metabolites. 
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Materials and Methods 
Animals 
Male rats of the Sprague-Dawley Stock (CD rats, Charles River Laboratories, 
Wilmington, Massachusetts) with body weights in the range of 301-325 g were purchased 
at least one week prior to the biliary cannulation. They were caged individually. 
Laboratory rodent chow (Ralston Purina, St. Louis, Missouri) and water were available ad 
libitum. The other animal housing facilities and care procedures were the same as 
previously described (see Materials and Methods in Chapter III). 
Chemicals 
The labelled and unlabeled parent heteroarotinoid, ethyl (E)-4-[2-(3,4-Dihydro-4,4-
-dimethyl-2H-l-benzopyran-6-yl)-1-propenyl]benzoate, and its potential metabolites 
(standards) were synthesized by Dr. Berlin's group in the Department of Chemistry, 
Oklahoma State University (Waugh et al., 1985; Sunthankar et al., 1990; Sunthankar et 
al., 1991). The other reagents used in sample preparation and analysis were methanol 
(Optima grade, Fisher Scientific, Fair Lawn, New Jersey), water of either Optima grade 
(Fisher Scientific, Fair Lawn, New Jersey) or laboratory double distilled, and acetic acid 
(Tracemetal grade, Fisher Scientific, Fair Lawn, New Jersey). Compressed N2 gas· 
(HPLC grade, Sooner Supplies, Inc., Shawnee, Oklahoma) was used for sample 
condensing, and He gas (HPLC grade, Sooner Supplies, Inc., Shawnee, Oklahoma) was 
used for solvent degasing. 
Biliruy Cannulation Procedures 
Detailed description of the bile duct cannulation procedures done in a standard 
veterinary hospital is referred to in the recent publication by Rolf et al. (1991 ). The same 
operation as conducted in a regular laboratory setting will be briefly described here. The 
entire procedure was done under anesthesia. Initially, the animal was lightly anesthetized 
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with diethyl ether in a closed container. It was then removed and placed on an operating 
table installed on the edge of a fume hood. The anesthesia was continued throughout the 
surgical procedures through a nose cone with halothane (Fluothane, Fort Dodge 
laboratories, Inc., Fort Dodge, Iowa). 
A 4x6 cm area, centered on the midline from the xiphoid cartilage caudally, and a 
lxl cm area, centered on the points of the scapulae, were shaved with an electric clipper 
and scrubbed with a solution of 1:5 dilution of chlorohexidine diacetate (Nolvason, Fort 
Dodge Laboratories, Inc., Fort Dodge, Iowa). A 3-cm midline incision through the linea 
alba was made extending caudally from the xiphoid cartilage. The bile duct was located, 
and elevated with a mosquito hemostat. Pancreatic tissue and mesenteric fat was dissected 
gently with a moistened cotton-tipped applicator. A 4-0 silk (Ethicon Inc., Somerville, 
New Jersey) ligature was placed loosely around the distal duct to block the bile flow and 
cause distension of the proximal duct. An incision was made with a pair of ophthalmic 
scissors on the ventral surface of the bile duct. Catheters (Polyethylene, 0.58 mm I.D. x 
0.96 mm O.D., Clay Adams, Parsippany, New Jersey) that were specially shaped at the tip 
(Rolf et al., 1991) were inserted, with one end towards the proximal aspect and the other 
towards the distal aspect of the bile duct. They were secured to the duct with the silk 
ligatures. The splinted catheters were then sutured to the body wall. 
With the rat positioned laterally, a 0.5 cm stab incision was made between the 
scapulae. A pair of straight Crile hemostatic forceps was inserted into the incision, 
tunnelled down through the subcutaneous tissue, penetrated the abdominal wall, grasped 
the loop of the catheter, and retracted through the tunnel to the neck incision. Catheter 
position in the alxlominal cavity was adjusted to eliminate any kinks to ensure free flow of 
bile. 
The two incisions, one on the alxlomen and one on the back of the neck, were 
closed with 4-0 monofilament polypropylene (Ethicon Inc., Somerville, New Jersey). The 
catheter segments were sutured to the skin around the neck incision with 3-0 monofilament 
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nylon (Ethicon Inc., Someiville, New Jersey) or silk. The catheters were trimmed to about 
one and a half inches in length from the neck, and the ends joined with a 22 gauge stainless 
steel cannula. Wounds were sprayed with Furazolidone (Topazone Aerosol Powder, 
Norden Laboratories, Inc., Lincoln, Nebraska). 
Post:ewerative Animal Care 
After a successful operation, the animal usually awakened within 0.5 hour, and 
began eating and drinking within 2 hours. The animal was given saline solution (0.45% 
NaCl) as its drinking water during the first 24 hours following the operation. A heating 
pad at medium setting was also provided for the first 1-2 nights. The recovery period took 
about 48 hours, during which time about 50-70 g of the body weight was lost. If no 
infections developed, the animals began gaining weight rapidly after the first 2 days. Skin 
sutures were removed in 7 days. Normal eating, drinking and steady weight-gain were the 
general indications of stabilized post-surgery conditions (about one week), at which time 
the first bile collection was performed. 
The animals were under close obseivation daily. Any obvious problems, such as 
loosened or clogged tubings and minor infections, were taken care of immediately upon 
notification. As long as the catheter loop was positioned properly so that it did not contact 
the pinnae, the rats were rarely bothered by it. Close attention was paid to keep the catheter 
loop closed. Any spillage of bile on the skin was cleaned promptly to prevent skin 
irritations. Animals under good care could sUIVive for as long as 1.5 months while bile 
was collected at various time inteivals. 
Bile Samplin~ Procedure 
The time inteivals between two bile collections were at least 3-4 days. Bile was 
collected for 6 hours continuously each time. Bile that was collected with no prior injection 
seived as a blank. Exactly 500 µg of the parent compound (DHA) dissolved in 1 ml of 
vehicle (50% normal saline:50% aldehyde free ethanol, v:v) was injected intraperitoneally 
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into the rat under light sedation with diethyl ether. The metal connector of the bile-passing 
loop on the upper back of the rat was opened, and bile flow was immediately led into a 
cylinder placed in ice. The animal was allowed to move freely to retain the normal 
physiological status throughout the experiment. Control bile was collected in exactly the 
same manner after an injection of 1 ml of the vehicle. 
Bile Sample Processin~ 
The procedure for purification and isolation of metabolites from a bile sample is 
shown in Figure 65. A bile sample, usually about 7 ml in volume, was diluted immediately 
with an equal amount of methanol. The sample was either dried immediately under N2 in a 
32°C heating block or kept under a N2 atmosphere at -20°C when storage was required. 
The dry bile extract was suspended in about 2 ml of methanol, and the solution was passed 
through a Sep~Pak Plus C1s Environment cartridge (Waters Chromatography Division, 
Millipore Corporation, Milford, Massachusetts) to remove cell wall debris and protein 
precipitates. The filtrate was then chilled with dry ice and filtered through a pre-chilled 
millipore filter (FH 0.5 µm, Millipore Corporation, Milford, Massachusetts). The filtrate 
was again dried under N2 at 32°C. The 0.5 ml suspension of the sample (5% CH30H in 
0.01 M HAC) was loaded on a pre-conditioned Sep-Pak Plus C1s cartridge, and eluted first 
with 3.0 ml of double-distilled H20, and then with three 1.5 ml-2.0 ml portions of solvents 
sequentially as indicated in Figure. 65. The rate of elution was controlled at around 0.3 
mVmin. Four fractions ranging from most non-polar (Fraction-IV) to most polar (Fraction-
!) were obtained. The fractions were dried under N2 and kept either dry or in methanol at 
-20°C. Metabolites in each fraction were analyzed either by the on-lined HPLC 
Plasmaspray Liquid Chromatography/Mass Spectrometry (LC/MS) or further separated by 
HPLC. Individually separated metabolites were pooled and analyzed by means of UV and 
MS spectroscopies. 
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dilute with equal amount of MeOH 
t N2 blow dry at 320c 
d . 1 .t 1 isso vein 2m MeOH 
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Figure 65. Procedure for Bile Sample Purification, Metabolite 
Isolation and Identification. 
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HPLC Analysis of the Synthetic Standards 
Purification, separation and detection of the heteroarotinoid standards could be 
achieved with a Waters Associates HPLC System (Waters Associates, Milford, 
Massachusetts), consisting of a Model 680 automated gradient controller, 2 Model 6000A 
solvent delivery systems, a Model 440 dual wavelength absorbance detector (254 nm and 
350 nm), and a Hewlett-Packard Model 1040A HPLC Detection System (Hewlett-Packard 
Co., Waldbronn, Federal Republic of Germany), consisting of an HP-1040A diode-array 
UV Nisible spectroscopic detector mainframe, an HP-85 Personal Computer, an HP-
9021D Flexible Disc Drive and an HP-7470A Graphics Plotter. Also used in this HPLC 
system were a C1g reversed phase column (P/10 ODS 3, 0.47 x 23.5 cm, Particle size 5 
µm, Whatman Inc., Clifton, New Jersey), a six-port sampling value (N60, Valeo 
Instruments Co., Inc., Houston, Texas), and an Omni Scribe dual wavelength recorder 
(Model B5217-1. Houston Instrument, Austin, Texas). 
Control Studies 
Feasibility of the Purification Procedures. In order to test the effectiveness and the 
efficiency of the bile sample processing procedure presented in Figure 65, a mixture of 
standards was processed according to the procedure. HPLC profiles were obtained before 
and after the processing. The number of the peaks, the retention times and the relative 
intensities of the standards were compared between the two chromatograms. 
Solvents. All the solvents used as the HPLC mobile phase were checked for any 
contamination and/or interfering UV absorption by running the solvents either individually 
or in gradient programs similar to those used in the real sample analyses through the HPLC 
analysis system. 
Dosini: Vehicle. The HPLC profiles of a blank bile (bile sample obtained without 
prior injections) and a control bile (bile sample obtained after an injection of the dosing 
vehicle only) from the same animal were compared to check whether or not the introduction 
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of the dosing vehicle (1 ml 50% normal saline:50% alcohol) interferes with the animal's 
normal metabolism. A principle desire of this metabolism study was to investigate the 
metabolism of the selected heteroarotinoid DHA under normal physiological conditions. 
Whenever possible, a test animal's normal physiological processes during an experiment 
were not to be disturbed. If the dosing vehicle interfered with the animal's normal 
metabolism, an altered pattern of the endogenous metabolites would be observed in 
comparing the HPLC profiles. 
Artifacts Derived from the Parent Compound. "Artificial metabolites" might be 
produced simply during a bile sample processing or through interactions between the parent 
compound and a bile matrix at any stages of the bile sample processing procedure. 
Therefore, small amount of parent compound DHA was added to a control bile. The bile 
sample was then processed and analyzed according to the procedure. The HPLC profile 
was compared to that of the control bile. 
Artifacts Derived from Metabolites. "Artificial metabolites" might be derived 
through interactions between the real metabolites and a bile matrix during sample 
processing. These possible interactions would result in the missing of real physiological 
metabolites and the detection of false metabolites. The existence of such possible artifacts 
was examined by adding a mixture of standards into a control bile, the mixed bile sample 
was then processed according to the procedure, and analyzed along with the control bile. 
The HPLC profiles of the mixed bile sample and the control bile were compared. Although 
this test could not provide an absolute answer to the possible problem since the real 
metabolites might react with the bile matrix differently from that of the synthetic standards. 
Nevertheless, before any metabolites were known, results from such a test would give a 
good indication of the possible existence of the problem as the standards were logically 
designed based on the known knowledge of the retinoid metabolism. 
Variations Amon~ Animals. Metabolism varies even among animals of the same 
species, resulting in different metabolites appeared in the bile samples taken from different 
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rats. Therefore, sample bile was always analyzed along with, and compared with the blank 
and control bile from the same rat . 
Deterioration of Bile Samples. Alteration in the original components of a biological 
fluid such as bile may be due to a changing environment and/or the presence of enzymes. 
To prevent any possible deterioration, bile samples were always processed immediately or 
diluted with methanol and kept at -200C, if storage was required. Frequent freeze-and-
thaw processes were avoided whenever possible. Processed bile samples were stored dry 
or in methanol and purged with N2 before stora~e. Samples were never left at room 
temperature for longer than a few minutes during analyses. Even though all these measures 
were taken to reduce deterioration, standards and bile samples were checked by HPLC 
analyses to determine the degree of deterioration. 
Isomerization. One of the most distinctive nature of retinoids is that they are very 
sensitive to light, which induces isomerization. To prevent light-induced isomerization, all 
experimental procedures were done under special yellow light (Gold F40/GO, 40W, 
Sylvania, GTE, USA). Any samples that were brought under natural or fluorescent 
lighting were protected with aluminum foil. 
Identification of the Biliary Metabolites b.y 
Plasmasm:ay LC/MS Technig,µe 
HPLC Analysis. After processing, bile samples were analyzed directly on the 
HPLC system described previously. A mixture of standards and the corresponding control 
bile samples were always included with the analyses of the biles containing metabolites. 
The procedure for the metabolite identification was established as follows: 1) to work out a 
HPLC gradient program using synthetic standards that has a good separation and is 
applicable to the Plasmaspray LC/MS system; 2) to distinguish metabolites of interest from 
the endogenous metabolites by comparing the HPLC profile of a sample bile with that of 
the corresponding control bile; 3) to identify the metabolites of interest by comparing their 
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retention times and UV spectra with that of the possible corresponding standards; and 4) to 
apply the same solvent gradient program in the on-line HPLC-Plasmaspray LC/MS system 
described earlier for mass spectrometic analysis. 
Plasmaspray LC/MS Analysis. The Plasmaspray LC/MS analysis of the individual 
standards and a mixture of standards (see Chapter VI) established a suitable and effective 
program for the analysis of the biliary metabolites. Each sample bile along with its 
corresponding control bile and a mixture of the standards were analyzed by the same on-
line HPLC-Plasmaspray LC/MS system (see Methods and Materials in Chapter VI) using 
the solvent gradient program developed with the standards. 
Identification of the Individually Isolated Metabolites 
Using LSIMS Technique 
Fractionation. Owing to the malfunctioning of the on-line HPLC Plasmaspray 
LC/MS system after some initial identification studies described above, direct identification 
of metabolites in the biliary mixture became impossible. Focus was, therefore, shifted to 
the fractionation and isolation of individual metabolites according to the procedures shown 
in Figure 65. All four fractions obtained were analyzed initially by HPLC. Numerous 
solvent gradients were tried to establish a good program for the separation and isolation of 
the metabolites of interest in each fraction. For a chosen fraction, repeated separation and 
isolation procedures were done in a semi-preparative fashion using the HPLC system and a 
fraction collector (Isco Instrumentation Specialties Co., Model 328, Lincoln, Nebraska). 
Alternatively, fractionation was also achieved using a FOXY Fraction Collector in 
conjunction with a Model 2150 Peak Separator (Isco Instrumentation Specialties Co., 
Lincoln, Nebraska), and a Cole-Palmer Model 8373-20 Recorder.(Cole-Palmer Instrument 
Company, Chicago, Illinois). Fractions were immediately placed on ice and kept in the 
dark during a collection. The fractions containing metabolites of interest were then pooled, 
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and their UV spectra were obtained. Pooled samples were dried under a gentle N2 stream 
in a 320 Cheating block, and stored dry under N2 at-200 C until further analysis. 
Standards were grouped according to their polarities. Metabolites in each bile 
fraction were compared with a mixture of corresponding standards that were in the same 
polarity region. Both the standards and the corresponding control bile were fractionated, 
fractions were pooled, dried, and stored in exactly the same manner as was done to the 
sample bile. 
Metabolites isolated from the HPLC fractionation procedures were further separated 
and purified by HPLC using isocratic solvent delivery programs. Two to three 
components were usually found in each initial peak, and were separated and collected in 
this step . Their UV spectra were obtained and compared with that of the standards. 
LSIMS Analysis. The LISIMS technique described previously (see Methods and 
Materials in Chapter VI) was employed to analyze the individually isolated biliary 
metabolites. All isolated components in the previous HPLC separation step were subjected 
to the LSIMS analysis. 
Desalting. In the trial LSIMS analysis of the metabolites isolated from the HPLC 
procedures, high content of Na+ ions was found in the samples. As the result of this 
problem, no metabolite ions could be detected as the matrix-conjugated Na+ ions 
overwhelmed the entire spectra (data not shown). The LSIMS analysis was, therefore, 
preceded by a desalting step . Considering the generally labile nature of the metabolites, a 
gentle rinsing instead of an ion-exchange procedure was designed to prevent any structural 
alterations, such as isomerization, from taking place. The desalting procedure was 
illustrated in Figure 66. Additionally, doubly distilled H20, instead of normal saline, was 
used for rinsing and flushing the tubings during bile sample collection to eliminate external 
sources of salt. 
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Isolated metabolite 
i 
Suspend in 0.5 ml doubly-distilled H2D 
i 
Load on a C 18 Sep-Pak 
i 
Rinse with 4 ml doubly-distilled H2D (rate about 0.5 ml/min) 
i 
Elute with 1.5 ml CH3DH 
i 
Condense under N2 stream in a 320 C heating block 
Figure 66. The Bile Sample Desalting Procedure. 
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Confirmatory Study Using Isotope-labelled Parent Compound 
A triple-14C labeled parent compound DHA * was synthesized (Sunthankar et al., 
1990) and used in this preliminary study. The structure of DHA * is shown in Figure 67. 
The purpose of this study was · to develop methodologies in metabolism studies using 
isotope-labelled tracers. Bile was obtained from cull chickens weighing about 2 lbs 
(Department of Animal Science, Oklahoma State University). No attempt was made to 
identify the metabolites detected in this trial because rats were to be used, according to the 
plan, in the main course of the metabolism study 
Purification of the Labelled Parent Compound 
22 mg of crude DHA* with a total radioactivity of 16.20 µci was purified by a 
Waters HPLC system described previously using a Cs reversed phase column (Whatman, 
Spherical 5 µm, I.D. 0.46 x 12.5 cm), and an isocratic program.(70% CH30H:30% 0.01 
M HAC). A Fisher Recordall UV recorder (Series 5000, Model D5117-1AQ, Bausch & 
Lomb, Houston Instrument Division, Austin, Texas) was used to record the HPLC profile. 
DHA * was collected at a retention time of 24 min. The DHA *-containing fractions were 
pooled and evaporated to dryness with a rotary evaporator (Rotavapor-R, BUCH!, 
Glasappatefabrik Flawil, Switzerland) in a 38° C water bath controlled by an automatic 
temperature controller (Buchler Instruments, Fort Lee, New Jersey). This purification 
process was repeated twice. Total radioactivity recovered from each purification was 
counted using a Packard-1900CA Liquid Scintillation Analyzer (Packard Instrument 
Company, Laguna Hills, California). 
Administration of the Labelled Parent Compound 
Purified DHA * (total radioactivity of 4.12 µci) was dissolved in 2 ml of dosing 
vehicle (50% normal saline:50% aldehyde free ethyl alcohol, v:v) and injected into the test 
chicken intraperitoneally. The control chicken was injected with 2 ml of dosing vehicle 
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Figure 67. The Structure of a 14C-labelled Diaryl Heteroarotinoid (DHA*), 9,10,U-14C 
Ethyl (E)-4-[2-(3,4-Dihydro-4,4-dimethyl-2H-l-benzopyran-6-yl)-l-
propenyl]benzoate. 
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only. The animals were given 5 ml of water through the mouth in 3 hours, and were 
sacrificed 6 hours after the drug administration. A total of about 1.5 ml bile and 2 pieces of 
liver tissue (about 20% of total liver) were collected from both chickens. A total 
radioactivity of 0.19 µci was recovered from the bile of the test chicken. The liver tissues 
were rinsed with cold distilled H20, frozen immediately with dry ice, and stored at -200 C. 
All experimental procedures, including the analysis procedures described previously, were 
done parallell with samples collected from both the test and the control chicken. 
Bile Sample Processing and Analysis 
Bile samples were processed according to the procedure in Figure 65. No 
fractionation was done and the total bile preparation was counted as 0.095 µci. Half of the 
total bile preparation (containing 0.047 µci radioactive 14C material) was analyzed by the 
same HPLC system described previously using the same C1s reversed phase column. 
About two hundred 1.0 ml fractions were collected using the automatic fraction collector , 
and the radioactivity of each fraction was counted by the liquid scintillation analyzer. 
Liver Sample Processing and Analysis 
The liver sample processing procedure is presented in Figure 68. Ten grams of 
frozen liver tissue from both the test chicken and the control chicken were cut into small 
pieces with a No.10 surgical blade and homogenized in a sequential of 15, 30, and 20 ml 
of mixed solvent (CHCl3:CH30H = 2:1, v:v) for 30 seconds each time using an electric 
blender (Omni-Mixer, Ivan Sorvall, Inc., Norwalk, Connecticut). The homogenate was 
filtered through a Whatman #1 filter, and pooled. The pooled filtrate was passed through a 
Whatman #1 filter one more time, and a total volume of 50 ml filtrate was obtained. The 
liver extract was then mixed with 11 ml of normal saline in an 150ml separation funnel, 
shaken gently, and set for about 20 min to allow partitioning. This process was repeated 
three times, and the lower organic phase was separated from the upper aqueous phase. 
Liver Tissue (10 g) 
i 
Homogenize with CHCl3: CH30H = 2: 1(15 ml), 30 sec. 
i 
Homogenize with CHC13 : CH30H = 2 : 1 (30 ml), 30 sec. 
t 
Homogenize with CHCl3 : CH30H = 2 : 1 ( 20 ml), 30 sec. 
Filter (Whatman #1) 
i---------- Filtrate pooled 
i 
Filter (Whatman #1) 
~ 
Filtrate (50 ml) Normal Saline (11 ml) 
------r--
Shake to mix 
t 
Partition, 20 min 
t 
A 
Aqueous Phase Organic Phase 
t 
Dry with N2 Stream 
+ Dissolve in ~teOH 
l 
Filter, C1s Sep-Pak 
t 
Filter, Millipore 
t 
Condense with Nz Stream 
~ 
HPLC Analysis 
Figure 68. Procedure for the Hepatic Metabolite 
Extraction, Purification and Analysis. 
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Both phases were collected. The total volume of the organic phase was about 30 ml, and 
that of the aqueous phase was about 25 ml. 
One milliliter out of each phase was taken to dryness under N2 stream in a 320 C 
heating block. Their radioactivity was counted, and the total radioactive material in either 
phase was estimated. The total organic phase was taken to dryness under N2, redissolved 
in CH30H, chilled with dry ice, and filtered through a C1s Sep-Pak and a millipore filter, 
sequentially. Sample was then condensed under N2 at 320 C, and analyzed on HPLC 
using a 70% CH30H:30% 0.01M HAC isocratic program. Fifty seven fractions of 1ml 
each were collected using the automatic fraction collector, and counted in the liquid 
scintillation counter. 
Results and Discussions 
HPLC Analysis of the Synthetic Standards 
All the standards listed in Table VI absorb light in the UV or near the UV region 
(230-320 nm). Their UV spectra were obtained using the HPLC system described. 
previously with 254 nm and 340 nm wavelength settings on the Model 440 Dual 
Wavelength Absorbance Detector (spectra not shown). Cis- and trans- isomers could 
usually be separated and distinguished by their different UV absorbancies. Although the 
standards were both chemically and conformationally pure from purification procedures 
following their synthesis (Sunthankar et al., 1991), further purifications could be readily 
achieved by HPLC. 
By using proper solvents and solvent gradients, mixtures of the standards were 
well separated and detected by the HPLC system. An example of a HPLC separation 
profile of a mixture of twelve standards is shown in Figure 69. 
Figure 69. HPLC Separation of a Mixture of Twelve Standards. 
Instrument: Waters-(j()()(} HPLC System 
Hewlett-Pac.kard-1040A Dicx:le-array UV Nisible 
Spectroscopic Detector 
Detector Wavelength Setting: 254 nm 
Column: Whatman C1s ODS-3, 5 µm Particle, 0.47 x 23.5 cm 
Flow Rate: 1.0 ml/min 
Solvent Program: 72% HAC (0.01M) 
28% CH30H Hold 15 min j Linear, 90 min 
100% CH30H Hold 5 min 
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Control Studies 
The following conclusions were made from the control studies (no spectra from the 
control studies are shown here): 
(1) The bile processing procedure shown in Figure 65 was successful when tested 
with standards. No contamination was introduced during the processing, and no 
isomerization was caused by repeating the filtration and condensation steps. 
(2) Normal metabolism was not significantly disturbed by the injection of the 
dosing vehicle as the pattern of the major endogenous metabolites, including their retention 
times, and relative intensities, was not affected. 
(3) No artificial "metabolites" were produced due to any interactions which might 
have occurred between the parent compound and the bile matrix during bile sample 
processing. 
(4) No significant interactions occurred between the standards and the bile 
constituents during bile sample processing. Therefore, endogenous metabolites would not 
be expected to interact with the metabolites of DHA. The existence of the endogenous 
metabolites, however, might cause problems in the detection and isolation of the 
metabolites of interest since considerable overlapping was expected to occur, and most 
identification work was done with non-radioactive compounds. 
(5) As expected, no two rats had exactly the same metabolism. It could be 
concluded, however, from numerous comparisons that the major endogenous components 
of bile samples obtained from different rats varied only slightly. More importantly, the 
peaks representing some major metabolites of DHA in bile from different rats remained 
fairly consistent in terms of the number of the metabolites, their retention times and their 
relative intensities. Based on these results, samples from different rats were combined after 
they had been individually analyzed in order to obtain large preparations of the metabolites. 
(6) Deterioration of the bile samples appeared to be negligible if the measures 
discussed in Materials and Methods of this chapter were strictly followed. Isomerization 
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did not seem to be a serious problem as standards appeared to be conformationally stable if 
they were not exposed to light and were stored dry at -20° C. 
Identification of Biliary Metabolites Usin~ the on-line 
HPLC-Plasmaspray LC/MS System 
Two biliary metabolites were tentatively identified, initially by HPLC analysis 
(Figure 70) and later confirmed by the on-line HPLC plasmaspray LC/MS technique. They 
are, designated as M-1 and M-2 [Figure 70(b)], identical to the standard S-1 and S-2, 
respectively, based on their chromatographic and spectroscopic identities. The 
corresponding HPLC profile of the control bile is shown in Figure 70(a). The 
corresponding peaks of the two standards, S-1 and S-2, can be referred to in Figure 71. 
The parent compound, DHA, was also recovered in the bile [peak M-P in Figure 70(b)]. 
The UV spectra of peak M-1, M-2, and M-P along with those of standards S-1, S-2 and 
DHA are presented in Figure 72 through Figure 74, respectively. The UV spectrum of the 
metabolite M-2 did not match the spectrum of S-2 (see Figure 73). This may be due to the 
fact that M-2 was not pure since the spectrum of M-2 was obtained from the analysis of the 
bile mixture, although it could not be excluded that M-2 and S-2 do not have the same 
structure. Nevertheless, the UV spectra of M-1 and M-P appeared similar to that of S-1 
and DHA (Figure 72 and 74), respectively. 
As a confirmatory measure, the same bile sample was spliced with a small amount 
of standard S-1 and S-2, respectively, and analyzed again on HPLC under the same 
conditions. The results supported the initial identification as the height of peak M-1 and 
peak M-2 increased distinctively in response to the spike with standard S-1 and S-2, 
respectively, [Figure 75(a) and (b)]. 
The bile sample was then subjected to LC/MS analysis using the same HPLC 
program and analytical conditions as those used in the analysis of the standards (see the 
previous description in Materials and Methods, Chapter VI). The reconstructed TIC of the 
Figure 70. (a) Regional HPLC Profile of the Control Bile. (b) Regional HPLC Profile of 
the Biliary Metabolites. 
Instrument: Waters-6000 HPLC System 
Hewlett-Packard-1040A Diode-array UV Nisible 
Spectroscopic Detector 
Detector Wavelength Setting: 254 nm 
Column: Whatman C1g ODS-3, 5 µm Particle, 0.47 x 23.5 cm 
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Figure 71. Regional HPLC Profile of the Synthetic Standards. 
Instrument: Waters-6000 HPLC System 
Hewlett-Packard-1040A Diode-array UV Nisible 
Spectroscopic Detector 
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Figure 72. UV Spectra of the Metabolites M-l(a), and the Standard S-1 (b). 
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Figure 73. UV Spectra of the Metabolites M-2(a), and the Standard S-2 (b). 
-~ 
< E 
_. 
~ 
CJ 
= 
= ,.Q 
r., 
= flJ 
,.Q 
< 
~ 
;> 
·-
-= 
-~ 
=-= 
214 
(a) 
1007.-.-------------------------------, 
0 
22 .o 320.0 
(b) 
0 
22 . 0 320.0 
Wove length [nm] 
M-2 
Lmax=232 nm 
A:97.8 mAU 
420.0· 
S-2 
Lmax=242 nm 
A:659.2 mAU 
% 
CO:!C2Hs 
420. 0 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
' 
Figure 74. UV Spectra of the Metabolites M-P(a), and the Standard DHA (b). 
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Figure 75. Regional HPLC Profiles of Biliary Metabolites Spilced with the Standard S-1 
(a), and with the Standard S-2 (b). 
Instrument: Waters-6000 HPLC System 
Hewlett-Packard-1040A Diode-array UVNisible 
Spectroscopic Detector 
Detector Wavelength Setting: 254 nm 
Column: Whatman C1s ODS-3, 5 µm Particle, 0.47 x 23.5 cm 
Flow Rate: 1.0 ml/min 
Solvent Program: 72% HAC (O.OlM) 
28% CH30H Hold 10 min ! linear, 90 min 
100% CH30H Hold 15 min 
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bile sample is shown in Figure 76. The metabolites M-1 and M-2 were detected. 
Metabolite M-P (recovered DHA), however, was not detected. Although Peak M-2 was 
relatively small and almost undetectable in the entire TIC, it could be seen in the enlarged 
portion of the chromatogram (see Figure 76 insert). The mass spectra of M-1 and M-2 
along with the mass spectra of their corresponding standards, S-1 and S-2, are presented in 
Figure 77 and Figure 78, respectively. It can be seen that the mass spectrum of M-1 
[Figure 77(a)], including the molecular ion m/z = 337 [M + H + CH30H- H20]+, and the 
two major fragment ions, m/z = 323 [M + H]+ (the existence of the peak at m/z = 323 is 
clearly seen, although the peak at m/z = 322 is more intense) and m/z =305 [M + H -
H20]+, matches well with that of the standard S-1 [Figure 77(b)]. It was noticed that the 
retention time of M-1 was a few minutes later (see Figure 76) than that of S-1 (see Figure 
37). The delay was probably due to electronic drift , which is not uncommon, from one 
run to another. The retention time of M-2 is very close to that of S-2 (see Figure 76 and 
Figure 37). Fewer peaks are shown in the mass spectrum of M-2 when compared to that 
of S-2 [Figure 78(a) and (b)]. Nevertheless, the molecular ion, m/z = 367 [M + H]+, and 
one of the major fragment peaks, m/z = 303 [M + H - H20 - C2H50H]+ [Figure 78(a)], 
match well with those in the spectrum of S-2 [Figure 78(b)]. It was not too surprising that 
the spectrum of M-2 was poor, however, since the signal of M-2 was weak and might not 
be yielding a satisfactory spectrum. 
Two other major metabolites of DHA were also detected. They were labelled as 
UM-1 at scan 2951 and UM-2 at scan 2250, respectively, in Figure 76 (UM stands for 
unknown metabolite). The mass spectra of these two unknown metabolites are shown in 
Figure 79 and Figure 80, respectively. Neither the retention times nor the mass spectra of 
these two compounds match those of the synthetic standards. 
Similar results were obtained in a second analysis (data not shown), but additional 
trials failed owing to the malfunctioning of the Plasmaspray LC/MS system. 
Unfortunately, the on-line HPLC-Plasmaspray LC/MS system was never restored to 
Figure 76. Reconstructed Total Ion Chromatogram (TIC) of the Biliary Metabolites. 
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Figure 77. The Plasmaspray LC/MS Spectra of the Metabolite M-1 (a), and the Standard 
S-l(b). 
Instrument: Waters-6000 HPLC System 
Plasmaspray LC/MS, VG-TS 250 
Mode: Positive Ionization 
223 
(a) 
100 7 
90 M-1 
80 
~ 
- 70 ·-fl.) 
= QJ 60 
-= ,.... 
QJ 50 
~ 
·- 40 
-~ 
-QJ 30 ~ 5 
20 
10 
0 
150 200 250 300 350 400 450 500 
m/z 
(b) m 
95 S-1 MW= 322.4 (M+H+CH3<)H-H20)t 
98 
es 
~-88 
7S 
~ 79 38S 
-·-
65 (M+H-H20)+ fl.) 
C 68 QJ 
-C 55 ,.... 
Sil~ 
(M+H)+ 
QJ 3Z3 
~ 45 ! 
·- :J -~ -~ ~ :j 
29 
IS 163 189 
11 I 
I 171 281 216 
: . I I 223 281 31! 
111 Jllll 2118 221 ~ 268 291 31111 
m/z 
Figure 78. The Plasmaspray LC/MS Spectra of the Metabolite M-2(a), and the Standard 
S-2(b). 
Instrument: Waters-6000 HPLC System 
Plasmaspray LC/MS, VG-TS 250 
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Figure 79. The Plasmaspray LC/MS Spectrum of the Metabolite UM-1. · 
Instrument: Waters-(,()()() HPLC System 
Plasmaspray LC/MS, VG-TS 250 
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Figure 80. The Plasmaspray LC/MS Spectrum of the Metabolite UM-2. 
Instrument: Waters-(i()()() HPLC System 
Plasmaspray LC/MS, VG-TS 250 
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normal. Experience from these efforts, however, gave us other useful information. It was 
clear that direct analysis of a complicated biological mixture, such as a bile sample, by 
LC/MS was technically difficult although it is ideal and possible. In addition, a 
considerable amount of sample was needed ( over a hundred times more than the amount 
applied on HPLC) in order for some metabolites to provide strong enough signals for MS 
analysis. This was a high demand since most of the metabolites existed only in trace 
amounts in the bile matrix. 
Identification of the Individually Isolated 
Metabolites by LSIMS 
Fractionation. According to the bile processing procedure (Figure 65), the 
metabolites were fractionated into four fractions based on their polarities. From the non-
polar fraction (Fraction IV), only the parent compound (DHA) was detected (data not 
shown). The existence of drug metabolites in Fraction I and Il was obvious. Identification 
of these metabolites without the use of radioactive tracers, however, was extremely difficult 
due to extensive overlapping from endogenous metabolites (data not shown). 
The HPLC profile of Fraction Ill is presented in Figure 81. The corresponding 
fraction of the control bile and the standards in this region are shown in Figure 82 and 83,, 
respectively. A few metabolites or clusters of metabolites, labeled as BM-1 to BM-6, were 
apparently from the_ parent compound in this fraction, and they were well separated and 
detected (Figure 81 ). Direct comparison of retention times between these metabolites, BM-
1 through BM-6 (Figure 81), with the corresponding seven standards (Figure 83) revealed 
that if the entire chromatogram of Fraction Ill was shifted 1-2 min towards the later time, 
the retention time of BM-2 was very close to that of S-2. Likewise, the retention times of 
BM-3, BM-4, BM-5, and BM-6 were very close to that of S-4, S-8, S-1, and DHA, 
respectively (see Figure 81 and 83). Repeated separation and isolations were done using 
Figure 81. HPLC Profile of the Control Bile Fraction III. 
Instrument: Waters-6000 HPLC System 
Hewlett-Packard-1040A Diode-array UV Nisible 
Spectroscopic Detector 
Detector Wavelength Setting: 254 nm 
Column: Whatman C1s ODS-3, 5 µm Particle, 0.47 x 23.5 cm 
Flow Rate: 1.0 ml/min 
Solvent Program: 35% HAC (0.01M) 
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Figure 82. HPLC Profile of the Biliary Metabolite Fraction ID. 
Instrument: Waters-6000 HPLC System 
Hewlett-Packard-1040A Diode-array UV Nisible 
Spectroscopic Detector 
Detector Wavelength Setting: 254 nm 
Column: Whatman C1g ODS-3, 5 µm Particle, 0.47 x 23.5 cm 
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Figure 83. HPLC Profile of a Mixture of Seven Synthetic Standards in the Same Polarity 
Region Corresponding to the Biliary Metabolite Fraction ID. 
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the same HPLC program. Peaks BM-1 to BM-6 were collected each time using a fraction 
collector and pooled. 
Purification. In the initial analysis of the isolated metabolites by LSIMS, high 
content of Na+ ions was found in all samples, and no metabolite ions could be detected 
(data not shown). This phenomenon was confirmed by analyzing the corresponding 
samples from the control bile. Because of the salt content in the bile, the LSIMS spectra of 
the metabolite and their controls appeared almost the same (data not shown). Therefore, all 
samples were desalted according to the procedure shown in Figure 66. After desalting, 
these metabolites were further purified by HPLC using various isocratic programs. 
Figure 84 through Figure 88 show the UV spectra of the metabolite BM-2 through 
BM-6 along with the UV spectra of the perspective standards. No standard in this polarity 
region corresponds with BM-1. The UV spectrum ofBM-1 is presented in Figure 89. As 
shown, not every UV spectrum of each of the unknown metabolites (BM-2 to BM-6) 
matches well with its respective standard. BM-2 [Figure 82(a)] has a maximum UV 
absorbance at 220 nm, which was lower than the maximum UV absorbance of S-2 
[235nm, Figure 84(b)]. Nevertheless, both BM-2 and S-2 have a second-to-maximum 
absorbance around 290-300 nm. Metabolite BM-3 displays a maximum UV absorbance at 
304 nm [Figure 85(a)], while that of S-4 is around 286nm [Figure 85(b)]. BM-4 has a 
maximum UV absorbance at 298 nm [Figure 86(a)], which well matches that of the 
standard S-8 [Figure 86(b)]. Likewise, the UV spectrum of BM-5 (Figure 87) and BM-6 
(Figure 88) matches well with that of S-1 and DHA,, respectively. Besides the fact that 
different UV spectra between the metabolites and the possibly matching-standards, such as 
BM-2 and S-2, BM-3 and S-4, might indicate the differences in their structures, the 
impurity of the metabolites was probably the major problem in obtaining accurate UV data. 
LSIMS Analysis, Results obtained from the HPLC analysis and UV spectroscopy 
had narrowed down the possibility that metabolites represented by peak BM-2, BM-3, BM-
4, BM-5, and BM-6 may be structurally similar, or even the same in some cases, to that of 
Figure 84. UV spectra of the Metabolite BM-2 (a), and the Standard S-2 (b). 
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Figure 85. UV spectra of the Metabolite BM-3 (a), and the Standard S-4 (b). 
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Figure 87. UV spectra of the Metabolite BM-5 (a), and the Standard S-1 (b ). 
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the standards S-2, S-4, S-8, S-1, and DHA, respectively. To confirm the findings 
discussed above, they were subjected to LSIMS analysis, which was successfully applied 
to the mass spectrometric analysis of the standards (see Results and discussions in Chapter 
VI). Unfortunately, no satisfactory LSIMS spectra of the metabolites were obtained except 
for that of BM-3. Not enough sample material might be the reason for the overall 
unsatisfactory results from the LSIMS analysis. 
A straight negative LSIMS spectrum of BM-3 is shown in Figure 90(a). It can be 
seen that the general pattern of the LSIMS· spectrum of BM-3 is very similar to that of S-4 
[Figure 90(b)]. Although, the molecular ion and one major fragment ion, m/z = 381.7, m/z 
= 352.7, in the spectrum of BM-3 are 2 mass units more than their corresponding peak at 
m/z = 379.6 and m/z = 350.7, respectively, in the spectrum of S-4. Other major fragment 
ions of BM-3, m/z = 338.7, m/z = 324.9, m/z = 311.3, and m/z =298.0, correspond well 
with those peaks at m/z = 338.0, m/z = 325.0, m/z = 311.4, and m/z =298.0 in the 
spectrum of S-4. m/z = 367.0 is a major matrix peak as indicated in the LSIMS- spectrum 
of the matrix (spectrum not shown). Although both the UV and mass spectrometric 
information indicated that BM-3 and S-4 are structurally similar, more study is definitely 
needed to elucidate the actual structure of BM-3. 
Purification of 14C-Labelled Parent Compound DHA * 
Prior to the purification, possible radioactive contamination from the injector, as 
well as from other parts of the HPLC system, was tested by injecting 400 µl of pure 
CH30H into the system, and running the HPLC with the same program that would be used 
for the purification. 1.0-ml Fractions were collected for 10 min, and all fractions were 
assayed for radioactivity. Only background level of radioactivity was detected (data not 
shown). Hence, no radioactive contamination existed in the HPLC system. 
As described earlier, purification of the crude 14C-labelled DHA (total amount of 22 
mg with a total radioactivity of 16.20 µci) was carried out on HPLC using a Cg reversed 
Figure 90. LSIMS Spectra of the Metabolite BM-3 (a), and the Standard S-4 (b). 
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phase column, and an isocratic program. The HPLC chromatogram of the first purification 
is shown in Figure 91. Verified by the unlabeled parent compound (DHA), the radioactive 
DHA* and its isomer were eluted at about 24 and 16 min, respectively. Both isomers were 
collected in the first-time purification. The crude sample contained a large amount of 
contaminants, most of which were more polar compounds and eluted earlier. The 
radioactive trace of the crude material (see Figure 91 insert) however, indicated that very 
little of the contaminants were 14C-labelled. The only two peaks that contained radioactive 
material are DHA * and its isomer. 
Figure 92 shows the HPLC profile of the second purification. The radioactive trace 
of the same HPLC profile is shown in the insertion of Figure 92. It is clear that the non-
radioactive and radioactive profiles are the same. This result indicated that, after a double 
purification procedure, the sample contained very little contamination, either chemical or 
radioactive. Only DHA * was collected from this purification, and the isomer was 
discarded. The average yield of purification was 52.5%. 
Li~ht-sensitive Isomerization ofDHA* 
A small amount of double-purified DHA * dissolved in 80% CH30H:20% HAC 
(O.OlM) was exposed to fluorescent light for 3 min. The sample was then analyzed by 
HPLC using the same eluting program as that used for the purifications. Fifty 1-ml 
fractions were collected and counted. The result is shown in Figure 93. The relative 
percentages ofDHA* and its isomer were estimated by their DPM counts and by.measuring 
their relative peak areas from Figure 92 and 93, respectively. The results were summarized 
in Table VII. The values obtained from the two methods were very similar. The average 
percentage of DHA * to its isomer was 85.8%: 14.2% after the light exposure compared to 
86.6%: 13.4% prior to the light exposure. Therefore, only 0.9% of DHA * was isomerized 
to its isomer during the 3-min light exposure. 
Figure 91. HPLC Profile of the First Purification of DHA *. 
DHA*: 9,10,ll-14C Ethyl (E)-4-[2-(3,4-Dihydro-4,4-dimethyl-2H-1-
benzopyran-6-yl)-l-propenyl]benzoate. 
Instrument: Waters-6000 HPLC System 
Fisher Recordall UV Recorder 
UV Detector Wavelength Setting: 254 nm 
Column: Whatman Cs ODS-3, Spherical 5 µm, 0.46 x 12.5 cm 
Flow Rate: 1.0 mVmin 
Solvent Program: 70% CH30H:30% 0.01M HAC Isocratic 
Insert: 14C Radioactive Trace of the First Purification of DHA * 
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Figure 92. HPLC Profile of the Second Purification of DHA *. 
DHA*: 9,10,l l-I4c Ethyl (E)-4-[2-(3,4-Dihydro-4,4-dimethyl-2H-1-
benzopyran-6-yl)-1-propenyl]benzoate. 
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Figure 93. 14C Radioactive Trace of the Purified DHA * After 3-min Light Exposure. 
DHA *: 9,10, 1 t-14C Ethyl (E)-4-[2-(3,4-Dihydro-4,4-dimethyl-2H-1-
benzopyran-6-yl)-1-propenyl]benzoate. 
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TABLE VII 
RELATIVE PERCENTAGE OF DHA * AND ITS ISOMER BEFORE AND 
AFTER A LIGHT EXPOSURE OF THREE MINUTES 
Before Light Exposure After Light Exposure 
(%) (%) 
by area byDPMs average by area byDPMs average 
DHA* 86.1 87.1 86.6 85.1 86.5 85.8 
ISOMER 13.9 12.9 13.4 14.9 13.5 14.2 
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Metabolites of DHA * in Bile 
The radioactive trace of the parent compound DHA * before its administration into 
the chicken is shown in Figure 94. The single radioactive peak of DHA * was eluted at 
about 140 min. This result indicated that the purification of DHA* from the crude 
radioactive material was effective. Only a dose of highly purified, radioactive parent 
compound was injected into the animal. The bile sample was collected, processed, and 
then analyzed by the HPLC system. Figure 95 shows the total radioactive trace of the 
biliary metabolites of DHA *. Despite the low specific activity of DHA * injected, the 
chromatogram revealed a number of metabolites within the range of 55-140 min with a 
major one eluting at 110 min. The parent compound was recovered in the bile, and was 
detected at 140 min. In addition, 2 or 3 metabolites that were eluted after the parent 
compound could also be observed although their intensities were very low. 
Metabolites of DHA * in Liver 
Liver extract was analyzed by HPLC using an isocratic program. The radioactive 
trace of the liver metabolites is shown in Figure 96. It can be seen that there were at least 
two metabolites in the liver. They are more polar than the parent compound, which was 
detected at about 24 min. Overall, the DPM values were very low for the liver metabolites. 
Therefore, after 6 hr of metabolism, very little of the metabolites remained in the liver. 
This indicated that the 6-hour bile collection is sufficient to obtain most metabolites secreted 
into the bile. 
Owing to the low specific radioactivity of the starting material (0.74 µci/mg of 
crude DHA *) and still lower radioactivities of the metabolites detected, this preliminary 
study was only intended to verify the feasibility of the experimental procedures designed to 
carry out metabolism studies with radioactive materials. No further identification was 
intended. 
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Figure 94. Radioactive Trace of the Purified DHA * Prior to the Drug Administration. 
DHA *: 9, 10,11-I4c Ethyl (E)-4-[2-(3,4-Dihydro-4,4-dimethyl-2H-1-
benzopyran-6-yl)-1-propenyl]benzoate. 
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Figure 95. Radioactive Trace of a Chick Biliary Metabolites of DHA *. 
DHA*: 9,10,l t-14C Ethyl (E)-4-r2-(3,4-Dihydro-4,4-dimethyl-2H-1-
benzopyran-6-yl)-1-propenyl]benzoate. 
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Figure 96. 14c Radioactive Trace of a Chick Liver Metabolites of DHA *. 
DHA *: 9,10,ll-14C Ethyl (E)-4-[2-(3,4-Dihydro-4,4-dimethyl-2H-1-
benzopyran-6-yl)-1-propenyl]benzoate. 
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Conclusions 
Methods have been developed to study the metabolism of heteroarotinoids in vivo. 
A successful rat bile cannulation procedure was established for convenient collection of 
biliary metabolites under normal or near normal physiological conditions, and for extended 
use of the animals. Methods for bile sample processing and purifications designed to 
eliminate artifacts generated from chromatographic procedures and various other sources of 
isomerization, oxidation, and deteriorations by controlling temperature, air and light 
exposure. 
Three major biliary metabolites of a selected heteroarotinoid, ethyl (E)-4-[2-(3,4-
dihydro-4,4-dimethyl-2H-1-benzopyran-6-yl)-l-propenyl]benzoate, were tentatively 
identified using combined techniques of HPLC, UV, Plasmaspray LC/MS and LSIMS. 
The structures of these metabolites are shown in Figure 97. 
Studying drug metabolism in a biological fluid as complicated as bile without 
labeled compounds is very time-consuming and labor intensive. Isotope-labeling of some 
drugs, like the heteroarotinoids studied here, is difficult and costly, especially with 
expected specific activities. Nevertheless, results obtained from this study are 
encouraging. It is possible that a majority of the work in the identification of drug 
metabolites can be accomplished using non-radioactive compounds. With suitable 
application of modem techniques such as HPLC and other chromatographic methods, 
metabolites can be separated and isolated effectively. Plamaspray LC/MS is a powerful and 
an ideal technique in the analysis of drug metabolism without requiring excessive 
separation and isolation procedures. Should metabolites be isolated of sufficient quantity 
and purity, other spectroscopic techniques, such as LSIMS and lH- or 13C-NMR, can be 
applied to further examine the structures. Isotope-labeled compounds may be required in 
the final confirmatory step(s). 
Figure 97. The Structures of the Tentatively Identified Biliary Metabolites of DHA in Rats. 
DHA: Ethyl (E)-4-[2-(3,4-Dihydro-4,4-dimethyl-2H-1-benzopyran-6-yl)-1-
propenyl]benzoate. 
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CHAPTER VIII 
SUMMARY AND CONCLUSIONS 
Heteroarotinoids are a family of newly developed retinoids. They retain the basic 
features of the retinoid skeleton with the incorporation of at least one heteroatom and an 
aryl ring. They have shown marked anticancer activities in the tracheal organ culture assay, 
the omithine decarboxylase assay, and in the HL-60 cell line. Equally important is that 
some have shown reduced toxicity when compared to naturally occurring retinoids and 
other synthetic retinoids. Investigations of their biological activities and the metabolism of 
these heteroarotinoids will provide important information for pharmacological evaluation 
and future clinical utilization. 
One of the most important biological functions of vitamin A is its essential role in 
promoting normal growth. A growth assay was developed and utilized to evaluate the 
growth-promoting activity of the heteroarotinoids by monitoring the weight-changes of 
vitamin A-deficient rats fed with or without supplementation of these heteroarotinoids. 
Vitamin A-deficiency was introduced synchronously in all the test animals. A diaryl 
heteroarotinoid (DHA), ethyl (E)-4-[2-(3,4-dihydro-4,4-dimethyl-2H-1-benzopyran-6-yl)-
1-propenyl]benzoate, and a monoaryl heteroarotinoid (MHA), (2E,4E,6E)-3,7-dimethyl-7-
(1,2,3,4-tetrahydro-4,4-dimethyl-6-chromanyl)-2,4,6-heptatrienoic acid or its ethyl ester, 
were tested. The drugs were given to rats, either by periodic supplementation and 
withdrawal of a fixed amount of the test compounds (periodic feeding approach), or by 
continuous supplementation of the compounds over an extended period of time (continuous 
feeding approach). The activity of heteroarotinoids was compared to that of all-trans-
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retinoic acid (RA). The results demonstrated that DHA supported growth at a rate very 
similar to that of RA when both were fed at the level of 100 µg/day. At a higher dose level 
(200 µg/day), DHA was more potent in stimulating growth than RA. Neither DHA nor RA 
supplemented at 10 µg/day was sufficient to maintain normal growth in rats. In contrast, 
while MHA apparently sustained growth for a short time, it did not support growth 
effectively, even when it was supplemented at a level as high as 200 µg/day/rat. 
The vitamin A..;like activity of DHA and MHA, as well as all-trans-retinoic acid 
(RA), in terms of promoting the differentiation of epithelial cells was evaluated in vivo 
using a modified vaginal-smear assay performed on vitamin A-deficient ovariectomized 
rats. The vaginal epithelium of vitamin A-deficient rats was marked by persistently 
comified epithelial cells. The comified epithelium, in ovariectomized rats, responded 
solely to the total body vitamin A status, and as manipulated in this assay, to the topically 
administrated compounds exhibiting vitamin A-like activities. DHA, MHA and RA, each 
in the amount ranging from 10-14 mol to 10-8 mol, were applied intravaginally to the rats in 
27 µl of a mixture of aldehyde-free alcohol : normal saline (2: 15, v/v) immediately after the 
first vaginal smear was taken (at time 0). Vaginal smears were then taken 18 hours after 
drug application, and every 24 hours thereafter for 6-7 days. The anti-keratinization 
activity of the tested heteroarotinoids was clearly demonstrated by the reversal of the 
comified epithelial cells after drug administration. In most cases, the responses first 
became significant at 42 hours, and reached a peak at about 66 hours. Comified vaginal 
epithelium, as the result of vitamin A deficiency, was reversed by dose levels as low as 10-
14 moles. The relative activity of DHA (EDso = 1.0 x 10-11 moVvagina) was slightly 
higher than that of RA (EDso = 4.0 x 10-11 moVvagina), while MHA (ED50 = 4.0 x 10 -10 
moVvagina) was ten-fold less active than RA. 
Rats that were used in the continuous feeding experiment were submitted to a 
postmortem examination. They had been supplemented daily with DHA, MHA and RA, 
each at various doses, for continuous 26-40 days at which time they were sacrificed. 
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Epithelial tissues were taken from various organs that were known to be most susceptible 
to vitamin A deficiency. The tissues were evaluated histopathologically and compared to 
those of the control rats. The control rats were age-paired rats of the same strain raised on 
a normal diet. Results demonstrated that both DHA and MHA, similar to RA, maintained 
the integrity of the epithlial tissues taken from the liver, trachea, lung, and all organs of the 
gastrointestinal tract. Lesions similar to those resulting from vitamin A-deficiency, 
including atrophy, edema, metaplastic keratinization and inflammation, were seen in the 
epithelial tissues of the prostate, epididymis, testes, and the urinary bladder of most of the 
drug-treated rats. The most severe lesions were observed in the epithelia of the three male 
genital organs, but no distinctive differences could be generalized on the effects of the 
different drugs (inter-compound comparisons), or of the same drug at different dose levels 
(intra-compound comparisons). While epithelial degeneration of the urinary bladder, 
manifested as desquamation of the epithelial cells, was more severe in RA-treated animals 
than heteroarotinoid-treated animals, the atrophy in the kidney was more profound in 
heteroarotinoid-treated rats, and was observed only occasionally in RA-treated rats. Intra-
compound differences were not obvious overall.. In conclusion, the effects of the 
heteroarotinoids on maintaining the integrity of epithelial tissues are similar to that of 
retinoic acid. They are tissue-specific in that they are able to promote the normal epithelial 
growth of some organs, but not of others. Among the epithelia that these compounds fail 
to preserve are the epithelial tissues of the genitourinary tract. 
A metabolism study of DHA was conducted in vivo using bile-duct cannulated rats. 
Procedures for bile sample purification were established. Methods were developed to 
isolate and identify major biliary metabolites derived under normal physiological conditions 
using combined HPLC, UV, Plasmaspray LC/MS and LS IMS techniques. Three major 
oxidative metabolites of DHA were identified. Methods employing the utilization of 
radioactive tracers in confirmatory studies were also established. 
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